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Abstract 
 
 
Nicotinic acid has been used in the clinical treatment of elevated blood lipid levels for over 50 
years. Although it has a beneficial effect on myocardial infarction and blood lipid profiles, its 
widespread use has been hampered by side effects such as skin rashes and a burning sensation 
on the upper body. Since elevated blood lipid levels, especially ones of VLDL and LDL 
cholesterol are a frequent indication and high risk factor for coronary and cardiac diseases, 
finding a compound with an enhanced pharmacological profile, still holding the desired 
effects, but without inconvenient side effects, is a very appealing aim to many pharmaceutical 
companies. These efforts have already produced two marketed drugs, Acipimox and Acifran, 
but they have not been able to overcome the restrictions already imposed on the treatment by 
nicotinic acid. Although proposed long before, in the year 2000 the gene for the nicotinic acid 
receptor in mouse PUMA-G was cloned, and in 2003 the discovery of the genes HM74 and 
HM74A followed, which comprise the homologous low and high affinity receptors for 
nicotinic acid in humans. The discovery of this G Protein-coupled receptor target allowed a 
more directed approach for the search of alternative compounds. 
 
This work is the first report of the heterologous overexpression of the high affinity GPCR 
gene HM74A in the methylotrophic yeast Pichia pastoris. The protein product, NAR1, was 
pharmacologically characterized, and displayed a binding affinity of 224.8 nM to its ligand 
nicotinic acid, showing a similar activity profile compared to those displayed in human tissue, 
which were determined to be 60 nM to 90 nM. Additionally, inhibitory constants (Ki) for 
Acifran and Acipimox were determined to be 4.5 µM and 50.5 µM, respectively. 
Furthermore, the total yield of NAR1 reached 42 pmol/mg membrane protein, which 
corresponds to 0.4 mg of receptor produced per liter yeast culture, opening up the perspective 
of large scale protein production to facilitate high throughput screening drug discovery efforts 
and structural studies. In addition, NAR1 could be solubilized in n-decyl-β-D-
maltopyranoside and purified to homogeneity after immobilized metal affinity 
chromatography and a second affinity chromatography step on immobilized monomeric 
avidin, yielding a single peak on gel filtration, while the purified receptor was able to bind 
ligand, as shown in NMR Saturation Transfer Difference (STD) measurements. 
 Abstract 
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It could be shown that NAR1 is desensitized by β-arrestin 1 in vivo in confocal microscopy 
studies on HEK and BHK cells. This finding provides a native binding partner for the 
stabilization of the receptor upon solubilization and purification. 
 
Finally human β-arrestin 1 could be produced as a constitutively active variant, comprising 
residues 1-382 in Pichia pastoris and Escherichia coli. The purified protein was used for in 
vitro binding experiments and shown to be capable of interacting with NAR1. Although the 
interaction and formation of the complex was only possible to a limited extent, it leaves open 
the perspective of crystallizing NAR1 in its active conformation, bound to nicotinic acid and 
β-arrestin 1. 
 
 Zusammenfassung 
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Zusammenfassung 
 
 
Nikotinsäure wird seit über fünfzig Jahren in der klinischen Therapie eingesetzt. Damals 
entdeckten Robert Altschul und Kollegen [11], dass Nikotinsäure Blutfettwerte verbessern 
und den Cholesterinspiegel senken kann. Diesen Effekt erzielt Nikotinsäure durch die 
Inhibition der Lipolyse in Fettgewebe [12]. Dies führt zu einer Konzentrationsminderung von 
freien Fettsäuren und Triglyceriden im Blutplasma, wodurch die Synthese von 
Triacylglyceriden und Very Low Density Lipoproteins (VLDLs) in der Leber, mangels 
Substrat, reduziert wird. Damit einhergehend verschiebt sich das Gleichgewicht von Very 
Low Density Lipoproteins (VLDLs) und Low Density Lipoproteins (LDLs) und darin 
enthaltenem Cholesterin („schlechtes Cholesterin“) zu Gunsten der High Density Lipoproteins 
(HDLs) und darin gebundenem Cholesterin („gutes Cholesterin“) (Abbildung 6). Im Jahr 
2000 gelang es der Gruppe von U. Schwabe den G-Protein gekoppelten Rezeptor für 
Nikotinsäure in Mäusen (PUMA-G, Protein Upregulated in Macrophages by Interferon-γ) zu 
identifizieren [13], und 2003 publizierten 3 Gruppen unabhängig voneinander die 
Identifizierung zweier Gene für die humane Nikotinsäurerezeptoren HM74 (GPR109B) und 
HM74-A (GPR109A) [14-16]. Die Sequenzhomologie dieser beiden Gene beträgt 96 %, und 
ihre physikalische Nähe auf Chromosom 12q24.31 lassen auf kürzlich zurückliegende 
Genverdopplung schließen. Das Gen mit der Bezeichnung HM74A codiert für den hoch 
affinen Rezeptor, und seine Nukleinsäuresequenzhomologie zu dem murinen PUMA-G 
beträgt 82 %. 
Dadurch ergibt sich für die therapeutische Wirkung von Nikotinsäure folgender Effekt. 
Nikotinsäure aktiviert den G-Protein gekoppelten Rezeptor HM74A, der über die Kopplung 
mit heterotrimeren G-Proteinen der Gi Familie die Adenylylcyclase inhibiert, und zu einer 
Aktivitätsminderung der hormonsensitiven Triglyceridlipase führt (Abbildung 6). Dadurch 
entstehen die oben bereits beschriebenen Effekte. Allerdings sind für die Therapie mit 
Nikotinsäure oral einzunehmende Dosen von 1,5 g – 3.0 g täglich nötig, und werden seit jeher 
von ungewollten Nebenwirkungen begleitet. Diese sind vor allem Vasodilation, die zu einer 
deutlichen Rötung im Gesicht und am Oberkörper, sowie ein sonnenbrandähnliches Gefühl an 
ebendiesen Stellen führen. Wenn auch die Nebenwirkungen nicht dramatisch sind, schränken 
sie die Akzeptanz der Patienten bei länger anhaltenden Therapie drastisch ein. Der 
Nikotinsäurerezeptor wird neben Fettgewebe auch in dermalen dendritischen Zellen und 
Makrophagen exprimiert, in denen durch Gi Kopplung und Phospholipase A2 Aktivierung Zusammenfassung 
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Arachidonsäure freigesetzt wird. Arachidonsäure wird von der Cyclooxygenase-1 zu 
Prostaglandin D2 und E2 umgewandelt, und verursacht so die beschriebenen Nebenwirkung. 
Die derzeit verfügbaren, alternativen Medikamente Acifran und Acipimox mildern die 
Nebenwirkungen, vermeiden sie aber auch nicht. 
 
Diese Arbeit beschreibt erstmals die heterologe Überexpression des Nikotinsäurerezeptors in 
der methylotrophen Hefe Pichia pastoris. Dies beinhaltet die Generierung verschiedener 
Vektorkonstrukte, die Transformierung von Pichia pastoris Zellen und die Isolierung von 
Klonen, die mehrere Kopien des Expressionskonstruktes in ihr Genom integriert haben, und 
eine hohe Expression des Nikotinsäurerezeptorproteins (NAR1) ermöglichen. Der auf diese 
Weise produzierte Rezeptor wurde eingehend charakterisiert, und es konnte gezeigt werden, 
dass seine pharmakologischen Eigenschaften denen des Rezeptors aus homologem 
Gewebeproben entsprechen. Die Affinität für Nikotinsäure liegt mit 224.8 nM unter den in 
nativem Gewebe gemessenen Werten, die zwischen 60 nM und 90 nM liegen. Die 
Inhibitionskonstanten (Ki) für Acifran (Ki = 4,57 µM) und Acipimox (Ki = 50,5 µM) sind auch 
dementsprechend verschoben. Diese Beobachtung wurde aber bereits für andere Rezeptoren 
gemacht, und liegt in der Tatsache begründet, dass sowohl die Zusammensetzung der 
Membranlipide in Pichia pastoris anders ist als auch Proteinkomponenten, welche die 
Aktivität von GPCRs modulieren, gar nicht vorhanden sind. Die maximale Produktionsmenge 
des Nikotinsäurerezeptors lag bei einem Bmax-Wert von 42 pmol/mg Membranprotein. Dies 
entspricht 0.4 mg Rezeptorprotein pro Liter Hefekultur. Die hier produzierte Menge erlaubt 
erstmals Hochdurchsatz Screening Methoden in vitro durchzuführen, und neue therapeutische 
wirksame Substanzen zu identifizieren. Zusätzlich konnte die Auswirkung verschiedener 
Pufferkomponenten in funktionellen Tests gemessen werden. So konnte gezeigt werden, dass 
der heterolog exprimierte Rezeptor sensitiv gegenüber hohen Konzentration an Natriumionen 
ist. Dies stimmt mit den Messungen von Lorenzen et al. 2001 [13] überein, die in nativem 
Gewebe ebenfalls eine Aktivitätsabnahme in Gegenwart hoher Natriumkonzentrationen 
beschreiben. GPCRs der Familie A wie der Nikotinsäurerezeptor haben alle eine konservierte 
Disulfidbrücke zwischen den extrazellulären Verbindungen der Transmembranhelices zwei 
und drei, sowie vier und fünf. Diese ist für strukturelle und funktionelle Integrität des 
Rezeptors unerlässlich, und es konnte gezeigt werden, dass die Reduktion dieser durch 
Zugabe von DTT zu einem Aktivitätsverlust führt. 
Des Weiteren ermöglicht die hier produzierte Menge erstmals umfassende Studien zu 
Solubilisierung und Proteinreinigung, die neben der funktionellen Expression die ersten Zusammenfassung 
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wichtigen Schritte auf dem Weg zu Experimenten zur Strukturaufklärung sind. Es konnte 
gezeigt werden, dass aus einem Testsatz von 18 Detergenzien alle mit Ausnahme von n-
Decyl-β-D-Glucopyranosid in der Lage waren den Nikotinsäurerezeptor NAR1 aus der 
Membran zu extrahieren. Die Messung der Bindungsaktivität wurde jedoch durch die 
Verwendung von Detergenzien erschwert. Durch die Extraktion des Rezeptors aus der 
Membran ist zum einen eine Abnahme der Affinität zu erwarten, zum anderen muss der 
ungebundene Ligand von dem freien separiert werden, was durch das Auflösen der Membran 
nicht mehr mit dem bisherigen Filtrationsversuch möglich ist. Dies konnte dadurch gezeigt 
werden, dass bei Erreichen der kritischen mizellaren Konzentration (cmc) von Detergenz im 
Bindungstest keinerlei Aktivität mehr zu messen war. Titrationskurven mit den Detergenzien 
n-Decyl-β-D-Maltopyranosid, n-Dodecyl-β-D-Maltopyranosid und Cymal-6 belegen dies 
eindeutig. Es konnte weiterhin gezeigt werden, dass die anschließende Extraktion des 
Detergenz zu einer partiellen Rückgewinnung der Aktivität führte. Die besten Werte lieferte 
dabei n-Decyl-β-D-Maltopyranosid mit über 30 % der Ausgangsaktivität. Ein 
Proteinstabilitätsscreening konnte zusammen mit verschiedensten Reinigungsstrategien n-
Decyl-β-D-Maltopyranosid als am besten geeignetes Detergenz bestätigen, weil es das größte 
Ausmaß an Rezeptorstabilität und Funktionalität gewährleistet. Letztlich konnte der Rezeptor 
über Immobilisierte Metall-Affinitätschromatographie und einen zweiten 
affinitätschromatographischen Schritt mit Hilfe immobilisierten monomeren Avidins gereinigt 
werden. Der so vorliegende Rezeptor ergab ein einzelnes Signal in der analytischen 
Gelfiltration, das von einer homogenen Proteinpräparation zeugt. Die Aktivität des 
gereinigten Rezeptors konnte mittels NMR basierenden STD (Saturierungs Transfer 
Differenz) Messungen gezeigt werden. 
 
Die Kristallisation von Membranproteinen gestaltet sich häufig schwierig, da in vielen Fällen 
die hydrophilen Anteile des Proteins nicht über die Detergenzmizelle hinausreichen, und 
somit kaum eine Möglichkeit zur Ausbildung von Kristallkontakten besteht. Um dieses 
Problem zu lösen werden Anitkörperfragmente an das zu kristallisierende Membranprotein 
gebunden, um die polare Oberfläche zu vergrößern, was die Bildung von Kristallkontakten 
ermöglicht. Da die Suche nach einem geeigneten Antikörperfragment schwierig und 
langwierig ist, wurde nach Alternativen gesucht, und β-Arrestine als potentielle Kandidaten 
entdeckt. Der Aktivitätszyklus eines G-Protein gekoppelten Rezeptors stellt sich wie folgt dar: 
Der Rezeptor bindet den extrazellulären Liganden, und wird so durch eine 
Konformationsänderung in den aktiven Zustand überführt. Dieser ermöglicht die Aktivierung Zusammenfassung 
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des gekoppelten heterotrimeren G-Proteins, dessen α-Untereinheit sich von dem βγ-Komplex 
löst und beide Effektorenzyme aktivieren. Der dissozierte βγ-Komplex rekrutiert G-Protein 
gekoppelte Rezeptorkinasen, die Tyrosin-, Serin- und Threoninseitenketten phosphorylieren. 
Die Phosphoaminosäuren stellen zusammen mit der aktiven Rezeptorkonformation die 
Bindungsstelle für Arrestinproteine dar, die zum einen die Aktivierung weiterer 
heterotrimerer G-Proteine unterbinden und die Verbindung zu Clathrin ummantelten Vesikeln 
herstellen. Der Komplex aus Rezeptor Ligand und Arrestin ist langlebig, da Arrestin den 
Rezeptor zu den Endosomen begleitet, wo über seine Wiederverwendung oder Abbau 
bestimmt wird. Mit 40 kDa ist β-Arrestin ähnlich groß wie der Rezeptor, aber ein lösliches 
Protein, und vergrößert so die hydrophile Oberfläche des Komplexes im Vergleich zu der des 
Rezeptors alleine. 
 
In vivo Experimente mit HEK- (Human Embryonic Kidney) und BHK- (Baby Hamster 
Kidney) Zellen zeigten erstmals die Interaktion beider Proteine nach Stimulation mit 
Nikotinsäure. Hierzu wurden Plasmide mit GFP markiertem Nikotinsäurerezeptor und CFP 
markiertem β-Arrestin hergestellt und in die Zellen transfiziert. Daraufhin konnte beobachtet 
werden, dass sich die blaue Fluoreszenz β-Arrestins als Volllängenkonstrukt, als auch in der 
konstitutiv aktiven Variante der Aminosäuren 1 bis 382 im Zytoplasma befindet, während 
sich die grüne Fluoreszenz des Rezeptors auf die Zellmembran und definierte intrazelluläre 
Membrankompartimente beschränkte. Zugabe von Nikotinsäure zum Medium bewirkte eine 
Verlagerung des β-Arrestin Fluoreszenzsignals an die Membran, zu dem Rezeptor. 
 
β-Arrestin 1 konnte als konstitutiv aktive Variante, die die Aminosäuren 1 bis 382 (β-Arrestin 
1-382) umfasst, sowohl in Pichia pastoris, als auch in Escherichia coli produziert werden, 
wobei die Ausbeute in Pichia pastoris das vierfache der Menge in Escherichia coli betrug. 
Jedoch ist die Handhabung von Escherichia coli deutlich angenehmer, und die Verwendung 
von  Pichia pastoris nicht zwingend. In beiden Expressionssystemen gestaltete sich die 
Expression von β-Arrestin 2 als schwierig, und brachte nicht die erforderlichen 
Proteinmengen ein. Ein [
15N] markierte Präparation der konstitutiv aktiven Version β-Arrestin 
1-382 stellte sich in NMR-spektroskopischen Messungen als dynamisch gefaltetes Protein 
dar, jedoch waren die spektralen Eigenschaften β-Arrestins 1-382 nicht ausreichend um eine 
Auflösung eines Signals für jede Aminosäure zu ergeben. Dadurch war die Zuordnung und 
Strukturbestimmung mittels NMR nicht möglich. Auch konnte keine Interaktion mit einem Zusammenfassung 
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Rezeptorpeptid beobachtet werden, die eine Eingrenzung der interagierenden Aminosäuren 
erlaubt hätte. 
 
Dennoch konnte in vivo gezeigt werden, dass der gereinigte Rezeptor an β-Arrestin 1 bindet, 
und sich somit die Möglichkeit zur Herstellung einer konformationssensitiven 
Affinitätsmatrix bietet. Ebenso eröffnet die Interaktion die Möglichkeit der Kristallisation des 
Komplexes aus Nikotinsäurerezeptor, dem Agonisten Nikotinsäure und β-Arrestin 1. Jedoch 
war die Rekonstitution des Komplexes nicht quantitativ, und erfordert zusätzliche 
Erkenntnisse, über die Faktoren, die die Ausbildung des Komplexes bestimmen, um die 
angeführten Ziele letztendlich in die Tat umzusetzen. Ein hierbei augenscheinliches Problem 
stellt der oligomere Zustand des Rezeptors dar. Für eine Vielzahl von Rezeptoren [17-20], 
unter anderem Rhodopsin [6, 21], konnte gezeigt werden, dass sie in der Membran als Dimere 
vorliegen. Auch wurde im Falle von Rhodopsin gezeigt, dass diese Organisation durch 
Zugabe von Detergenz bis zur Solubilisierung aufgelöst wird. Da sich zusätzlich die Daten 
mehren, dass β-Arrestin das Rezeptordimer bindet [22, 23], muss die Suche nach 
Bedingungen, die zum einen den dimeren Zustand des Rezeptors konservieren, als auch die 
quantitative Bindung mit β-Arrestin verstärken, eines der dringendsten Ziele sein. Diese 
könnten dann zur Herstellung der oben genannten konformationssensitiven Affinitätsmatrix 
genutzt werden und die Kristallisation des Komplexes aus dem Nikotinsäurerezeptor NAR1, 
Nikotinsäure und β-Arrestin ermöglichen. 
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1 Introduction 
1.1 Signal  Transduction 
“Life just wants to be there!” is a quote from Bill Bryson’s Aventis-Prize for Science Books 
2004 award winning book “A Short History of Nearly Everything” [24]. But living imposes 
certain requirements on every cell, the smallest living entity, and the building block of multi-
cellular organisms. One of these requirements is certainly the capability to perceive 
environmental stimuli and react accordingly. The field of research dedicated to these 
processes is called signal transduction. The term was originally used by physical scientists 
and electronic engineers to describe the conversion of energy and information from one form 
into another. It first occurred in biological literature in 1974 and as a title word in 1979. Its 
widespread use was triggered by an important review by Martin Rodbell, published in 1980 
[25]. He was the first to draw attention to the role of GTP and GTP-binding proteins in 
metabolic regulation and he deliberately borrowed the term to describe their role. By the year 
2000, 12% of all papers using the term cell also employed the term signal transduction [25, 
26]. 
The environmental stimuli a cell has to perceive are manifold, such as light, ions, gases like 
nitric oxide, small organic molecules such as biogenic amines, lipids or nucleotides, steroids 
and sugars to peptides and even entire proteins. Some of these signaling molecules can readily 
cross the cell’s membrane and act within the cytoplasm on their cognate receptors, like the 
steroid hormones testosterone and cortisol that bind to steroid receptors and modulate 
transcription, or nitric oxide that binds to nitric oxide sensitive guanylate cyclase and changes 
its enzymatic activity. Other signaling molecules are either too hydrophilic or just too large to 
cross the cell membrane, and therefore need specific target receptors on the cell’s surface, that 
translate the signal into the cell’s own language. These molecules act predominantly on three 
classes of transmembrane receptors. 
 
The first of these are the ligand-gated ion channels. They serve in the nervous system for the 
rapid conversion of a chemical signal into an electrical one. Neurotransmitters like 
acetylcholine, glutamate, γ-aminobutyricacid (GABA) or glycine bind to their cognate ion 
channel and lead to its opening or closing. The passage of ions into or out of the cell leads 
then to a change in the membrane potential. 
 Introduction 
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The second class of transmembrane receptors is the family of receptor tyrosine kinases 
(RTKs). The roughly 60 members of this family identified to date can be further divided into 
20 subfamilies, according to either a prototypic ligand or receptor [27]. They all share a 
common architecture, which is made up by an extracellular ligand binding domain, a single 
membrane spanning helix followed by a juxtamembrane region and a conserved intracellular 
protein tyrosine kinase domain as well as regulatory sequences. Most of their ligands are 
protein hormones. Hormone binding to the receptor leads to a clustering of monomeric forms, 
or the rearrangement of pre-existing dimers, juxtaposing the kinase domains for mutual 
phosphorylation, activation and initiation of downstream signaling. 
Tyrosine phosphorylation within regulatory segments creates binding sites for proteins 
containing SH2 or PTB domains, and leads to passing the signal on to Phosphatidylinositol-3-
Kinase, Phospholipase Cγ, the Ras- and MAPK-pathways or STAT proteins for example. 
 
The third class of transmembrane receptors are G-protein coupled receptors (GPCRs) and are 
now discussed in more detail. 
 
1.1.1 GPCRs 
1.1.1.1 GPCR Evolution 
The evolution of the 5 major classes of GPCRs in the human genome (Glutamate, Rhodopsin, 
Adhesion, Frizzled and Secretin) took place before the split of the nematode from the 
chordate linage, as has been shown by recent phylogenetic analyses [5, 8]. The large 
expansion in GPCR numbers is thought to have arisen from genome duplication events that 
occurred 650-350 million years ago in early chordate [28], or in two waves, the latter 430-80 
million years ago, at the time of the mouse-human split and a first at the vertebrate-amphioxus 
split about 750-430 million years ago [8, 29]. Since that time GPCRs constitute the major 
class of transmembrane receptors. The nematode Caenorhabditis elegans has as many as 1149 
predicted GPCRs [5], comprising 5% of its entire genome. Mammalian genomes are less 
dominated by GPCRs, although they still comprise the largest gene family. Mice have 
approximately 1318 predicted GPCRs [5], and there are 720-800 functional GPCRs found in 
the human genome, which accounts for about 2% of all its genes [4]. 
GPCRs are found throughout the eukaryotic kingdom (Figure 1), but not in prokaryotes [8]. 
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1.1.1.2 GPCR Distribution among Species 
Among the classes of transmembrane receptors, the GPCR superfamily is the largest [8]. They 
can be found in almost every eukaryotic organism, including plants [30], fungi and throughout 
the bilateria [5]. In yeast, only a few GPCRs are found. In the yeast Saccharomyces cerevisiae 
only three GPCRs have been described, including the yeast pheromone receptors (Ste2 and 
Ste3) and one of the Adhesion-family (Gpr1) being a sugar sensing receptor. Nine are found 
in the genome of Schizosaccharomyces pombe, and further ones have been found in the fungal 
pathogen  Cryptococcus neoformans, among which is the amino acid methionine sensing 
Gpr4, which is coupled via the G-protein α subunit Gpa1 to the cAMP-PKA pathway. Other 
yeasts are able to grow in diverse environments and are therefore confronted with a wider 
Figure 1: Phylogenetic GPCR tree of the different species. Numbers in red indicate the time in 
million years since the split at that node occurred. Blue GPCRs and numbers give the number 
predicted in this species, based upon [5], taken from [8]. Introduction 
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variety of environmental stimuli. They need to have extensive sensing and signaling 
capacities. In the genome of Neurospora crassa ten putative GPCRs have been identified, 
belonging to families of microbial opsins, pheromone receptors, glucose sensors, nitrogen 
sensors and one sharing similarity with sequences from Dictyostelium discoideum, in which 
four related cARs (cAMP receptors) sense cyclic AMP (cAMP) levels during multicellular 
development and sporulation. Similarity exists as well to predicted proteins in Caenorhabditis 
elegans and Arabidopsis thaliana [31]. 
Although a few proteins sharing the 7TM signature motif have been identified in plants, only 
one, the Arabidopsis thaliana Gcr1, shares similarity to a Dictyostelium discoideum cAMP 
receptor and has been shown to interact with the single Gα subunit Gpa1 of A. thaliana [32]. 
Nevertheless, it is not yet clear to what extent signaling occurs through heterotrimeric G-
proteins and Gcr1’s effect on seed germination is at least in part heterotrimeric G-protein 
independent [33]. 
 
1.1.1.3 GPCR Identification 
GPCRs are characterized by a signature motif of seven transmembrane helices, and their 
functional coupling to a heterotrimeric G-proteins. With the availability of fully sequenced 
genomes of higher eukaryotes, the prediction of formerly unknown genes and putative GPCRs 
has become possible. 
In the absence of high degrees of sequence similarity [34, 35] and functional data of G-protein 
coupling, GPCRs were predicted by the mere existence of seven stretches of 25 to 35 
predominantly hydrophobic amino acids expected to form seven membrane-crossing α 
helices. The first helix is preceded by an extracellular N-terminus of varying size, and the 
seven transmembrane helices (TM1-7) spanning the lipid bilayer in alternating orientation are 
connected by hydrophilic loops, termed either extracellular loop (EL) 1-3 or intracellular loop 
(IL) 1-3 according to their appearance, alternating between the inside and the outside of the 
cell. The seventh helix is followed by a C-terminal tail, which frequently contains a 
palmitoylated cysteine residue. This initial ordering led to several synonyms for this protein 
superfamily, like 7-transmembrane receptors, heptahelical receptors and serpentine-like 
receptors [36]. 
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1.1.1.4 Retinal Binding Proteins vs. GPCRs 
Interestingly, the fold of seven helices criss-crossing the membrane not only occurs in GPCRs 
but as well in bacterial retinal-binding proteins and subunit III of the cytochrome c oxidase. 
With bacteriorhodopsin being the model protein for the class of bacterial retinal-binding 
proteins, and rhodopsin being the best studied GPCR and a retinal-binding protein as well, 
some confusion arose about the origin of GPCRs. However they are two functionally distinct 
groups of membrane proteins. Bacteriorhodopsin is a light-driven proton pump, having all-
trans-retinal as a covalently bound chromophore which photo isomerizes upon light 
absorption to 13-cis-retinal. It is not involved in signal transduction. The GPCR in contrast 
binds an extracellular ligand and drives intracellular changes mediated by a heterotrimeric G-
protein. There is though one GPCR, rhodopsin, that somehow belongs to both classes. It binds 
retinal and therefore belongs to the class of retinal-binding proteins. But on the other hand it 
couples light absorption of its chromophore 11-cis-retinal and photo isomerization to all-
trans-retinal to the activation of the heterotrimeric G-protein transducin. Rhodopsin is the 
protein responsible for vision, and although it binds the same chromophore as the bacterial 
retinal-binding proteins, there is no homologue found in bacteria. Furthermore there is no 
obvious evolutionary relationship between these two proteins, regarding sequence similarities 
or gene organization. This was further demonstrated in 2000, when the structure of bovine 
rhodopsin [37] became available and was compared to the one of bacteriorhodopsin from 
1997 [38]. It was found that the helices are arranged in a different way [39]. 
 
1.1.1.5 GPCR Classification 
Human GPCRs have been classified in three main families based on their amino acid 
sequence. Family A consists of the rhodopsin-like receptors, and constitutes the largest and 
best studied family. It contains the opsins, olfactory GPCRs, small molecule and peptide 
hormone receptors as well as the glycoprotein hormone receptors (Figure 2A-C). Despite their 
low overall sequence homology, they are characterized by several highly conserved amino 
acids within the core of the seven transmembrane helix bundle. The only residue that is 
conserved among all family A GPCRs is the arginine residue within the highly conserved 
DRY motif at the cytoplasmic end of transmembrane helix 3 [40]. Apart from very few 
exceptions (melanocyte stimulating/adrenocorticotropic hormone (MSH/ACTH) and 
cannabinoid receptors), a disulfide bridge between conserved cysteine residues bridging 
extracellular loops one and two is also highly conserved. The high degree of conservation of Introduction 
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these residues implies that they are crucial for maintaining the structure and function of the 
receptor. In addition, most of them contain a palmitoylated cysteine in their intracellular 
cytoplasmic tail [41]. The binding of small molecules occurs within the core of the seven 
transmembrane helix bundle (Figure 2A) and that of peptides (Figure 2B) and glycoprotein 
hormones (Figure 2c) at the N-terminus, the extracellular loops and the loop proximal parts of 
the transmembrane helices [4]. 
 
The secretin-like family B receptors share none of the above mentioned characteristic features 
of family A receptors, with the exception of the disulfide bond bridging the first and second 
extracellular loop (Figure 2D). They are characterized by a relatively long N-terminal tail, in 
general about 100 amino acids, that contains three additional conserved disulfide bonds, 
forming a network and contributing to the globular domain structure which is, alongside with 
the seven juxtamembrane regions of the transmembrane helices, implicated in ligand binding. 
Like family A receptors, family B receptors share a number of conserved proline residues 
within the transmembrane segments, which are believed to be responsible for conformational 
dynamics of the receptor[4, 40]. Members of this family are the calcitonin, CGRP and CRF 
receptors, the PTH and PTHrP receptors, the glucagon, glucagon-like peptide, GIP, GHRH, 
PACAP, VIP, secretin receptors and the laxotroxin receptor [40]. 
 
Family C GPCRs are characterized by an extraordinarily long N-terminal tail (500-600 amino 
acids) and a long C-terminal tail (Figure 2E). The disulfide bridge between extracellular loops 
one and two is found in family C receptors too. Another characteristic element is a short third 
extracellular loop. A few of the conserved residues found in family A receptors are also 
conserved among family C receptors, indicating a common origin of these two families. The 
large N-terminal domain contains a cysteine rich domain (CRD) which links the 
transmembrane core to another domain that resembles bacterial periplasmic binding proteins. 
This so-called “venus flytrap” module contains the ligand binding site. For the metabotropic 
glutamate receptor, the crystal structures of the venus flytrap module have been solved in the 
liganded and unliganded state, showing a disulfide linked homodimer that undergoes 
considerable conformational rearrangement upon ligand binding [4, 40]. Family C contains 
the metabotropic glutamate receptors, the metabotropic GABA receptors, calcium receptors, 
vomeronasal receptors and the taste receptors. 
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A fourth family of receptors comprises the members of the frizzled-smoothened family, for 
which direct coupling to heterotrimeric G-proteins is still a matter of debate. 
 
Despite the low overall homology between GPCRs, within each family and their 7 
transmembrane core region, the families’ members share in general more than 25% of 
sequence similarity. 
 
 
 
 
A further distinction has to be made among GPCRs according to the origin of their ligands 
[4]. On the one hand are the pheromone, odorant, tastant and light receptors as sensory 
receptors, responding to environmental stimuli and on the other are those that respond to 
endogenous ligands. 
Of the 720-800 predicted human GPCRs about 380 have been identified as unique, functional 
and nonsensory. For these, endogenous ligands are either known or expected to be found. 
Figure 2: Classification of GPCRs in 3 main families. A-C depict variations of rhodopsin-like 
family A GPCRs, A. binding of small biogenic amine ligand; B. peptide binding GPCR and C. 
glycoprotein ligand (Ligand binding regions depicted in red). Highly conserved residues are 
displayed in green, and the conserved disulfide bond between ECL1 and ECL2 is given in yellow). 
D. Family B GPCRs and E. family C GPCRs. Taken from Jacoby et al., 2006 [4] Introduction 
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These are referred to as endo-GPCRs that modulate various physiological functions. From a 
comparative analysis between mouse and human GPCR sequences, 367 were found in 
humans and 392 in mouse, with 343 present as homologues in both species [42]. Of these 367 
human receptors 284 belong to the family A rhodopsin-like GPCRs, including 98 receptors 
without any known ligand, therefore termed orphan receptors. 50 belong to the family B 
secretin receptor-like GPCRs, 34 of which are orphan receptors, 17 to family C with 6 orphan 
receptors, and 11 to the frizzled/smoothened receptor-like family (F/S). In total, the human 
genome comprises 224 receptors with an identified ligand and 143 orphan receptors, for 
which the search of a ligand is still ongoing [42]. 
Due to recent phylogenetic analyses, a reclassification of the GPCRs in the human genome 
into five major groups has taken place. These groups are, as noted already above the 
Glutamate-, Rhodopsin-, Adhesion-, Frizzled/taste2- and Secretin-like groups, and the new 
system is called GRAFS. This new GRAFS system displays some differences to the A, B, C 
system outlined above. First, the adhesion receptors are formed by Family B receptors that 
have a long N-terminus forming adhesion molecule repeats like EGF domains. These are 
expressed in leukocytes and the nervous system and thought to be involved in cell-cell 
interactions. Second, the taste receptors have been subdivided into the glutamate group and 
the frizzled/taste2 group [43] [4]. 
 
1.1.1.6 GPCR Research History 
The first GPCR that was purified was the β2-adrenergic receptor in 1979 in Robert 
Lefkowitz’s laboratory [44]. With the protein in hand and the identification of small peptide 
stretches, researchers at Merck were able to design oligonucleotide probes and identify and 
clone the β2-adrenergic receptor gene from a hamster cDNA library [45]. The purification and 
the cloning the β2-adrenergic receptor heralded the dawn of the molecular age of GPCR 
research. With the sequencing of the entire human genome, the identification of putative 
GPCRs has become fairly simple. Depending on the stringency of data mining methods, there 
are 720-800 GPCRs identified in the human genome, which comprises about 2 % of all open 
reading frames, making them the largest gene family therein [4]. And as large as their number 
is the diversity of the signals they respond to, reaching from photons in the case of rhodopsin, 
to extracellular endogenous chemical messengers like biogenic amines, purines and nucleic 
acid derivatives, lipids, peptides and proteins, ions like calcium, and protons to environmental 
stimuli like tastants, pheromones and odorants. Introduction 
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1.1.2 GPCR Signaling 
1.1.2.1 Heterotrimeric G proteins 
The name G Protein-Coupled Receptors stems from their ability to recruit and activate 
intracellular heterotrimeric G proteins composed of a guanosine nucleotide binding α-subunit 
(Gα) and a stable complex of a β and a γ subunit (Gβγ). Ligand binding to the receptor triggers 
conformational changes and rearrangement of the helix bundle that enable the receptor to act 
as a nucleotide exchange factor on the heterotrimeric G protein. The activated receptor 
induces a conformational change within the α-subunit of its associated heterotrimeric G 
protein, releasing GDP and thus allowing GTP to enter the now empty nucleotide binding site, 
GTP binding induces further conformational changes that distort the binding interface 
between Gα and Gβγ which results in the dissociation of Gα and Gβγ. In its GTP-bound state the 
Gα-subunit is capable of activating downstream effector enzymes. The same is true for the 
Gβγ-complex [40]. Gα and Gβγ are permanently localized to the cell membrane due to lipid 
anchors on Gα and Gγ, which locate them in the vicinity of receptors and effector enzymes. 
The human genome contains at least 20 genes for α-subunits, 5 for β-subunits and 15 for γ-
subunits. The α-subunits are further divided into 4 classes termed Gαs, Gαi, Gαq and Gα12. All 
theoretical combinations of Gα and Gβγ-complexes produces more than thousand possible 
heterotrimeric G Proteins. Although not all of them are known to exist in vivo, this potential 
demonstrates the incredible opportunities of diverse and flexible signaling inherent to GPCRs.  
This is further highlighted by reports, where receptors signal in a context specific manner 
through different G proteins. The β2-adrenoreceptors signals upon initial ligand binding 
through Gs, activating adenylyl cyclase and in turn PKA. PKA phosphorylates residues within 
the third intracellular loop, and redirects signaling to Gi, which inhibits adenylyl cyclase. The 
fact that GPCRs may signal in a context specific manner through Gα-subunits with opposing 
effects on effector enzymes, and that Gβγ-complexes may oppose the effect of their Gα-subunit 
in a context specific manner, as Gαs stimulates but Gβγ inhibits adenylyl cyclase, demonstrates 
the complexity of these signaling networks. 
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Figure 3: Classical Scheme of GPCR signaling: 1) GPCR (ribbon diagram of rhodopsin) resides 
in the membrane; 2) Ligand (here epinephrin) is present in the extracellular fluid; 
  3) the ligand binds, and 4) activates the GPCR.
5) The heterotrimeric G protein, bound to GDP, is stimulated by the activated GPCR to release 6) 
GDP Introduction 
  25
 
9) The GRK phosphorylates serine and threonine residues, leading to 10) arrestin recruitment. 
Arrestin can initiate signaling via the MAPK cascade, NRTKs and stress fiber formation. 
GDP is substituted by 7) GTP. 8) Gα and the Gβγ complex dissociate. Gα can activate ion 
channels, adenylyl cyclases, phosphodiesterases, PLC-β, PKC, DAG, Rho and RhoGEFs; the Gβγ 
complex acts on ion channels, adenylyl cyclases, PLC-β, PI3-K and GRKs. 
11) Finally the receptor is removed from the 
cell surface by endocytosis, mediated by 
interaction between arrestins, AP-2 and NSF. 
 
 
PLC-β: Phospholipase Cβ; PKC: Protein kinase 
C; DAG: Diacylglycerol; Rho: a small G-
protein; RhoGEFs: Rho Guanidine Exchange 
Factors; GRK: G-Protein Coupled Receptor 
Kinase; MAPK: Mitogen Activated Protein 
Kinase; NRTKs: Non-Receptor Tyrosine 
Kinases; AP-2: Adaptor Protein 2; NSF: N-
maleimide sensitive factor. Introduction 
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1.1.2.1.1 Gα Subunits 
•  Gαs-subunits are characterized by their upregulation of adenylyl cyclase, hence the 
name stimulatory, and drive the opening of Ca
2+ channels. Furthermore, they are 
constitutively activated by Cholera toxin, which ADP ribosylates an arginine residue, 
permanently inactivating its intrinsic GTPase activity. This leads to a permanent 
activation of downstream effector enzymes without being stimulated by a hormone 
[46]. 
•  Gαi-subunits in contrast decrease Ca
2+ influx through channels, but open potassium 
channels. In addition they inhibit the activity of adenylyl cyclase, which lead to the 
subscript  i for inhibitory, and stimulate the activity of cGMP specific 
phosphodiesterase. Pertussis toxin ADP ribosylates a cysteine residue near the C-
terminus, which prevents activation of the G-protein by the receptor, permanently 
blocking signal transmission. In the case of Gαt (transducin) cholera toxin deactivates 
as well the GTPase activity by arginine ADP ribosylation [46]. 
•  Gαq-subunits couple to phospholipase cβ in an activating manner, and they are not 
sensitive to pertussis toxin [46]. 
•  Gα12-subunits use Rho specific nucleotide exchange factor proteins as downstream 
effector molecules and the GTPase activating protein RasGAP [46]. 
 
One thing that all Gα-subunits share is their low intrinsic GTPase activity, leaving Gα a long 
time in the activated GTP bound state. For example, kcat values of GTP hydrolysis for Gαt are 
in the range of 0.05s
-1. The relatively long time they remain in the activated state ensures the 
productive coupling to downstream effector molecule, which frequently act as GTPase-
activating proteins (GAP), increasing the kcat value of GTP hydrolysis up to two orders of 
magnitude, turning the signal off, once it is received by a downstream effector enzyme [46]. 
 
1.1.2.1.1.1  Effector Enzymes 
Activated G proteins pass the ligand initiated signal on to enzymes or channels, which 
catalyze concentration changes of small diffusible signaling molecules called second 
messengers. Among these second messengers are cAMP, cGMP, diacylglycerol (DAG), 
inositol trisphosphate (IP3) and Ca
2+ ions. 
•  The first GPCR effector enzyme was adenylyl cyclase. It catalyzes the formation of 
3’-5’-cyclic AMP (cAMP) from ATP. Its activity can be stimulated by Gαs *GTP, Introduction 
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Ca
2+/calmodulin, protein kinase C (PKC) and Gβγ-subunits, resulting in an increase of  
intracellular cAMP concentration, or inhibited by Gαi *GTP, Ca
2+ and Gβγ-subunits 
causing the opposite effect. cAMP was the first second messenger to be discovered, 
and acts mostly through the activation of protein kinases. Kinases that are activated by 
cAMP are classified as protein kinase A (PKA). They exist in the cytosol as tetramers, 
composed of two regulatory subunits and two kinase subunits. Upon binding of cAMP 
to the regulatory subunits, the kinase subunits are released from the regulatory 
subunits and their inhibitory effect. Apart from the kinases, cAMP effects cAMP gated 
ion channels. cAMP binding on their cytoplasmic side results in their opening or 
closing. The effect of the adenylyl cyclases is opposed by an enzyme called 
phosphodiesterase, which degrades existing cAMP molecules, thus restoring the 
resting state level of cAMP. 
•  The second most prominent effector enzymes belong to the class of phospholipases 
Cβ. Phospholipases are enzymes that cleave off the headgroups of membrane lipids, 
and are differentiated according to their attack point on the lipid. Cleavage of 
phosphatidylinositol-4,5-bisphosphate (PIP2) by phospholipase Cβ produces two 
second messengers. The first being inositol-1,4,5-trisphosphate (IP3) and the second 
being diacylglycerol (DAG) [46]. 
•  Inositol trisphosphate (IP3) mobilizes Ca
2+ release from specific storage compartments 
in the ER and mitochondria. The free cytosolic Ca
2+ concentration in resting cells is 
very low, about 10
-7M, compared to the high Ca
2+ concentrations in specific 
compartments within the cytosol and in the extracellular space, which reach 
millimolar concentrations. IP3 binds to the IP3 Receptor that opens Ca
2+-channels, 
leading to efflux of Ca
2+ ions from intracellular storage compartments, and giving rise 
to a steep increase in cytosolic Ca
2+ concentrations. Ca
2+ signals are three dimensional, 
according to time, space and concentration, and are deciphered by a wide variety of 
Ca
2+ binding proteins within the cell’s cytosol. Among the Ca
2+ binding proteins 
within the cell, Calmodulin is outstanding. Upon Ca
2+ binding it undergoes a structural 
rearrangement that allows it to bind further proteins. Members of the G-protein 
coupled receptor kinases, IP3Receptors, protein kinases and phosphatases are targets 
of Ca
2+/calmodulin, which regulates their activity, thus affecting regulation of 
proliferation, mitosis, neuronal signal transduction, muscle contraction and glucose 
metabolism. Introduction 
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Diacylglycerol has at least two functions. First, it is an important source for the release 
of arachidonic acid, being a precursor in the prostaglandin biosynthesis, and second it 
stimulates the activity of protein kinase C (PKC) [46]. 
 
1.1.2.1.2 Gβγ-Complex 
Although neglected as a competent partner in GPCR signaling for a long time, we now turn to 
the Gβγ-complex. Upon release from the Gα-subunit, previously masked interaction surfaces 
become available on the Gβγ-complex. A number of proteins that interact with and are 
regulated by the Gβγ-complex have been identified. Adenylyl cyclase, phospholipase C, 
potassium channels, Ca
2+ channels, G-protein coupled receptor kinases (GRKs), phosducin, 
regulators of G protein signaling (RGS) and PI3-kinase (Phosphatidylinositol 3 kinase) type γ 
are some of them, and from that large array of interaction partners, the Gβγ-complex has 
evolved in our understanding from a previously passive partner to versatile contributor of 
GPCR signaling. Only one of its functions needs to be described here in more detail. The Gβγ-
complex recruits the G-protein coupled receptor kinase (GRK) to the membrane, by exposure 
of an interaction surface, previously masked by the Gα-subunit. The GRK becomes activated 
by membrane recruitment and IP3 and in turn phosphorylates serine and threonine residues 
within cytoplasmic loops and the C-terminal tail of activated receptors, rendering them 
incapable of activating further heterotrimeric G-proteins on the one hand, and creating a 
binding site for β-arrestin on the other hand. 
 
1.1.2.2 Arrestins 
Arrestins are proteins involved in the desensitization of GPCRs. Four arrestin genes have 
been identified in the human genome: two of them are expressed exclusively in the retina, the 
remaining two, called β-arrestin 1 and β-arrestin 2, are expressed ubiquitously. These two β-
arrestins are thought to be involved in the downregulation of signaling of most non-visual 
GPCRs. 
 
1.1.2.2.1 Desensitization and Endocytosis 
Weakening of a long lasting GPCR signal is a process that is called desensitization. This 
effect is mediated by arrestins and was their classically attributed role. They function as Introduction 
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molecular coincidence detectors, scanning for activated receptor conformations and binding 
only to GRK phosphorylated receptors. In addition to decoupling the receptor from G 
proteins, they serve as a scaffold for the assembly of signaling complexes. Upon GPCR 
binding arrestins undergo a large conformational rearrangement and expose further binding 
sites for other proteins (Figure 4). 
They redirect signaling to the MAPK pathway, by recruiting JNK, ERK or recruitment of 
non-receptor tyrosine kinases via a poly-proline SH3 interaction like c-Src and Hck. Arrestin 
serves also as scaffold for proteins of the endocytotic machinery like Clathrin, AP-2 and NSF 
[47]. By means of endocytosis, brought about by arrestins bridging receptors to endocytotic 
proteins, the receptor-ligand complex is sequestered from the plasma membrane. The receptor 
containing vesicles traffic to endosomes. Here the sorting machinery decides upon the 
receptor’s fate of either being degraded by the lysosomal pathway, or being recycled back to 
the membrane. After disassembly of the clathrin coat and arrestin, dephosphorylation and 
removal of the ligand the receptor is ready for a new round of signal reception and 
transduction.  
 
 
 
 
1.1.3 Dimerization 
Another aspect of GPCR signaling that has recently come to close investigation is the 
phenomenon of dimerization. A number of GPCRs have been shown to form homo- or 
Figure 4: β-arrrestin structure: Active conformation of β-arrestin1, adapted from Xiao et. al. 2004 
[3], showing the concave shaped N- and C-domain, and the released tail that contains peptide motifs 
for interaction with AP-2 and Clathrin. Figure taken from [7]. Introduction 
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heterodimers and complex receptosomes that incorporate in a context-dependent manner 
intra- and extracellular soluble proteins and other membrane proteins. For some receptors, 
dimerization is required for correct membrane transport [18], while for others modulation of 
ligand specificity has been reported, as well as negative and positive cooperativity [4, 17, 48]. 
Even the stoichiometry of the most important GPCR interactions is still a matter of debate. It 
was assumed that one GPCR interacts with one heterotrimeric G protein. However, evidence 
now accumulates that a large number of receptors exists as dimers, raising the question of 
whether a receptor dimer interacts with a single heterotrimeric G protein or with two of them. 
The same speculation exists for the interaction with arrestins. While most textbooks still show 
a complex of one rhodopsin molecule with either one heterotrimeric G protein or one arrestin 
molecule, a recent study suggested a model of a rhodopsin dimer interacting with one 
heterotrimeric G protein or one molecule of arrestin [6, 49].  
 
1.1.4 GPCRs as Drug Targets 
Long before the first GPCR was purified and sequenced, drugs were used in clinics that had 
GPCRs as targets, including β blockers, antihistamines, anticholinergics, analgesic opiates 
and neuroleptics. Abnormalities in GPCR signaling affects most tissues and organs in our 
body, and are the causative agents in disorders such as hyperfunctioning thyroid adenoma, 
precocious puberty, nephrogenic diabetes and color blindness [50]. Around 30% of today’s 
marketed prescription drugs are directed against GPCRs, furthermore they comprise 30% of 
all drug targets investigated so far, rendering them the most successful therapeutic target 
family [4]. A wide variety of medical indications is covered by drugs targeting GPCRs. They 
are used in the treatment of allergies, hypertension, gastric ulcers, migraine, cancer, 
neurological pain, stroke, schizophrenia and asthma. In addition, they have been implicated in 
additional diseases and further medical indications. The human immunodeficiency virus 
(HIV) for example uses the chemokine receptors CCR5 and CXCR4 as co-receptors along 
with CD-4 to enter leukocytes [17]. Virally encoded GPCRs have been implicated in Kaposi’s 
sarcomagenesis and atherosclerosis. The potential of drug development against GPCR targets 
seems to be inexhaustible [4]. 
 
1.1.4.1 Structure Based Drug Design for GPCRs 
The high resolution structure of rhodopsin opened up the perspective of structure based drug 
design for GPCRs. Homology modeling techniques, in combination with ligand receptor Introduction 
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interaction data obtained by mutagenesis and the substituted-cysteine accessibility method 
allowed the discovery of new antagonists for the NK1, the dopamine D3, the muscarinic M1 
and the vasopressin V1a receptors for example[3, 51, 52]. Because the structure of rhodopsin 
is in the off-state, it can only be used as a model for the antagonist bound state, and virtual 
screening for agonists has been more complicated and less successful to date. Our 
understanding of how the transition to the active state is brought about and what it looks like 
is very limited. It is assumed that agonist induced activation of GPCRs disrupts an ionic lock 
between transmembrane helices three and six, resulting in a separation of these two helices 
accompanied by a twist of the latter. This results in an opening of the seven helix bundle. The 
rearrangement of the helices exposes the cytoplasmic end of helices two, three, six and seven, 
with the cytoplasmic ends of helices four and five retracted into the membrane. The intrinsic 
thermodynamic constraints and the limited conformational entropy imposed on the receptor 
by folding are overcome by these agonist-induced perturbations [50]. As mentioned above, 
dimerization is becoming more and more an issue in GPCR research, and it is not yet clear 
how that fits into this picture. A recent study supported by molecular modeling described how 
the G Protein Transducin binds Rhodopsin dimers and tetramers [6, 21]. Another study on the 
leukotriene B4 BLT1 receptor suggests the formation of a pentameric complex consisting of 
two receptor molecules and one heterotrimeric G Protein [53]. But still we know very little 
about how an activated GPCR looks, and how it interacts with the heterotrimeric G Proteins 
and Arrestins. Given the fact, that it is already becoming feasible not only to drug active sites 
of proteins, but also protein-protein interfaces by small molecules, as demonstrated for the 
interface between a Gβγ-complex and Phospholipase Cβ2 or PI-3Kinase γ, we need to know 
more about the interaction of GPCRs and their effectors [54, 55]. 
 
1.2  Crystallization of Membrane Proteins 
A full understanding of how GPCRs work will require more high resolution structures of 
GPCRs, not just one the one of rhodopsin in the inactive state. It will require structures of 
multiple receptors bound to different ligands, agonists, partial agonists, inverse agonists and 
antagonists, and further it will require complex structures of receptors interacting with their 
modulators and downstream effectors like G proteins or arrestin. A systematic approach, 
improving expression, purification and crystallization and joining X-ray crystallography and 
NMR spectroscopy will eventually lead to a structural understanding of GPCRs and their 
modes of signaling [4]. Unfortunately the elucidation of membrane protein structures has been Introduction 
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tricky. Despite the fact that membrane proteins make up 30% of all open reading frames in the 
genome of every cell, the number of their structures in the protein data base are 
underrepresented. This is due to the amphipathic surface of membrane proteins. They are 
designed to integrate into the hydrophobic interior of the lipid bilayer and simultaneously 
protrude out into a hydrophilic environment, resulting in an amphipathic surface. This dual 
nature of their surface makes them difficult to handle in a standard biochemical aqueous 
buffer system, and to accommodate them in solution, the use of surfactants or detergents has 
been established. Typical detergents are small amphipathic molecules with a hydrophilic 
headgroup and a hydrophobic hydrocarbon tail that form spherical or elliptic aggregates 
capable of shielding the hydrophobic surface of a membrane proteins’ transmembrane 
domain, thus preventing their aggregation by unspecific hydrophobic interactions. Despite the 
fact that in some cases the suitability of detergents for the purpose of membrane protein 
handling was questioned because of their destabilizing effect, alternatives like lipid cubic 
phases and amphipols are being developed, but are still in their infancy. Therefore the method 
of choice in membrane protein biochemistry remains the use of detergents and dealing with 
the requirements they impose. A detergent solubilized membrane protein carries a detergent 
micelle around its transmembrane domain like a life belt. The bigger the hydrophilic domains, 
the further they extend away from the micellar life belt and the more likely is the occurrence 
of protein-protein contacts and their potential arrangement in a crystal lattice. Membrane 
proteins with limited polar surfaces, like class A GPCRs, have less mass to extend out of the 
detergent micelle and are therefore harder to crystallize. One method to overcome this 
obstacle is the use of antibody fragments (Figure 5). 
 
Proteolytically produced Fab- or recombinant Fv–fragments can bind to the hydrophilic portion 
of a membrane protein with high affinity and reach out of the detergent micelle, extending the 
polar surface and allowing the formation of stable crystal contacts. A number of membrane 
proteins have been crystallized due to this method, like the cytochrome c oxidase [56], the bc1 
complex [57] and KcsA [58]. The crystal lattice is clearly brought about by the antibody 
fragments outreaching the detergent micelle. Further advantages of the use of antibody 
fragments are their potentially stabilizing effect on the conformation of the protein and 
providing a simple immuno-affinity purification method [1, 59]. However, raising 
conformationally sensitive antibodies that bind with high affinity without adversely affecting 
protein functionality is a difficult and time consuming task. Introduction 
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1.3  Nicotinic Acid Receptor 
1.3.1 Nicotinic Acid in Clinical Use 
Nicotinic acid (Niacin) belongs to the water-soluble vitamin B complex. Alongside its effect 
of being a vitamin, it was discovered more than 50 years ago by Robert Altschul et al. [11] 
that nicotinic acid could modify lipoprotein profiles in humans. Roughly ten years later, in 
1963, Carlson and coworkers found that nicotinic acid inhibits lipolysis in adipose tissue, 
resulting in a rapid decrease of free fatty acid levels in blood plasma. After a delay of 
approximately one day, it is followed by a decrease of triacylglycerol (TAG), very-low-
density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol levels and 
accompanied by an increase in high-density lipoprotein (HDL) and HDL cholesterol 
concentration. Soon after these observations, nicotinic acid was introduced into clinics as the 
first antidyslipidemic drug. In the Coronary Drug Project and its follow-up study, it was 
shown that nicotinic acid, administered in oral doses (1.5-3.0 g/day) reduced myocardial 
infarction and had a beneficial effect on mortality respectively [60, 61]. Unfortunately, the  
Figure 5: Crystal Packing is mediated by an antibody fragment in the crystallization of the bc1 
complex [1]. Introduction 
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Figure 6: Physiological effects of nicotinic acid on different types of tissues, create desired effects 
in adipocytes and undesired effects in dermal dendritic cells and dermal macrophages. Adapted from 
[2] and [9] Introduction 
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administration of nicotinic acid is accompanied by side effects including rashes of the skin 
and a burning sensation in the upper body. These side effects, although harmless, reduce the 
compliance of patients dramatically. 
 
1.3.2 Discovery of the Nicotinic Acid Receptor 
Although the existence of a GPCR for nicotinic acid had been proposed long before, it was 
only in 2003 that three research groups independently cloned the human gene for the nicotinic 
acid receptor, called HM74A (GPR109A) [14-16]. HM74A turns out to be the high affinity 
receptor for nicotinic acid, while two closely related genes, both located in close proximity on 
chromosome 12q24.31, and called HM74 (GPR109B) and GPR81 only bind nicotinic acid 
with low affinity or not at all, respectively. The sequence similarity between HM74A and 
HM74 is 96%, and the similarity to GPR81 is 64%. The high degree of similarity in these 
GPCR genes suggests a fairly recent gene duplication, especially for HM74 and HM74A. The 
ortholog mouse receptor termed PUMA-G (Protein Upregulated in Macrophages by 
Interferon-γ), shares 82% sequence similarity with HM74A. 
 
1.3.3 Nicotinic Acid Receptor Drugs 
Currently, two compounds that mimic the effect of nicotinic acid are marketed: one is called 
Acipimox, which is selective for HM74A (GPR109A, NAR1) and PUMA-G, and does not 
activate HM74 (GPR109B), while the other one, Acifran is an agonist for both receptors. No 
ligand that activates GPR81 has been described, and so it still waits for its deorphanization. 
 
1.3.4 Nicotinic Acid Receptor Expression and Signaling 
The nicotinic acid receptor is expressed preferentially in adipocytes, spleen, lymphoid cells, 
lung, dermal dendritic cells and dermal macrophages (Figure 6). It couples to G proteins of 
the Gαi family. In adipocytes, the result is a decrease in cytosolic cAMP levels, which in turn 
inhibits PKA and results ultimately in the dephosphorylation of hormone sensitive triglyceride 
lipase, reducing its activity. The hydrolysis of triglycerides and free fatty acids from storage 
fat is thereby abolished. The antilipolytic effects brought about by the treatment with nicotinic 
acid results in increased HDL (“good cholesterol”) levels in plasma, while the plasma levels 
of “bad cholesterol”, VLDL and LDL, are decreased. Introduction 
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Unfortunately, on bone marrow derived cells like dermal dendritic cells and dermal 
macrophages, the result of stimulation of the nicotinic acid receptor is different. Activation of 
Gαi in cells of this origin raises intracellular Ca
2+ levels, which in turn activates phospholipase 
A2 that liberates arachidonic acid from membrane lipids. Arachidonic acid is subsequently 
converted by cyclooxigenase 1 (Cox1) into prostanoids like prostaglandin D2 (PGD2) and 
prostaglandin E2 (PGE2). PGD2 and PGE2 mediate in an auto- and paracrine fashion the 
stimulation of Prostaglandin D2- (DP), prostaglandin E2- (EP2) and prostaglandin E4- (EP4) 
receptors leading to cutaneous vasodilation, which evokes flushing and the sensation of 
burning on the face and in the upper body. How nicotinic acid affects other tissues like spleen, 
lymphoid cells and lung is not yet known (Figure 6). 
 
1.3.5 Physiological Ligand 
Nicotinic acid levels in plasma never reach concentrations that are required for the activation 
of HM74A (GPR109A). Despite the fact that this receptor was deorphanized by finding its 
activation by agonists such as nicotinic acid, Acifran and Acipimox, the physiological ligand 
remains to be discovered. Recent data have suggested D-β-hydroxybutyrate as a potential 
physiological ligand [62]. 
D-β-hydroxybutyrate, acetoacetate and acetate are small water-soluble carboxylic acids and 
belong to the group of ketone bodies. During starvation, storage fat in adipose tissue is 
released and transported to the liver via the blood stream. Hepatic breakdown of free fatty 
acids and synthesis of ketone bodies from acetyl-CoA derived from β-oxidation is an 
important energy source for the brain and other tissues during prolonged fasting. Serum levels 
are usually around 50 µM after a meal and reach overnight to levels of up to 400 µM. Upon 
prolonged fasting, D-β-hydroxybutyrate levels plateau at ~6-8 mM. Hepatic formation of 
ketone bodies is at least in part limited by lipolysis in adipose tissue. Activation of GPR109A 
by D-β-hydroxybutyrate at millimolar concentrations could represent a negative feedback-
loop to prevent ketoacidosis, by exerting an antilipolytic effect and controlling the rate of free 
fatty acid release during starvation. Introduction 
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1.4  Aim of the Project 
The aim of this PhD project was to find a means for the supply of large quantities of the 
human GPCR HM74A/GPR109A which has a low abundance in native tissues and is an 
important drug target. This ought to be accomplished by the heterologous overexpression in 
the methylotrophic yeast Pichia pastoris. The produced protein material had to be 
functionally characterized whether it resembles activity profiles of the receptor in native 
tissues. Upon characterization a way for the large scale production of the receptor should be 
found, to supply enough material suitable for structural studies and eventually future 
crystallization trials, with the ultimate goal of structure determination. Therefore the receptor 
should be solubilized by detergent and purified while its activity is to be carefully monitored 
to preserve it in an active and native-like state. 
A second aspect of this project was to find a native binder, which interacts with the GPCR 
HM74A/GPR109A tightly and could potentially substitute for Fv fragments in the 
crystallization process. Therefore its interaction with β-arrestins had to be shown in vivo. 
Upon that they needed to be overexpressed and purified, thereby comparing the two 
heterologous host organisms P. pastoris and E. coli. Finally the complex of β-arrestin and 
HM74A/GPR109A in its active conformation with nicotinic acid bound should be 
reconstituted in vitro and evaluated regarding the possibility of crystallizing this complex. 
 
 
 
 Material & Methods 
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2  Material & Methods 
2.1 Chemicals 
2.1.1 General Chemicals 
All chemicals that were used in this work that are not listed below were either purchased from 
Sigma-Aldrich Chemie GmbH, Steinheim, Germany, Carl Roth GmbH &Co, Karlsruhe, 
Germany (depicted Roth below) or AppliChem, Darmstadt, Germany in ultra pure quality, 
p.a. grade. 
 
a-Cyano-3-hydroxy cinnamic acid  Bruker Daltonic GmbH, Bremen, Germany 
Acifran  Sanofi-Aventis Deutschland GmbH 
Acipimox  Sanofi-Aventis Deutschland GmbH 
Acrylamide ready.made solutions for 
polyacrylamide gels 40 and 30% (37.5:1) 
Roth, Karlsruhe, Germany 
Agarose, Seakem LE, for electrophoresis  Cambrex BioScience Inc., Rockland, ME USA 
Asolectin  Sigma, Steinheim, Germany 
Ammonium-persulfate  Sigma, Steinheim, Germany 
Ampicillin, sodium salt  Sigma, Steinheim, Germany 
Bacto agar, Difco  Becton, Dickinson and Co., Sparks, MD, USA 
Bacto tryptone, Difco  Becton, Dickinson and Co., Sparks, MD, USA 
Bacto yeast extract, Difco  Becton, Dickinson and Co., Sparks, MD, USA 
Biotin  Roth, Karlsruhe, Germany 
Bovine Serum Albumin (BSA)  Sigma, Steinheim, Germany 
BCIP (5-Bromo-4-chloro-3-indolylphosphate, 4-
toluidine salt 
MBI Fermentas GmbH, St. Leon-Rot, Germany 
β-Cyclodextrin  Sigma, Steinheim, Germany 
Cholesteryl hemisuccinate (CHS)  Sigma, Steinheim, Germany 
Coomassie Brilliant Blue R-250  Serva Electrophoresis GmbH, 
Heidelberg, Germany 
Deoxynucleoside-5’-phosphates (dNTPs) 
(supplied with AccuPrime) 
Invitrogen GmbH, Karlsruhe, Germany 
DMF  Roth, Karlsruhe, Germany Material & Methods 
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DMSO (Dimethyl sulfoxide)  Roth, Karlsruhe, Germany 
DTT  Biomol Feinchemikalien GmbH, Hamburg 
Ethidium-bromide  Bio-Rad Laboratories GmbH, Munich 
EDTA(ethylenediaminetetratacetic acid, 
disodium salt) 
Roth, Karlsruhe, Germany 
G418, Geniticin sulfate  Calbiochem, Merck Bioscience, 
Darmstadt, Germany 
Glass beads (0.5mm)  Euler, Frankfurt am Main, Germany 
Glycine  GERBU Biotechnik GmbH, 
Gaiberg, Germany 
Glutathione (reduced)  Sigma, Steinheim, Germany 
HEPES  Roth, Karlsruhe, Germany 
Imidazole  Roth, Karlsruhe, Germany 
Isopropanol  Roth, Karlsruhe, Germany 
IPTG (Isopropyl-β-D-thiogalactoside)  Sigma, Steinheim, Germany 
Kanamycin  Roth, Karlsruhe, Germany 
Leupeptin  Biomol Feinchemikalien GmbH, Hamburg 
Methanol, p.a.  Roth, Karlsruhe, Germany 
Milk powder, non-fat  Roth, Karlsruhe, Germany 
Nicotinic acid  Sigma, Steinheim, Germany 
NBT (Nitrobluetetrazolium, toluidine salt)  Biomol Feinchemikalien GmbH, Hamburg 
Pepstatin A  Biomol Feinchemikalien GmbH, Hamburg 
Peptone  Sigma, Steinheim, Germany 
PMSF (Phenylmethylsulfonylfluoride)  Roth, Karlsruhe, Germany 
Polyethyleneimine (PEI)  Sigma, Steinheim, Germany 
Scintillation mix Rotiszint eco plus  Roth, Karlsruhe, Germany 
Streptavidin PVT SPA Scintillation Beads  GE Healthcare Europe GmbH, 
Munich, Germany 
Streptavidin YSi SPA Scintillation Beads  GE Healthcare Europe GmbH, 
Munich, Germany 
TEMED (N,N,N’N’-tetramethylethylendiamine)  Sigma, Steinheim, Germany 
Tris-(hydrooxymethyl)-aminomethane  Roth, Karlsruhe, Germany 
Tween 20  New Brunswick Scientific Deutschland GmbH, 
Nürtingen, Germany Material & Methods 
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Yeast Nitrogen Base (YNB), w/o amino acids, 
with ammonium sulphate, Difco 
Becton, Dickinson and Co., 
Sparks, MD, USA 
 
2.1.2 Labeled Chemicals 
[
3H]-nicotinic acid  BioTrend, Cologne, Germany 
[
14C]-nicotinic acid  BioTrend, Cologne, Germany 
[
15N] NH4Cl EURISO-TOP  GmbH,  Saarbrücken, 
Germany 
[
15N] NH4SO4 EURISO-TOP  GmbH,  Saarbrücken, 
Germany 
[
2H]-Glycerol EURISO-TOP  GmbH,  Saarbrücken, 
Germany 
1,2-Dimyristoyl-sn-Glycero-3-
Phosphoethanolamine-N-(Lissamine Rhodamine 
B Sulfonyl) (Ammonium Salt) 
(14:0 Lissamine Rhodamine PE) 
Avanti Polar Lipids, Inc., Alabaster, 
AL, USA 
Oregon Green ® 488 1,2-dihexadecanoyl-sn-
glycero-3-phosphoethanolamine (Oregon Green 
® 488 DHPE)  
 
Molecular Probes Europe BV, Leiden, 
The Netherlands 
 
2.1.3 Detergents 
n-octyl-β-D-glucopyranoside (OG)  Glycon Biochemicals, 
Luckenwalde, Germany 
n-nonyl-β-D-glucopyranoside (NG)  Glycon Biochemicals, 
Luckenwalde, Germany 
n-decyl-β-D-glucopyranoside (DG)  Glycon Biochemicals, 
Luckenwalde, Germany 
n-decyl-β-D-maltopyranoside (DM)  Glycon Biochemicals, 
Luckenwalde, Germany 
n-undecyl-β-D-maltopyranoside (UM)  Glycon Biochemicals, 
Luckenwalde, Germany Material & Methods 
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n-dodecyl-α-D-maltopyranoside (α-LM) Anatrace,  Maumee,  OH,  USA 
n-dodecyl-β-D-maltopyranoside (LM)  Glycon Biochemicals, 
Luckenwalde, Germany 
C12E9 (nonaethylene glycol monodecyl ether)  Sigma, Steinheim, Germany 
Cymal-6 (Cyclohexyl-hexyl-β-D-
maltopyranoside) 
Anatrace, Maumee, OH, USA 
Digitonin  Sigma, Steinheim, Germany 
Laurylsucrose (LS) (n-Dodecanoylsucrose)  Calbiochem, Merck Bioscience, 
Darmstadt Germany 
CHAPS (3-[(3-cholamidopropyl)-
dimethylammonio]-1-propane sulfonate) 
Sigma, Steinheim, Germany 
FOS-Choline 12 (FOS-12) (N-
dodecylphosphocholine) 
Synphabase AG, Muttenz, Switzerland 
FOS-Choline 14 (FOS-14) (N-
tetradecylphosphocholine) 
Synphabase AG, Muttenz, Switzerland 
FOS-Choline 16 (FOS-16) (N-
hexadecylphosphocholine) 
Synphabase AG, Muttenz, Switzerland 
LDAO (n-dodecyl-N,N-dimethylamine-N-oxide) Fluka Chemie GmbH, Buchs, Switzerland 
Zwittergent 3-12 (N-Dodecyl-N,N-dimethyl-
3ammonio-1-propanesulfonate) 
Sigma, Steinheim, Germany 
Cholate (sodium salt)  Sigma, Steinheim, Germany 
SDS (sodium-dodecyl-sulfate)  Sigma, Steinheim, Germany 
 
2.1.4 Columns, Chromatographic Matrices & Prepacked Columns 
Polypropylene Columns, 2 ml with glass frits  Pierce Laboratories GmbH, 
Munich, Germany 
Polypropylene Columns, 5 ml with glass frits  Pierce Laboratories GmbH, 
Munich, Germany 
Liquid Chromatography Columns, Luer Lock, 
non-jacketed, 2.5 cm x 10 cm 
Sigma, Steinheim, Germany 
Liquid Chromatography Columns, Luer Lock, 
non-jacketed, 1.0 cm x 20 cm 
Sigma, Steinheim, Germany 
Immobilized Monomeric Avidin  Pierce Laboratories GmbH, Material & Methods 
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Munich, Germany 
Ni-NTA agarose  Qiagen GmbH, Hilden, Germany 
Glutathione Sepharose 4B  GE Healthcare Europe GmbH, 
Munich, Germany 
HisTrap HP, 1 ml  GE Healthcare Europe GmbH, 
Munich, Germany 
DEAE Sepharose
TM FastFlow, 1 ml  GE Healthcare Europe GmbH, 
Munich, Germany 
Q Sepharose
TM FastFlow, 1 ml  GE Healthcare Europe GmbH, 
Munich, Germany 
ANX Sepharose
TM 4FastFlow, 1 ml  GE Healthcare Europe GmbH, 
Munich, Germany 
SP Sepharose
TM FastFlow, 1 ml  GE Healthcare Europe GmbH, 
Munich, Germany 
CM Sepharose
TM FastFlow, 1 ml  GE Healthcare Europe GmbH, 
Munich, Germany 
HiTrap Blue HP, 1 ml  GE Healthcare Europe GmbH, 
Munich, Germany 
Superdex 75 10/30GL  GE Healthcare Europe GmbH, 
Munich, Germany 
Superose 6 PC 3.2/30  GE Healthcare Europe GmbH, 
Munich, Germany 
HiTrap Heparin HP, 5 ml  GE Healthcare Europe GmbH, 
Munich, Germany 
Bio-Gel P60-Gel  Bio-Rad Laboratories GmbH, 
Munich, Germany 
Bio-Gel P100-Gel  Bio-Rad Laboratories GmbH, 
Munich, Germany 
 
2.1.5 Antibodies 
M2 anti-FLAG antibody (Mouse)  Sigma, Steinheim, Germany 
Anti-polyhistidine antibody (Mouse)  Sigma, Steinheim, Germany 
Streptavidin, alkaline phosphatase conjugated  Promega GmbH, Mannheim, Germany Material & Methods 
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Anti-Mouse alkaline phosphatase conjugated  Sigma, Steinheim, Germany 
Goat Anti-Mouse IgG G 12nm  Dianova, Hamburg, Germany 
 
2.1.6 Enzymes 
BamHI  MBI Fermentas GmbH, St. Leon-Rot, Germany 
BglII  New England Biolabs GmbH, 
Schwalbach, Germany 
EcoRI  MBI Fermentas GmbH, St. Leon-Rot, Germany 
NotI  New England Biolabs GmbH, 
Schwalbach, Germany 
PmeI  New England Biolabs GmbH, 
Schwalbach, Germany 
  
AccuPrime Taq Polymerase  Invitrogen GmbH, Karlsruhe, Germany 
CIAP (Calf Intestine Alkaline Phosphatase)  MBI Fermentas GmbH, St. Leon-Rot, Germany 
Quick Ligase  New England Biolabs GmbH, 
Schwalbach, Germany 
  
Endo-H (Endoglycosidase H)  New England Biolabs GmbH, 
Schwalbach, Germany 
PNGase F   New England Biolabs GmbH, 
Schwalbach, Germany 
  
Lysozyme  Sigma, Steinheim, Germany 
Benzonase  Merck KgaA, Darmstadt, Germany 
 
2.1.7 Kits & Markers 
Qiagen PCR purification kit  Qiagen GmbH, Hilden, Germany 
Qiagen gel excision kit  Qiagen GmbH, Hilden, Germany 
Qiagen plasmid miniprep kit  Qiagen GmbH, Hilden, Germany 
BCA protein assay kit  Interchim, Montluçon, France 
Prestained protein marker, broad range  New England Biolabs GmbH, Material & Methods 
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Schwalbach, Germany 
Prestained Seeblue+2  Invitrogen GmbH, Karlsruhe, Germany 
Gene Ruler DNA Ladder Mix  MBI Fermentas GmbH, St. Leon-Rot, Germany 
λ EcoRI/HindIII 3  MBI Fermentas GmbH, St. Leon-Rot, Germany 
 
2.1.8 Filters, Membranes & Concentrators 
Cellulose acetate 0.2 µm filters  Satorius, Göttingen, Germany 
Amicon Ultra-4/15 (30/50 kDa) Concentrators  Millipore GmbH, Schwalbach, Germany 
Gel blotting paper  Schleicher & Schuell BioScience GmbH, 
Dassel, Germany 
GF/C filters for binding assay  Whatman International LtD, Maidstone, UK 
1.2 µm membranes RA  Millipore GmbH, Schwalbach, Germany 
0.45 µm membranes HA  Millipore GmbH, Schwalbach, Germany 
Prefilters AP25  Millipore GmbH, Schwalbach, Germany 
PVDF membrane  Millipore GmbH, Schwalbach, Germany 
RED Devices  Pierce Laboratories GmbH, 
Munich, Germany 
Sterivex GP 0.22 µm 2L  Millipore GmbH, Schwalbach, Germany 
Sterile Filters Filtropur 0.22 µm  Sarstedt, Nümbrecht, Germany 
Nitrocellulose membrane  Schleicher & Schuell BioScience GmbH, 
Dassel, Germany 
ZelluTrans/ Roth Dialysis Membranes T1 
MWCO 4000-6000 
Roth, Karlsruhe, Germany 
  
 
2.1.9 Buffers & Solutions 
Agarose gel (1 %)  1 g Agarose 
  100 ml 1x TAE buffer 
  2.5 µl Ethidium bromide (10 mg/ml) 
TAE buffer (50x)  2 M Tris/HCl 
  1 M Acetic Acid 
 50  mM  EDTA Material & Methods 
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Loading buffer 6x (DNA)  30 mM EDTA 
  0.036 % (w/v) Xylene cyanol 
  0.03 % (w/v) Bromophenol blue 
  30 % Glycerol 
Ampicillin Stock Solution  100 mg/ml inH2O (filter sterilized, stored at -20 °C) 
AP buffer  100 mM Tris/HCl, pH 9.5 
 100  mM  NaCl 
 5  mM  MgCl2 
APS  10 % (w/v) in H2O 
BCIP-Solution  50 mg/ml in DMF (stored at -20°C) 
Pre-Soak buffer  50 mM Tris/HCl pH 7.4 
  0.3 % PEI (v/v) 
Binding buffer (1x)  50 mM Tris/HCl, pH 7.4 
 1  mM  MgCl2 
  0.02 % CHAPS (w/v) 
Binding buffer (5x)  250 mM Tris/HCl, pH 7.4 
 5  mM  MgCl2 
  0.1 % CHAPS (w/v) 
Blotting buffer (1x)  38 mM Glycine 
 10  mM  Tris 
  20 % (v/v) Methanol 
Blotting buffer (5x)  190 mM Glycine 
 50  mM  Tris 
TBST buffer  10 mM Tris/HCl, pH 8.0 
 150  mM  NaCl 
  0.05 % Tween 20 
Breaking buffer  50 mM Sodium-Phosphate buffer, pH 7.4 
 100  mM  NaCl 
 1  mM  EDTA 
  5 % Glycerol 
 1  mM  PMSF 
  Pepstatin A (1 µg/ml) 
 Leupeptin  (0.1  µg/ml) 
Lysis buffer  25 mM Tris pH 8.5 Material & Methods 
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 150  mM  NaCl 
  5 mM DTT/ 10 mM β-Mercaptoethanol 
  10 % Glycerol (v/v) 
CB50  25 mM Tris pH 8.5 
 50  mM  NaCl 
  5 mM DTT/ 10 mM β-Mercaptoethanol 
  10 % Glycerol (v/v) 
CB100  25 mM Tris pH 8.5 
 100  mM  NaCl 
 5  mM  DTT 
  10 % Glycerol (v/v) 
CB1000  25 mM Tris pH 8.5 
 1000  mM  NaCl 
 5  mM  DTT 
  10 % Glycerol (v/v) 
NPB0  25 mM Hepes pH 7.5 / 25 mM Tris pH 9.0 
 0  mM  NaCl 
 5  mM  MgCl2 
  10 % Glycerol (v/v) 
  0.12 % DM / 0.015 % LM / 0.04 % Cymal-6 
  0.024 % / 0.003 % / 0.008 % CHS 
 Asolectin  (optional) 
  0.5 mM nicotinic acid (optional) 
NPB100A  25 mM Hepes pH 7.5 / 25 mM Tris pH 9.0 
 100  mM  NaCl 
 5  mM  MgCl2 
 0  mM  Imidazole 
  10 % Glycerol (v/v) 
  0.12 % DM / 0.015 % LM / 0.04 % Cymal-6 
  0.024 % / 0.003 % / 0.008 % CHS 
 Asolectin  (optional) 
  0.5 mM nicotinic acid (optional) 
NPB100B  25 mM Hepes pH 7.5 / 25 mM Tris pH 9.0 
 100  mM  NaCl Material & Methods 
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 5  mM  MgCl2 
 300  mM  Imidazole 
  10 % Glycerol (v/v) 
  0.12 % DM / 0.015 % LM / 0.04 % Cymal-6 
  0.024 % / 0.003 % / 0.008 % CHS 
 Asolectin  (optional) 
  0.5 mM nicotinic acid (optional) 
NPB1000  25 mM Hepes pH 7.5 / 25 mM Tris pH 9.0 
 1000  mM  NaCl 
 5  mM  MgCl2 
  10 % Glycerol (v/v) 
  0.12 % DM / 0.015 % LM / 0.04 % Cymal-6 
  0.024 % / 0.003 % / 0.008 % CHS 
 Asolectin  (optional) 
  0.5 mM nicotinic acid (optional) 
NPB-low salt  10 mM Hepes pH 7.5 / 10 mM Tris pH 9.0 
 0  mM  NaCl 
 1  mM  MgCl2 
  10 % Glycerol (v/v) 
  0.12 % DM / 0.015 % LM / 0.04 % Cymal-6 
  0.024 % / 0.003 % / 0.008 % CHS 
 Asolectin  (optional) 
  0.5 mM nicotinic acid (optional) 
IMA blocking buffer  100 mM Na-Phosphate pH 7.0 
 150  mM  NaCl 
 2  mM  D-Biotin 
IMA regeneration buffer  100 mM Glycine, pH 2.8 
Coomassie Stain  2 g Coomassie Brilliant Blue R250 
 600  ml  H2O 
  100 ml glacial acetic acid 
 300  ml  Methanol 
Destain 600  ml  H2O 
  100 ml glacial acetic acid 
 300  ml  Methanol Material & Methods 
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Kanamycin Stock Solution (1000x)  50 mg/ml in H2O, stored at 4 °C 
Loading buffer 4x (SDS-PAGE)  250 mM Tris/HCl, pH 6.8 
  8 % SDS 
  40 % Glycerol 
 400  mM  DTT 
  0.004 % Bromophenol blue 
Running buffer (10x)  500 mM Tris/HCl 
  1.92 M Glycine 
  1 % SDS 
Running buffer (1x)  50 mM Tris/HCl 
 192  mM  Glycine 
  0.1 % SDS 
Lower Tris (4x)  0.4 % SDS 
  3 M Tris/HCl pH 8.84 
Upper Tris (4x)  0.4 % SDS 
  0.5 M Tris/HCl pH 5.8 
PMSF Stock Solution  200 mM PMSF in Isopropanol 
(stored room temperature) 
Pepstatin A Stock Solution (1000x)  1 mg/ml in Methanol (stored at -20 °C) 
Leupeptin Stock Solution (100x)  1 mg/ml in H2O (stored at -20 °C) 
TB salts (10x) 100 ml  2.31 g KH2PO4 
  12.54 g K2HPO4 
M9 Salts (10x) 1 l  60 g Na2HPO4 
  30 g KH2PO4 
  5 g NaCl 
  10 g NH4Cl 
TFB-I  30 mM Potassium acetate pH 5,8 
 10  mM  CaCl2 
 50  mM  MnCl2 
 100  mM  RbCl 
  15 % Glycerol 
TFB-II  10 mM MOPS/KOH pH 6,8  
 10  mM  RbCl 
 75  mM  CaCl2  Material & Methods 
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  15 % Glycerol 
 
2.1.10 Vectors 
pPIC9K Invitrogen  GmbH,  Karlsruhe,  Germany 
pPIC3.5K Invitrogen  GmbH,  Karlsruhe,  Germany 
pcDNA3.1 Invitrogen  GmbH,  Karlsruhe,  Germany 
pTrcHIS2A Invitrogen  GmbH,  Karlsruhe,  Germany 
pET  Merck Biosciences, Darmstadt, Germany 
pGEX  GE Healthcare Europe GmbH, Munich, 
Germany 
 
2.1.11 cDNA-Templates 
All templates for human β-arrestin1, human β-arrestin 2 and HM74-A/GPR109A were 
provided by our industrial collaborator Sanofi-Aventis Deutschland GmbH, and verified by 
DNA sequencing. 
 
2.1.12 Primers 
2.1.12.1  Cloning 
barr1for 5’-ATCCGGAATTCGATGAGAACCTGTACTTCCAGGGCATGGG 
CGACAAAGGGACCCGAGTGTTCAAGAAGGCC-3 
barr1-BamHIrev 5’-P-GAGATACTCAGGATCGACCAGGACCACACC-3’ 
barr1-BamHIfor   5’-P-GGTGTGGTC CTGGTCGATCCTGAGTATCTC-3’ 
barr1-EcoRIrev   5’-P-CCAGACGCACAGAATTTCGCTTGTGGATCTTCTCCTCC-3’  
barr1-EcoRIfor 5’-P-GGAGGAGAAGATCCACAAGCGAAATTCTGTGCGTCTGG-
3’ 
barr1-flrev 5’-P-ATAAGAATGCGGCCGCTCATCTGTTGTTGAGCTGTGGA 
GAGCCGG-3’  
barr1R169Erev 5’-P-CCTCTCTGGGGCATACTGAACCTTCTCGATGACCAGAC 
GC-3’ 
barr1R169Efor 5’-P-GCGTCTGGTCATCGAGAAGGTTCAGTATGCCCCAGAGA 
GG-3’ Material & Methods 
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barr1-382rev   5’-ATAAGAATGCGGCCGCTCATGTGTCAAGTTCTATGAGATT 
GG-3’ 
barr1-393 5'-ATAAGAATGCGGCCGCTCAAGCAAAGTCCTCAAATACAAT 
GTCG-3' 
  
barr1-origfor 5'-CATGCCATGGGCGACAAAGGGACC-3' 
barr1-origrev 5'-CCCAAGCTTTCATGTGTCAAGTTCTAT-3' 
barr1-NcoI1for 5'-P-GGAGATCTATTACCACGGAGAACCCATCAGC-3' 
barr1-NcoI1rev 5'-P-GCTGATGGGTTCTCCGTGGTAATAGATCACC-3' 
barr1-NcoI2for 5'-P-GTGCCCTGTTGCAATGGAAGAGGC-3' 
barr1-NcoI2rev 5'-P-GCCTCTTCCATTGCAACAGGGCAC-3' 
  
  
barr2for 5'-ATCCGGAATTCGATGAGAACCTGTACTTCCAGGGCATGGG 
GGAGAAACCCGGGACCAGG-3' 
barr2-382rev 5'-ATAAGAATGCGGCCGCTCAGGTATCAAATTCAATGAGGTT 
GG-3' 
barr2-393rev 5'-ATAAGAATGCGGCCGCTCAGGCAAAGTCCTCAAACACAAT 
GTCATCATCTGTGGC-3' 
barr2-flrev 5'-ATAAGAATGCGGCCGCTGAGCTAGCGCCTGAACCTCCGGA 
GC-3' 
  
  
NAR1for 5’-TCACGGGGATC  CCAATCGGCACC-3’ 
NAR1-BamHIrev   5’-P-GGGAGCCAGAAGATGCGGAGCCGCACAACCAC GCTGG-
3’ 
NAR1-BamHIfor   5’-P-CCAGCGTGGTTGTGCGGCTCCGCATCTTCTGG CTCC-3’ 
NAR1rev 5’-CCGGTGCCGCCGCCGAATTC-3’ 
  
  
pPIC9Kfor 5’-GGTGGGAGATCTAAACGATGAGATTTCCTTCAATTTTTAC 
TG-3’ 
pPIC9KOLrev 5’-P-CCCTGAAAATAAAGATTCTCTCTAGCACCCAACCAAGCT 
TCAACATCTCTTTTCTCGAGAGATACCCC-3’ Material & Methods 
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pPIC9KOLfor 5’-P-GTGCTAGAGAGAATCTTTATTTTCAGGGCGGATCCGAGG 
CTGAAGCTTACGT AGAATTCC-3’ 
pIC9Krev 5’-CACGGTGCCTGACTGCGTTAGC-3’ 
  
stab-for   5’-GGGTGGGAATTCGAGAATCTTTATTTTCAGGGCGGCGGCG 
GCACCGGCGGC-3’ 
AOX1rev 5’-GGCAAAT  GGCATTCTGACATCC-3’ 
  
  
GSTfor 5’-ATCGCGGATCCGCCATGTCCCCTATACTAGGTTATTGGAAA 
ATTAAGGGCC-3’ 
GSTrev 5’-ATGCGGAATTCCGGATTTTGGAGGATG  GTCGCCACCACC-3’
  
  
MCSfor 5'-P-CTAGCCGCGGGATCCCGCGGAATTCCGAAATATGCGGCC 
GCTATAAACCCA-3' 
MCSrev 5'-P-AGCTTGGGTTTATAGCGGCCGCATATTTCGGAATTCCGCG 
GGATCCCGCGG-3' 
  
  
GFPfor 5'-ATCCGGAATTCATGGTGAGCAAGGGCGAGGAGC-3' 
GFPrev 5'-ATCCGGAATTCGATGAGAAACTGTACTTCCAGGGCATGGG 
GGAGAAACCCGGGACCAGG-3' 
  
  
CFPfor 5'-GTGTGTGGATCCTCTGGAATGGTGAGCAAGGGCGAGGAGC-
3' 
CFPrev 5'-GTGTGAATTCCTTGTACAGCTCGATCCATGCCG-3' 
 
 
2.1.12.2  Sequencing 
pTrcHISfor 5'-GAGGTATATATTAATGTATCGATTAAATAAGGAGG-3' 
pTrcHISrev 5'-GGCTGAAAATCTTCTCTCATCCGC-3' Material & Methods 
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AOX1for 5'-GACTGGTTCCAATTGACAAGC-3' 
AOX1rev 5’-GGCAAAT  GGCATTCTGACATCC-3’ 
alpha for  5'-CTACTATTGCCAGCATTGCTGCT-3' 
  
T7 prom  5'-TAATACGACTCACTATAGG-3' 
T7 term  5'-TAGTTATTGCTCAGCGGTGG-3' 
  
pGEX 5'  5'-GGCCTTTGCAGGGCTGGCAAGCCACGTTTGGTG-3'  
pGEX 3'  5'-CCTCTGACACATGCAGCTCCCGG-3'  
  
BGH seq  5'-TAGAAGGCACAGTCGAGG-3' 
 
 
2.1.13 Strains 
2.1.13.1  E. coli 
•  Mach1
™-T1
R  
F
- 
φ80(lacZ)ΔM15 ΔlacX74 hsdR(r
K
-
m
K
+
) ΔrecA1398 endA1 tonA  
Invitrogen, Karlsruhe, Germany 
•  BL21(DE3)pLysS 
F–, ompT, hsdSB (rB–, mB–), dcm, gal, λ(DE3), pLysS, Cm
r 
Promega GmbH, Mannheim, Germany 
•  BL21 Codon Plus®(DE3)-RIPL 
E. coli B F– ompT hsdS(rB– mB –) dcm+ Tetr gal λ(DE3) endA Hte [argU proL 
Camr] [argU ileY leuW Strep/Specr] 
Stratagene Europe, Amsterdam, The Netherlands 
•  Rosetta(DE3) 
F – ompT hsdSB(rB– mB–) gal dcm (DE3) pRARE6 (CamR) 
Merck Biosciences, Darmstadt, Germany 
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2.1.13.2  P. pastoris 
•  SMD1163 
Mut+, His-, protease deficient (his4, pep4, prb) 
From Invitrogen GmbH, Karlsruhe, Germany 
 
2.1.13.3  Mammalian Cells 
•  BHK cells 
European Collection of Cell Cultures, UK 
 
•  HEK-293 cells 
Sanofi-Aventis Deutschland GmbH, Frankfurt a. M., Germany 
 
2.1.14 Media 
2.1.14.1  Stock Solutions 
Biotin (500x)  0.02 % biotin 
Filter sterilize 
store at room temperature, shelf life approx. one year 
 
G418  50 mg/ml 
filter sterilize 
store at -20 °C 
 
Glucose (10x) 20 % 
Glucose 200  g/l 
filter sterilize 
store at room temperature, shelf life approx. one year 
 
Glycerol (10x)  10 % (v/v) 
autoclave 
store at room temperature, shelf life approx. one year 
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M9 salts (10x ) 
Na2HPO4 60  g/l 
KH2PO4 30  g/l 
NaCl 5  g/l 
NH4Cl 10  g/l 
autoclave 
store at room temperature, shelf life is greater than one year 
 
[
15N]-M9 salts (10x ) 
Na2HPO4 60  g/l 
KH2PO4 30  g 
NaCl 5  g/l 
[
15N]-NH4Cl 10  g/l 
autoclave 
store at room temperature, shelf life is greater than one year 
 
Potassium phosphate buffer (10x) 
K2HPO4 23.0  g/l 
KH2PO4 118.1  g/l 
adjust pH to 6.0 with phosphoric acid or KOH 
autoclave 
store at room temperature, shelf life is greater than one year 
 
TB salts (10x) 
KH2PO4  2.31 g/100 ml 
K2HPO4  12.54 g/100 ml 
autoclave 
store at room temperature, shelf life is greater than one year 
 
Yeast Nitrogen Base (YNB) (10x) 
YNB w/o amino acids, with ammonium-sulfate  34 g/l 
NH4SO4  100 g/l 
filter sterilize 
store at room temperature, shelf life is approx. one year Material & Methods 
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[
15N]-Yeast Nitrogen Base (YNB) (10x) 
YNB w/o amino acids, w/o ammonium-sulfate  134 g/l 
[
15N]-NH4SO4  100 g/l 
filter sterilize 
store at room temperature, shelf life is approx. one year 
 
2.1.14.2  E. coli 
LB Media 
Bacto tryptone  10 g/l 
Bacto yeast extract  5 g/l 
NaCl 10  g/l 
Bacto agar (for plates)  15 g/l 
 
TB Media 
Bacto tryptone  12 g/l 
Bacto yeast extract  24 g/l 
Glycerol 4  ml/l 
10x TB salts  100 ml/l 
 
M9 Minimal Media 
ddH2O 879  ml/l 
autoclave, cool down and add: 
10x M9 salts (autoclaved)  100 ml/l 
MgSO4 (1M) (autoclaved)  1 ml/l 
CaCl2 (100mM) (autoclaved)  10 ml/l 
Glucose Solution (20%) (filter sterilized)  10 ml/l 
 
2.1.14.3  P. pastoris 
BMGY 
Peptone 20  g/l 
Bacto yeast extract  10 g/l 
ddH2O 700  ml/l Material & Methods 
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autoclave, cool down and add: 
Potassium phosphate buffer (10x)  100 ml/l 
YNB (10x)  100 ml/l 
Glycerol (10x)  100 ml/l 
Biotin (500x)  2 ml/l 
store at room temperature, the shelf life is approx. two month 
 
BMMY 
Peptone 20  g/l 
Bacto yeast extract  10 g/l 
ddH2O 800  ml/l 
autoclave, cool down and add: 
Potassium phosphate buffer (10x)  100 ml/l 
YNB (10x)  100 ml/l 
Methanol 5  ml/l 
Biotin (500x)  2 ml/l 
store at room temperature, the shelf life is approx. two month 
 
BMG 
ddH2O 700  ml/l 
autoclave, cool down and add: 
Potassium phosphate buffer (10x)  100 ml/l 
YNB (10x)  100 ml/l 
Glycerol (10x)  100 ml/l 
Biotin (500x)  2 ml/l 
store at room temperature, the shelf life is approx. two month 
 
BMM 
ddH2O 800  ml/l 
autoclave, cool down and add: 
Potassium phosphate buffer (10x)  100 ml/l 
YNB (10x)  100 ml/l 
Methanol 5  ml/l 
Biotin (500x)  2 ml/l Material & Methods 
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store at room temperature, the shelf life is approx. two month 
 
MD plates 
Bacto agar  15 g/l 
ddH2O 800  ml/l 
autoclave, cool down and add: 
Glucose (10x)  100 ml/l 
YNB (10x)  100 ml/l 
Biotin (500x)  2 ml/l 
store at 4 °C, the shelf life is several month 
 
YPD 
Peptone 20  g/l 
Bacto yeast extract  10 g/l 
Bacto agar (optional, for plates)  20 g/l 
ddH2O 900  ml/l 
autoclave, cool down and add: 
Glucose (10x)  100 ml 
G418 (optional, for G418 plates) appropriate  conc. 
store at 4 °C, the shelf life is at least six month 
 
2.1.14.4  Mammalian Cell Culture 
Dulbecco’s Modified Eagle’s Medium (DMEM) w/o L-Glutamine  Cell Concepts, 
Umkirchen Germany 
Iscove’s Media  Cell Concepts, 
Umkirchen Germany 
Fetal Calf Serum (FCS)  GibcoBRL, Life 
Technologies 
GmbH, Karlsruhe 
PBS Cell  Concepts, 
Umkirchen Germany Material & Methods 
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L-Glutamine GibcoBRL,  Life 
Technologies 
GmbH, Karlsruhe 
Ham’s F-12 Media  PAA Laboratories, 
Pasching, Austria 
 
2.1.15  General Apparatus General 
Desintegrator-C Bernd  Euler, Frankfurt a. M., Germany 
Electrophoresis System Xcell SureLock with 1 
mm cassettes 
Invitrogen, Carlsbad, CA, USA 
Electroporation Device Gene Pulser  Bio-Rad, Munich, Germany 
Scintillation Counter TRI-CARB 1500  Camberra-Packard, Frankfurt a. M., Germany  
Wallac Micro Beta TriLux  PerkinElmer LAS (Germany) GmbH, 
Rodgau-Jügesheim, Germany 
Brandel Harvester  Adi Hassel, Munich, Germany 
MicroBeta Filtermate-96 Harvester  PerkinElmer LAS (Germany) GmbH, 
Rodgau-Jügesheim, Germany 
Shakers  Infors AG, Bottmingen, Switzerland 
Spectrophotometer  Thermo Spectronic, Cambridge, UK 
Microplate Reader Power Wave  Bio-Tek Instruments GmbH, Bad Friedrichshall, 
Germany 
OMNIFLEX MALDI TOF MS  Bruker Daltonik GmbH, Bremen, Germany 
DRX 600 Spectrometer  Bruker BioSpin GmbH, Rheinstetten, Germany 
EM 208 Electron Microscope  FEI Company, Hillsboro, OR, USA 
Molecular Imager Gel Doc XR  Invitrogen, Carlsbad, CA, USA 
 
2.1.15.1  Centrifuges 
Sorvall RC-5B  Du Pont de Nemours GmbH, Bad Homburg, 
Germany 
Avanti J-20 XPI  Beckman-Coulter, Fullerton, CA, USA 
Optima LE-80K ultracentrifuge  Beckman-Coulter, Fullerton, CA, USA 
Optima MAX ultracentrifuge (tabletop)  Beckman-Coulter, Fullerton, CA, USA Material & Methods 
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Sigma 3K 12 (tabletop)  Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany 
Centrifuge 5415D  Eppendorf GmbH, Hamburg, Germany 
 
2.2 Methods 
2.2.1 Genetic Engineering 
2.2.1.1 E. coli Cell Growth 
E. coli cells of the strain Mach1 were grown at 37 °C at 250 rpm shaking in LB media over 
night for the amplification of desired plasmids or preparation of glycerol stocks. Ampicillin 
was added at a concentration of 100 mg/ml for plasmid maintenance. Glycerol stocks were 
prepared by adding 15 % of sterile Glycerol, flash frozen in liquid nitrogen and stored at -80 
°C for later use. For plasmid preparation cells were harvested by centrifugation at 5000 g, 10 
min, at 4 °C and handled as described in plasmid preparation (2.2.1.4). 
 
2.2.1.2 Competent Cell Preparation 
Competent cells were essentially prepared according to Hanahan [63]. 50 ml LB media were 
inocculated with 100 µl of an over night culture, and grown at 37 °C, 240 rpm shaking until 
they reached an optical density OD600 = 0.5. The culture was chilled on ice for 10 min, and 
then harvested by centrifugation for 10 min, 2000 g at 0 °C. The pellet was carefully 
resuspended in 1ml ice cold TFB-I, and another 6.5 ml TFB-I were added, and mixed by 
gentle invertation. Cells were then incubated on ice for one hour, and pelleted by 
centrifugation for 10 min at 3000 g and 0 °C. The cell pellet was resuspended in 2 ml ice cold 
TFB-II. 100 µl aliquots were then prepared on ice, snap frozen in liquid nitrogen and stored at 
-80 °C for further use. 
 
2.2.1.3 E. coli Transformation 
Transformation of all E. coli strains was done essentially according to a protocol by Hannahan 
[63]. An aliquot of competent cells was thawed on ice, and 0.2 µg plasmid DNA, or 10 µl of 
the ligation reaction were added, swirled and incubated on ice for 30 min. The reaction was 
then heat-shocked for 45 seconds at 42 °C and chilled on ice for 2 min. After addition of 600 Material & Methods 
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µl plain LB media cells were allowed to recover and grow for 60 min at 37 °C with vigorous 
shaking. The transformation reaction was then pelleted at 2000 rpm on a tabletop microfuge 
and excess media discarded. The cell pellet was resuspended in 100 µl LB media and plated 
onto LB-agar plates containing the appropriate antibiotic (ampicillin 100 µg/ml, kanamycin 
25 mg/ml). Transformed colonies were selected the following day after incubation over night 
at 37 °C. 
 
2.2.1.4 Plasmid Preparation 
E. coli Mach1 cells were grown and harvested as described above (E. coli cell growth). The 
cell pellets were processed essentially as described in the Qiagen plasmid miniprep kit 
manual. DNA concentration was measured at UV absorption of 260 nm. Plasmid DNA was 
stored at -20 °C for further use. 
 
2.2.1.5 PCR 
PCR reactions typically had a volume of 50 µl. For amplification of sequences from plasmid 
DNA typically 0.05 µg were used as template, for reamplification of previously obtained PCR 
products 1 µl of the purified amplificated was used as template. 0.3 µM of forward and 
reverse primers were added, 5µl of the supplied 10x reaction buffer, containing dNTPs (2 
µM) and MgCl2 (1.5 mM) and 50 units of AccuPrime DNA polymerase. The reaction was 
started by a heat denaturing step to activate the enzyme for 2 min at 94 °C. The melting 
reaction was carried out according to the manufacturer’s recommendations at 94 °C for 30 s. 
The annealing step lasted 30 s and the temperature was calculated on the basis of the pairing 
primer sequence according to equation 
 
 T m = 81.5 + 0.41(% GC) - 675/N - % mismatch 
 
  N = length of the pairing sequence of the primer 
  % GC = the content of G and C nucleotides in the pairing sequence 
  % mismatch = the content of mismatching nucleotides. 
 
Temperature for the extension step was 68 °C according to the manufacturer suggestions and 
the time was calculated according to the length of the amplificate and the enzymes 
processivity (1 kb/min). In general between 16 and 25 cycles were used. Material & Methods 
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All PCR products were purified using the Qiagen PCR purification kit according to the 
protocol supplied. 
 
2.2.1.6 Restriction Digest 
All restriction endonucleases used in this work are of type 2, leaving cohesive overlapping 
ends at one strand. Restriction digestions were always carried out according to the 
manufacturer’s guidelines and performed in the supplied buffers at recommended 
temperatures. Plasmids that were opened by restriction digest for insert uptake were 
additionally treated with 5 Units/100 pmol termini calf intestine alkaline phosphatase (CIAP) 
to remove 5’ phosphates and minimize relegation. The reaction was performed in the 
restriction buffer for 30 min at 37 °C. All restriction digest reactions were purified using the 
Qiagen PCR purification kit. 
 
2.2.1.7 Ligation 
Stoichiometric amounts of insert and vector DNA, according to agarose gel electrophoresis 
were mixed in a volume of 10 µl. 10 µl of 2x Ligation buffer were added and 0.5 µl Quick 
Ligase. The reaction was mixed thoroughly and incubated at room temperature for 20 min, 
chilled on ice for 5 min and mixed with competent cells as described in E. coli transformation. 
 
2.2.1.8 Preparation of β-arrestin 1 Sequence for Cloning 
To remove intrinsic BamHI and EcoRI sites from the coding sequence of β-arrestin 1, a set of 
PCR overlap extensions was carried out. Three reactions with primers pairs barr1for and 
barr1-BamHIrev, barr1-BamHIfor and barr1-EcoRIrev, barr1-EcoRIfor and barr1-flrev, 
respectively were performed, and all three fragments were gel excised and purified with the 
Qiagen Gel Excision Kit, and subsequently used as templates in a new PCR reaction using 
primers barr1-for and barr1-flrev. The resulting fragment of 1291 bp was used as template for 
further cloning and amplification procedures of β-Arrestin 1. 
 
2.2.1.9 Introduction of the Activating Mutation R169E 
The amino acid arginine169 in β-arrestin 1 was substituted by a glutamate in a PCR overlap 
extension reaction. A 5’-fragment and a 3’ fragment were amplified by PCR, using primer Material & Methods 
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pairs barr1for and barr1R169Erev, and barr1R169Efor and barr1flrev, respectively. Both 
fragments were gel excised, and purified by the Qiagen gel extraction kit. Both purified 
fragments were then used as templates for another PCR reaction, using primers barr1for and 
barr1flrev, resulting in a fragment of ~1300 bp termed β-arrestin 1R169E. 
 
2.2.1.10  Removal of the Intrinsic BamHI Site from HM74A 
To facilitate cloning of the coding sequence of HM74A/GPR109B it was required to remove 
the intrinsic BamHI site from the sequence. Two fragments were amplified by PCR using 
AccuPrime, a 5’-fragment of 738 bp with the primer combination NAR1for and NAR1-
BamHIrev. A 3’-fragment with the primers NAR1-BamHIfor and NAR1rev that produced a 
fragment of 445 bp length. The two PCR fragments were gel excised and purified by the 
Qiagen gel extraction kit. These two fragments and the primers NAR1for and NAR1rev 
amplified the entire coding sequence in another PCR reaction. These primers introduced 
additionally desired restriction enzyme sites for directed cloning and affinity tags or the 
coding sequence for protease cleavage sites. 
 
2.2.1.11  Cloning of HM74A 
2.2.1.11.1  Construction of pPIC9K Derivatives 
For NAR1 expression in P. pastoris a different affinity tag, the nano9-tag, was employed that 
is used as affinity handle in conjunction with a Streptavidin matrix. In a first step the BamH1 
site that exists in the unmodified pPIC9K vector at position 938 was disrupted. The sequence 
between the BglII site up to the MCS was amplified by PCR, using a forward primer 
pPIC9Kfor and a reverse primer pPIC9KOLrev. This primer introduced the coding sequence 
for the nano9-tag and a TEV recognition site. In a second reaction the sequence from the 
MCS of the pPIC9K fhT-Tbio was amplified with a forward primer pPIC9KOLfor and a 
reverse primer pPIC9Krev. Both fragments were gel excised and purified with the Qiagen gel 
extraction kit. In a new PCR reaction both fragments were used as templates with primers 
pPIC9Kfor and pPIC9Krev, producing a fragment of 739 bp. This fragment was purified with 
the Qiagen PCR purification kit, digested with BglII and NotI and ligated into the pPIC9K 
vector previously treated with BamHI, NotI and CIAP. Ligation of compatible BamHI sticky 
ends to BglII sticky ends disrupts the BamHI site. Ligation was done with the Quick Ligase 
and transformed into E. coli Mach-1 cells. Transformed clones were grown according to Material & Methods 
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instructions given in the manual of Qiagen miniprep kit, DNA isolated and analyzed by 
restriction digest. Positive clones were verified by DNA sequencing. The resulting vector was 
called pPIC9KnT. 
In a second step the different C-terminal fusion sequences, Stab-tag, β-arrestin 1-382 
and β-arrestin 1-fl were amplified by PCR using the primers stab-for and AOX1rev for the 
stab-tag, barr1-for and barr1-382rev for the truncated β-arrestin 1, and primers barr1-for and 
barr1-flrev for the full length construct of β-arrestin 1. The resulting fragments were then 
digested by EcoRI and NotI restriction endonucleases and cloned into the likewise treated 
vector pPIC9KnT, additionally treated with CIAP. The prepared vector and amplificate were 
mixed, ligated using Quick Ligase, and transformed into competent E. coli Mach-1 cells 
(Stratagene). DNA of colonies growing on LB-ampicillin plates was purified using the Qiagen 
miniprep kit and analyzed by restriction digest and the desired DNA sequence of positive 
clones was verified by DNA sequencing, producing vectors pPIC9KnT-Tstab, pPIC9KnT-
Tβarr1-382 and pPIC9KnT-Tbarr1-fl. 
 
2.2.1.11.2  Cloning into P. pastoris Vectors 
The modified coding sequence of HM74A was then digested by restriction endonucleases 
BamHI and EcoRI and cloned into the likewise prepared vectors that additionally were treated 
with CIAP. The prepared vectors and amplificate were mixed, ligated using Quick Ligase 
(NEB) and transformed into competent E. coli Mach-1 cells (Stratagene). DNA of colonies 
growing on LB-ampicillin plates was purified using the Qiagen miniprep kit and analyzed by 
restriction digest and the desired DNA sequence was verified by DNA sequencing. 
 
2.2.1.12  Cloning of β-Arrestins 
2.2.1.12.1  pPIC3.5K GST-β-Arrestin 
The DNA coding for the Glutathione-S-Transferase was amplified from a pGEX vector by a 
PCR reaction using primers GSTfor and GSTrev. The amplificate was purified by the Qiagen 
PCR purification kit and digested with BamHI and EcoRI. The pPIC3.5K vector was likewise 
digested and treated with CIAP. Both, vector and amplificate, were purified with the Qiagen 
PCR purification kit, ligated and transformed into E. coli Mach-1 cells. The resulting vector, 
pPIC3.5KGST, was analyzed by restriction digest and positive clones were verified by DNA 
sequencing. Material & Methods 
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The β-arrestin sequences were amplified by PCR using primer and template combinations as 
depicted in table 1, and cloned into EcoRI and NotI sites of the vector pPIC3.5KGST. Positive 
clones were analyzed by restriction digest, and the correct sequence was verified by DNA 
sequencing. 
 
  forward primer  reverse primer  template 
β-arrestin 1-382  barr1-382rev  β-arrestin 1 
β-arrestin 1-393 R169E  barr1-39rev3  β-arrestin 1R169E 
β-arrestin 1-fl 
barr1for 
barr1-flrev  β-arrestin 1 
β-arrestin 2-382  barr2-382rev 
β-arrestin 2-393  barr2-393rev 
β-arrestin 2-fl 
barr2for 
barr2-flrev 
β-arrestin 2 
 
Table 1: Templates and primer used for the amplification of various β-arrestin constructs 
 
2.2.1.12.2  pET HIS-β-Arrestin 
The pET His vector was a kind gift from Dr. K. Saxena, University Frankfurt, and contained a 
hexahistidine-tag. The vector was opened with EcoRI and NotI, and dephosphorylated by 
CIAP. The β-arrestin cDNAs were amplified according to table 1, and the resulting fragments 
were cloned via EcoRI and NotI sites into the pET His vector, and transformed into Mach-1 
E. coli competent cells. Clones were analyzed by restriction digest and positive ones were 
further analyzed by DNA sequencing. 
 
2.2.1.12.3  pGEX β-Arrestin 
Cloning of β-arrestin constructs into the pGEX vector was done essentially as described 
above for the pET vector. 
 
2.2.1.12.4  pTrc β-Arrestin 1-382 
Cloning of β-arrestin 1-382 was done essentially as described [64]. To facilitate cloning as 
described, two NcoI sites in the original sequence of β-arrestin 1 had to be removed. 
Therefore three PCR reactions were carried out, the first using primers barr1-origfor and 
barr1-NcoI1rev, the second using the primer pair barr1-NcoI1for and barr1-NcoI2rev, and the Material & Methods 
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third the primer pair barr1-NcoI2for and barr1-origrev. All three fragments were gel excised 
and used altogether as template for a new PCR, using primers barr1-origfor and barr1-origrev, 
resulting in a β-arrestin 1 sequence without NcoI restriction sites. This β-arrestin 1-382 
sequence was cloned into the pTrcHisB between NcoI and HindIII sites, thus eliminating the 
his-tag. Positive clones were analyzed by restriction digest, and clones containing the 
appropriate DNA fragment were verified by DNA sequencing. 
 
2.2.1.12.5  pcDNA3.1 
The pcDNA3.1 vector was a kind gift from Dr. S. Marino. The old multiple cloning site was 
excised by NheI and HindIII restriction, and thoroughly dephosphorylated. A new multiple 
cloning site was produced by annealing primers MCSfor and MCSrev, that contained 
restriction sites BamHI, EcoRI and NotI in the desired orientation, and ligated into the vector, 
now termed pcDNA3.1J. The resulting clones were analyzed by restriction digest and positive 
clones were verified by DNA sequencing. 
In the following eGFP was amplified by PCR using primers GFPfor and GFPrev, and cloned 
between EcoRI and NotI restriction sites of pcDNA3.1J. Positive clones were analyzed by 
restriction digest and DNA sequencing. In the following the sequence of NAR1 was amplified 
using primers NAR1for and NAR1rev, and ligated into BamHI and EcoRI restriction sites, 
creating a fusion of NAR1 and eGFP. 
Likewise eCFP was amplified by PCR using primers CFPfor and CFPrev, and ligated 
between BamHI and EcoRI sites of pcDNA3.1J. Clones were analyzed by restriction digest 
and positive ones verified by DNA sequencing. In a second step the various sequences of β-
arrestin 1 were cloned between EcoRI and NotI sites. Therefore β-arrestin 1 was amplified 
using primers pairs as listed in table 1, digested with EcoRI and NotI and ligated into the 
pcDNA3.1J vector previously equipped with eCFP. Positive clones were analyzed by 
restriction digest and verified by DNA sequencing. 
 
2.2.2 Transformation of P. pastoris 
2.2.2.1 Preparation of Competent Cells 
P. pastoris cells of the strain SMD1163 were grown in YPD media till they reached an optical 
density of ~1.5. Cells were pelleted by centrifugation, 5 min, 2000 g at 4 °C. The pellet was 
resuspended in 1 culture volume of ice cold sterile H2O, and pelleted again as described Material & Methods 
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above. The supernatant was discarded, and cells were then resuspended in 2/50 volume of the 
original culture volume ice cold sterile 1 M sorbitol, and pelleted again. In a final step cells 
were resuspended 1/500 ice cold sterile 1 M sorbitol.  
 
2.2.2.2 Electroporation 
80 µl of the competent cells were mixed with 10 µg linearized vector DNA in an 
elctroporation cuvette, 0.2 mm gap, and incubated on ice for 5 min. The vector DNA was 
electroporated into the cells with the Gene Pulser, which was set to 1500 V, 25 µF and 600 Ω. 
The cells were removed from the cuvette with 1 ml ice cold, sterile 1 M sorbitol, spread onto 
3 MD plates and incubated for 3 days at 30 °C. 
 
2.2.2.3 Selection of Positive Transformands 
The selection of transformands was performed on MD agar plates. This is possible due to the 
fact that the strain is deficient in histidine biosynthesis, and therefore only the ones that 
incorporated the plasmid DNA that provides the gene encoding for histidinol dehydrogenase 
can grow on this media. 
 
2.2.2.4 Multi-copy Clone Selection 
2.2.2.4.1 G418 Screen 
The standard procedure suggested by the manufacturer for selection of multi-copy clones is 
screening of increased antibiotic resistance of the transformands. A high integration number 
results in a high gene dosage of the Kanamycin resistance gene from Tn903, that confers 
tolerance to higher G418 (Geneticin) concentrations. Out of all transformands 96 were 
selected and transferred each into 200 µl YPD media in a sterile 96 well plate and grown for 
two days at 30 °C. Cultures were resuspended and 20 µl aliquots were transferred into a new 
96 well plate containing 180 µl YPD media to ensure similar cell densities. Cultures were 
then stamped onto YPD plates containing 0.05, 0.075, 0.1, 0.2, 0.3, 0.5 and 1.0 mg/ml 
Geneticin®. First Geneticin® resistant colonies appeared after 3-5 days at 30 °C. 
 
2.2.2.4.2 Direct-Expression Colony-Blot Material & Methods 
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This method was essentially done as described by Böttner et al. [65] with slight modifications. 
For the purpose of the direct-expression colony-blot cells from each of the 96 cultures were 
spotted onto a nitrocellulose membrane covered BMGY agar plates and grown at 30 °C until 
they all reached approximately the same size. These nitrocellulose membranes were then 
transferred onto inducing BMMY agar plates, grown at 30 °C and harvested after 48 and 72 
hours. The membranes were placed on three layers of Whatman paper soaked in 100 mM 
Tris/HCl pH 8.5, 20 mM EDTA, 9 M urea, 2 % SDS and 150 mM β-mercaptoethanol and 
incubated for 3 h at 65 °C. The remaining cells were washed off the membranes, which were 
then treated like Western Blots. 
 
 
2.2.3 Protein Expression 
2.2.3.1 E. coli Expression Culture Growth 
2.2.3.1.1 Small Scale Expression Test 
5 ml pre-cultures were grown over night in the desired media at 37 °C, 250 rpm. Cell density 
was measured at OD600 and 25 ml of the same media were inoculated to an optical density of 
0.05. Cells were then grown at 30 °C until they reached an OD600 of 0.5 and protein 
expression was induced by the addition of IPTG to a final concentration of 1 mM. Cultures 
were grown for the indicated time at the indicated temperature, and then harvested by 
centrifugation for 10 min at 16000 g and 4 °C. Cell pellets were resuspended in 4x SDS-
PAGE loading buffer, boiled at 95 °C for 5 min and analyzed by SDS-PAGE. 
 
2.2.3.1.2 Large Scale Culture Growth 
500-1000 ml culture was grown in LB media containing the appropriate antibiotic over night 
at 37 °C, 250 rpm shaking. The Pre-Culture was used to inoculate 6-12 l LB media containing 
the appropriate antibiotic to a cell density of OD600 of 0.05. Cells were then grown at 30 °C 
and 170 rpm shaking in baffled flasks until cell density reached an OD600 of 0.5. Cells were 
induced by the addition of IPTG to a final concentration of 1 mM, and grown four additional 
hours, harvested by centrifugation 10 min, 10000 g at 4 °C. Cell pellets from 1 l culture were 
resuspended in 10 ml Lysis Buffer. 
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2.2.3.1.3 Metabolic Labeling with [
15N] 
100-200 ml of E. coli pre-culture from a freshly streaked plate were grown in LB, containing 
100 µg/ml Ampicillin at 37 °C at 250 rpm shaking over night. The pre-culture was used to 
inoculate a second preculture of 2 l [
15N]-M9 minimal media, containing 100 µg/ml 
ampicillin, and was grown overnight at 30 °C and 170 rpm shaking in a 5 l baffled flask. The 
second pre-culture was used to inoculate 12 l [
15N]-M9 minimal media, containing 100 µg/ml 
ampicillin, in six 5 l baffled flasks to an OD600 of 0.1. Cells were then grown at 30 °C and 170 
rpm shaking until they reached an OD600 of 0.5 and were induced with IPTG at a final 
concentration of 1 mM. The culture was then transferred to 20 °C, 170 rpm and grown 
overnight. Cells were harvested by centrifugation 10 min, 10000 g at 4 °C. Cell pellets from 1 
l culture were resuspended in 10 ml Lysis Buffer. 
 
2.2.3.2 P. pastoris Expression Culture Growth 
2.2.3.2.1 Small Scale Culture Growth 
Clones were freshly streaked from a glycerol stock onto YPD plates, and grown at 30 °C for 3 
days. A chunk of these cells was used to inoculate a 5 ml pre-culture in BMGY liquid media 
grown at 30 °C and 225 rpm over night. Optical cell density was measured at 600 nm, and just 
enough cells were pelleted at 2500 g at 4 °C for 5 min to be resuspended in 25 ml BMMY 
media containing 0.5 % methanol to reach a starting OD600 of 1. The 25 ml small scale 
expression culture was grown for 24 h at 30 °C with 225 rpm. After 18 h growth additional 
methanol was added to reach again a concentration of 0.5 %. Cells were harvested by 
centrifugation 5000 g, 10 min, 4 °C, washed once with ice cold breaking buffer, and either 
snap frozen in liquid nitrogen or directly entered membrane preparation. 
 
2.2.3.2.2 Optimization of Expression Conditions 
2.2.3.2.2.1  Expression Time 
Small scale cultures were inoculated as described above. Then cultures were grown either at 
22 °C or at 30 °C, and starting after 12 h every 6 h one 25 ml culture was harvested as 
described above, membranes prepared, protein content determined and subjected to 
radioligand binding analysis and Western-blotting. 
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2.2.3.2.2.2  DMSO & Nicotinic Acid 
For the optimization of culture conditions regarding DMSO and nicotinic acid cultures were 
grown as described above, with the difference that the culture media contained 0 %, 0.5 %, 1 
%, 2 %, 3 %, 5 % or 7.5 % DMSO or 0 nM, 100 nM, 1 µM, 10 µM, 100 µM or 1 mM 
nicotinic acid. Cultures were harvested after 24 h, membranes prepared, protein content 
determined and subjected to radioligand binding analysis and Western-blotting. 
 
2.2.3.2.2.3  Large Scale Expression Culture Growth (Optimized Conditions) 
Clones were freshly streaked from a glycerol stock onto YPD plates, and grown for 3 days at 
30 °C. A chunk of these cells was used to inoculate a 5 ml pre-culture in BMGY liquid media 
grown over night at 30 °C and 225 rpm. The culture was used to inoculate 1 l BMGY media 
in a 5 l baffled flask, and grown for 24 h to 48 h at 30 °C and 225 rpm till the optical density 
OD600 reached ~6. The culture was pelleted by centrifugation at 2500 g, 5 min at 20 °C, 
resuspended in inducing BMMY media containing 2% DMSO (v/v), and used to inoculate six 
5 l baffled flasks containing 1 l BMMY with 2 % DMSO (v/v) each. Cultures were then 
grown for 24 h at 22 °C and 225 rpm. After 18 h another 5 ml methanol were added. Cells 
were harvested after 24 h by centrifugation, 5000 g, 10 min at 4 °C, resuspended in breaking 
buffer, and again centrifuged at 5000 g for 10 min at 4 °C. Cell pellets were weighed, and 
resuspended in breaking buffer to give a 50 % (w/v) cell suspension, and either membranes 
were directly prepared or the cell suspension snap frozen in liquid nitrogen and stored at -80 
°C (NAR1). 
For preparation of cytosolic fractions containing β-arrestins, no DMSO was added to the 
culture media, and cell suspension were flash frozen in liquid nitrogen and stored at -80 °C 
for later use. 
 
2.2.3.2.3 Metabolic Labeling with [
15N] 
A 1
st pre-culture of 20 ml BMGY media in a 100 ml baffled flask, containing 50 µg/ml 
kanamycin was inoculated with a chunk of P. pastoris cells from a freshly streaked MD plate 
and grown overnight at 30 °C and 225 rpm shaking. 500 µl were used to inoculate a 2
nd pre-
culture of 25 ml BMG media in a 100 ml baffled flask, containing 50 µg/ml Kanamycin and 
grown at 30 °C, 225 rpm overnight. This culture was used to inoculate a 3
rd pre- culture 200 
ml [
15N]-BMG media, containing 50 µg/ml kanamycin in a 1 l baffled flask, and was grown 
for 48 h until it reached an OD600 of 10. The cells were harvested by centrifugation, 2500 g, Material & Methods 
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10 min at room temperature and resuspended in 2 l [
15N]-BMM expression media containing 
50 µg/ml kanamycin and distributed into two 5 l baffled flasks. The expression culture was 
grown for 80 h, further addition of 5 ml methanol per liter culture every 24 h. Cells were 
harvested by centrifugation, 5000 g, 10 min at 4 °C, resuspended in breaking buffer, and 
again centrifuged at 5000 g for 10 min at 4 °C. Cell pellets were then resuspended in 20ml 
lysis buffer, flash frozen in liquid nitrogen and stored at -80 °C. 
 
2.2.4 Cytosol & Membrane Preparation 
2.2.4.1 E. coli Lysis 
1ml lysozyme (10 mg/ml) and 2 µl benzonase and PMSF to a final concentration of 1 mM 
were added to the cell suspension (per liter of culture), mixed thoroughly and incubated on ice 
for 30 min. Cells were broken by sonication on ice, six cycles 60 s on, 60 s off. Lysates were 
cleared by centrifugation at 40000 g, 20 min, at 4 °C. The supernatant was passed through a 
0.2 µM filter and used directly for purification. 
 
2.2.4.2 P. pastoris Breakage 
2.2.4.2.1 Small Scale Breakage 
For small scale membrane preparation 50 % cell suspension (w/v) of above described cultures 
was prepared by resuspending in ice cold breaking buffer with freshly added PMSF (1 mM) 
and 1 ml thereof added into a 2 ml microfuge tube that was filled with glass beads (0.5 mm 
diameter) until a distance of 1-1.5 mm from beads to the surface of the liquid is reached. 
These were vortexed for 30 s and incubated on ice for 30 s, 8 cycles. The glass bead cell 
mixture was transferred into propylene columns with a glass fiber frit, and centrifuged at 3000 
g for 1 min at 4 °C. Glass beads were washed with 1 additional ml of ice cold breaking buffer, 
and again centrifuged at 3000 g, 4 min, at 4 °C to pellet cellular debris. 
 
2.2.4.2.2 Large Scale Breakage 
Cells of the suspension prepared as described above were broken at 4 °C in the desintegrator-
C filled with 80 ml glass beads. Therefore they were passed through the machine 3-4 times, Material & Methods 
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till ~90 % of the cells were broken. The cell homogenate was centrifuged at 5000 g for 10 min 
at 4 °C to remove cellular debris, organelles and unbroken cells. 
 
2.2.4.3 Separation of Membrane & Cytosolic Fractions 
2.2.4.3.1 Small Scale 
The cellular debris was pelleted as described above and the glass beads were retained in the 
polypropylene column. The homogenate (Small Scale P. pastoris Break Up) was transferred 
to a 1.5 ml ultracentrifuge tube, and centrifuged at 100000 g for 1 h at 4 °C. The supernatant 
was used if cytosolic fractions were intended to be recovered (β-arrestins), otherwise it was 
discarded and the pelleted membranes were resuspended by pottering in 500 µl membrane 
buffer (NAR1). Cytosolic Fractions entered purification or analysis immediately, while 
membranes were either used directly or were flash frozen in liquid nitrogen and stored for 
further use at -80 °C. 
 
2.2.4.3.2 Large Scale 
The homogenate (Large Scale P. pastoris Breakage) was centrifuged at 100000 g, for 1 h at 4 
°C. If β-arrestins were to be purified, the supernatant was passed through a 0.4 µM filter and 
entered purification procedures immediately. If membranes were intended (NAR1), the 
supernatant was discarded and pellets were resuspended in ~10 ml membrane buffer per 1 g 
of membranes with a homogenizer. A sample of the membrane suspension was used for the 
determination of the protein concentration as described below (2.2.14.4), and the remainder 
was aliquoted, snap frozen in liquid nitrogen and stored at -80 °C for later use. 
 
2.2.5 Radioligand Binding Assay 
2.2.5.1 Screening Conditions 
Functionality of GPCR containing membranes is routinely tested by their capability to bind 
their cognate radio labeled ligand. Therefore 50 µg of membrane protein were incubated with 
250 µM [
3H]-nicotinic acid, in a buffer of 50 mM Tris/HCl pH 7.4, 1 mM MgCl2, and 0.02 % 
(w/v) CHAPS in a total volume of 250 µl. For non-specific binding 1 mM unlabelled nicotinic 
acid was added, and incubated at room temperature for 3.5 h. The receptor with bound ligand Material & Methods 
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was separated from the unbound ligand by filtration using a Brandel Harvester over GF/C 
glass fiber filters, previously equilibrated in Pre-Soak buffer and washed twice with 2 ml ice 
cold H2O [13]. After sample Filtration, GF/C filters were washed 4 times with 2 ml ice cold 
H2O. The remaining radioactivity on the filters was then measured by liquid scintillation 
counting after 48 h. All samples were prepared in triplicates. 
Screen II was essentially prepared as above, except that a nicotinic acid mixture composed of 
[
1H]-nicotinic acid and [
3H]-nicotinic acid in a ratio of 50:1 was used, to reduce the amount of 
costly [
3H]-nicotinic acid. This mixture was added to a final concentration of nicotinic acid of 
2 µM. The concentration of diluted radio ligand allowed binding assays at saturating 
conditions 10 times above the Kd. Further activity calculations were corrected for this 
dilutional effect by reducing the specific activity by a factor of 50. Additionally the incubation 
time was reduced to 2 h. 
 
2.2.5.2 Evaluation of Buffer Components 
250 µl binding assay samples containing 50 µg membrane protein in binding buffer were 
prepared according to screening conditions (2.2.5.1) and the desired chemical (NaCl, KCl, 
LiCl, NH4Cl) was added to a final concentration of 0 mM, 1 mM, 2 mM, 5 mM, 10 mM, 50 
mM, 100 mM and 250 mM. For DTT concentrations were 0 mM, 0.0625 mM, 0.125 mM, 0.5 
mM, 1 mM, for imidazole 0 mM, 0.25 mM, 2.5 mM, 25 mM, 100 mM and 250 mM and for 
DMSO 0 %, 0.5 %, 1 %, 2 %, 5 % and 10 %. For pH dependence of NAR1 binding different 
binding buffers were used to adjust the pH accordingly (pH 4.5: Na-acetate, pH 5.0 and pH 
5.5: Na-citrate, pH 6.0: MES, pH 6.5: ADA, pH 7.0: MOPS, pH 7.5: HEPES, pH 8.0, pH 8.5 
and pH 9.0: Tris, pH 9.5: CAPSO) but contained corresponding to the standard buffer a final 
concentration of 1 mM MgCl2 and 0.02 % CHAPS in the sample. After 3.5 h incubation 
samples were harvested as described above. For the determination of unspecific binding 1 
mM of [
1H]-nicotinic acid was added. All experiments were performed in triplicates.  
 
2.2.5.3 Evaluation of Detergent Effects 
To evaluate the effect of detergent on the radio ligand binding assay, detergent stock solutions 
were prepared according to table 2, and added to the binding assay in concentrations of 0.1 
times cmc, at 1 time cmc and 10 times cmc. Samples were prepared in triplicates, and non 
specific binding was determined as described above (screening conditions, 2.2.5.1). Material & Methods 
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For the detergent mixtures DM+CHS, LM+CHS and Cymal-6+CHS detergent inhibition 
curves were recorded. Therefore detergent was added from 0.00005 % to 1%, covering at 
least ranges from 1/500 cmc (LM+CHS) to 10 times cmc (DM+CHS). Samples were then 
processed as described above. 
 
2.2.5.4 Binding Kinetics: NAR1 On- & Off-Rate 
To determine the on-rate of nicotinic acid, samples were prepared as described under 
screening conditions (2.2.5.1), and harvested after 30 min, 60 min, 120 min and 210 min. For 
the determination of background binding samples were prepared that contained 1 mM [
1H]-
nicotinic acid and were harvested at the same indicated time points. Harvesting and counting 
was done as described above. All measurements were performed in triplicates. 
For the determination of the off-rate of nicotinic acid binding to NAR1 samples were 
prepared as described above (2.2.5.1), after 3.5 h a pulse of 1 mM [
1H]-nicotinic acid was 
added, and samples were harvested 1 min, 2 min, 5 min, 10 min, 20 min, 30 min, 45 min and 
60 min thereupon. Control samples did not contain the pulse and were harvested at the same 
indicated intervals. 
 
2.2.5.5 Saturation Binding Curves 
Determination of the total amount of receptor present in a given membrane preparation can 
only be determined inaccurately by a single point measurement. The method of choice for 
calculating the total amount of receptor is the recording of binding curves, and fitting of the 
data to the model receptor ligand association according to Cheng & Prussof [66]. In an 
experiment the unoccupied receptor and the free ligand are in equilibrium with the receptor 
ligand complex. It is described by the equation  
 
R + L Ù RL     (equation 1) 
 
The equilibrium constants are given by the following equations 
 
R + L    k+1Æ     RL;        RL   k-1Æ     R + L 
 
Ka = [RL]/[R][L] = k+1/k-1 = 1/Kd  (equation 2) 
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The specific binding between the ligand and receptor is saturable, and the more ligand is 
added to a fixed amount of receptor, an increasing amount of binding sites is occupied. The 
total number of binding sites Bmax in a given sample at equilibrium is represented by the 
number of unoccupied receptors plus the number of receptors bound to ligand. Unfortunately 
the amount of unbound receptor cannot be measured. But substituting [R] in the equation by 
Bmax-[RL] and rearrangement, we derive following equation 
 
[RL] = Bmax*[L] / Kd+[L] (equation  3). 
 
The plotted data, [RL] vs. [L] can then be fitted by non-linear regression using equation 3. 
The program used for non-linear regression fitting was KaleidaGraph. 
 
For this procedure 50 µg of membrane protein were mixed in binding buffer with a nicotinic 
acid mixture composed of [
1H]-nicotinic acid and [
3H]-nicotinic acid in a ratio of 50:1, to 
reduce the amount of costly [
3H]-nicotinic acid. The total nicotinic acid concentrations were 2 
µM, 1 µM, 0.5 µM, 0.25 µM, 0.125 µM, 0.0625 µM, 0.03125 µM and 0.01625 µM, and 
unspecific binding was measured by addition of 1 mM [
1H]-nicotinic acid. Samples were 
processed as described above, and plotting of free ligand vs. bound ligand and correction for 
the 50 fold dilution of the radiolabeled ligand resulted in binding curves that were fitted to 
equation 3, and Bmax and KD values were calculated accordingly. All samples were prepared in 
triplicates. 
 
2.2.5.6 Inhibition Curves 
Inhibition curves were recorded by preparing samples that contained 25 µg of membrane 
protein in binding buffer and a concentration of [
3H]-nicotinic acid of 27 nM. Increasing 
amounts of [
1H]-nicotinic acid, Acifran or Acipimox were added at concentrations of 0 nM, 3 
pM, 10 pM, 30 pM, 0.1 nM, 0.3 nM, 1 nM, 3 nM, 10 nM, 30 nM, 0.1 µM, 0.3 µM, 1 µM, 3 
µM, 10 µM, 30 µM, 0.1 mM, 0.3 mM, 1 mM, 3 mM and 10 mM. Total sample volume was 
250 µl. All samples were produced in triplicate, incubated, harvested and measured as 
described above. 
 
The data obtained from the inhibition curve is described by the equation 
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Y = Nonspecific + (Total-Nonspecific)/1+10
log[D]-log(IC50)   (equation 4). 
 
This equation can be simplified to 
 
Y = Nonspecific + ((Total-Nonspecific)/1+[Drug]/IC50)   (equation 5) 
 
 
and according to Cheng and Prussoff [66] Ki and IC50 values can be calculated. 
 
Ki = IC50/(1+[radioligand]/Kd)   (equation 6) 
 
Assuming that in a homologous inhibition experiment, the hot and the cold ligand have the 
same affinities the Kd can be obtained from the equation 
 
Kd = Ki = IC50 – [Radioligand]   (equation 7). 
 
 
2.2.6 Solubilization 
2.2.6.1 Detergent Efficiency Test 
For solubilization membrane preparations were adjusted to a concentration of 5 mg/ml with 
buffer NPB100A and detergent:CHS (5:1) stock solutions were added to a concentration 1 % 
(w/v). Exceptions were Fos-16, that was used at a concentration of 0.1 % (w/v) and OG and 
CHAPS that were used at a concentration of 2.5 % (w/v). Solubilization samples were 
incubated for 1 h at 4°C with gentle shaking and centrifuged at 100000 g for 1 h at 4 °C to 
remove insoluble material. Supernatants were analyzed by Western-blotting, as well as 
pellets, resuspended in 4x loading buffer. 
 
 
Detergent  MW [Da]  cmc [mM]  cmc [%]  stock [%] 
β-LM  510,6 0,17 0,0086 10
α-LM  510,6 0,17 0,0076 10
NG  306,7 6,5 0,199 10Material & Methods 
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OG  292,4 20 0,58 10
UM  496,4 0,59 0,029 10
DM  482,6 1,8 0,086 10
DG  322,4 2,2 0,07 10
LS  524,6 0,3 0,015 10
FOS 12  351,5 1,5 0,052 10
FOS 14  380,5 0,12 0,0046 10
FOS 16  409,5 0,013 0,00053 1
LDAO  229,41 1,4 0,032 10
Cymal-6  508,5 0,56 0,028 10
C12E9  582,5 0,1 0,0058 10
Zwittergent 3-12  335,5 4 0,13 10
CHAPS  614,9 10 0,61 10
SDS  288,4 10 0,288 10
 
Table 2: List of Detergents used in this study and their properties, molecular weight (MW) and critical 
micellar concentration (cmc), concentration of the stock solution. 
 
2.2.6.2 Large Scale Solubilization for Purification 
Membrane preparations of large scale P. pastoris cultures in general contained membrane 
protein concentrations 20-25 mg/ml. These were diluted in the buffer NPB100A to obtain a 
membrane protein concentration of 5 mg/ml. Detergent was added to a final concentration of 
1 % and 0.2 % CHS. Solubilization mixture was incubated for 1 h at 4 °C with gentle stirring, 
and centrifuged 100000 g at 4 °C to remove insoluble material. The supernatant was passed 
through a 0.4 µM filter and used for purification. 
 
2.2.7 Protein Purification 
All protein purifications procedures were carried out in the cold room at 4 °C. 
 
2.2.7.1 β-Arrestin 1 
2.2.7.1.1 Glutathione Sepharose 4B – Batch Mode Material & Methods 
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Cleared cell lysates of GST-β-arrestin 1-382/393R169E/fl were incubated with 1 ml 
glutathione beads per liter culture at 4 °C for 1 h with gentle agitation. Beads were then 
washed with 10 bed volumes of buffer CB50, and were eluted three times with 5 ml of buffer 
CB50 containing 10 mM glutathione. Throughout the purification on Glutathione Sepharose 
4B 5 mM DTT was used as reducing agent. 
 
2.2.7.1.2 HisTrap
TMHP (IMAC) 
Cleared cell lysates of His-β-arrestin 1-382 were loaded onto a 5 ml HisTrap HP column in 
lysis buffer containing 10mM imidazole with a flow rate of 5 ml/min, using an Äkta Purifier. 
The column was then washed with lysis buffer containing 10 mM imidazole until baseline of 
UV280 nm monitor was reached. His-β-arrestin 1-382 was then eluted with a linear gradient 
of imidazole from 0 mM to 300 mM in buffer CB50 over 50 column volumes. Fractions were 
analyzed by SDS-PAGE and His-β-arrestin 1-382 containing fractions were pooled. Instead of 
DTT, the reducing agent β-mercaptoethanol was used at 5 mM throughout purifications on 
HisTrap HP material. 
 
2.2.7.1.3 TEV Cleavage (optional) 
If removal of the affinity tag (GST/His) was desired, pooled GST-β-arrestin 1-
382/393R169E/fl or His-β-arrestin1-382 were incubated with 200 µg TEV per 2 mg pooled 
elute overnight at 4 °C. 
 
2.2.7.1.4 HiTrap Heparin HP 
Purification of β-arrestins on HiTrap Heparin HP column was essentially carried out as 
described by Han et al 2001 [64]. 
Pooled elutes from Glutathione Sepharose 4B or HisTrap HP were loaded onto a 5 ml HiTrap 
Heparin HP column with a flow rate of 2 ml/min on an Äkta Purifier. The column was 
washed with buffer CB100 for 10 column volumes and eluted with a linear gradient from 400 
mM to 1000 mM NaCl over 10 column volumes at a flow rate of 1 ml/min. Fractions were 
analyzed by SDS-PAGE and β-arrestin containing fractions were pooled. 
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2.2.7.1.5 Superdex75 Gel Filtration (Preparative) 
Gel filtration was done as described by Han et al 2001 [64]. Only β-arrestin 1-382 was used, 
and tags were removed as described under TEV cleavage (2.2.7.1.3). Up to 2 ml of 
concentrated β-arrestin 1-382 were loaded onto the Superdex 75 gel filtration column that was 
previously equilibrated with 2 column volumes of buffer CB100. Fractions were analyzed by 
SDS-PAGE and β-arrestin 1-382 containing fractions were pooled and either snap frozen in 
liquid nitrogen and stored at -80 °C or immediately used for further experiments. 
 
2.2.7.2 NAR1 
2.2.7.2.1 HisTrap
TMHP (IMAC) 
Solubilized NAR1 was loaded onto a 1 ml HisTrap HP column, previously equilibrated in 
buffer NPB100A, containing 10mM imidazole with an Äkta Purifier at 1 ml/min. The column 
was then washed with buffer NPB100A until baseline of UV280 nm monitor was reached, 
washed to baseline with 15 % NPB100B buffer until baseline was reached. Additionally the 
column was washed with buffer NPB-low salt for 10 column volumes. NAR1 was eluted with 
a linear gradient 15 % to 100 % NPB100B buffer over 15 column volumes. Fractions were 
analyzed by SDS-PAGE and occasionally Western-blotting, NAR1 containing fractions were 
pooled and used for further purification. 
2.2.7.2.2 TEV Cleavage (optional) 
If NAR1 was to be cleaved off the tags, 200 µg TEV protease were added to 500 µg of 
NAR1, and digested overnight at 4 °C. 
 
2.2.7.2.3 Inverse HisTrap
TMHP 
For inverted HisTrap HP purification, NAR1 samples were pooled after HisTrap HP 
chromatography, TEV added as described above and dialyzed into buffer NPB100A overnight 
at 4 °C. The dialyzed sample was then treated as described under HisTrap HP, except the 
Flow Through was kept and a shallow linear gradient from 0 % to 15 % NPB100B buffer was 
applied and fractions were analyzed by SDS-PAGE. 
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2.2.7.2.4 Ion Exchange Chromatography: DEAE Sepharose
TMFastFlow, Q 
Sepharose
TMFastFlow, ANX Sepharose
TM4FastFlow, CM 
Sepharose
TMFastFlow, SP Sepharose
TMFastFlow 
Ion exchange chromatography separates proteins on the basis of the charge density on their 
surfaces, which differs largely according to the folding state of the protein. Unfolded proteins 
are usually in a random coil state that varies a lot and does not display a defined surface 
charge density. A good estimation of which resin a protein will bind to can be made by 
calculating the pI of the protein and deriving which charge it will have at a given pH. For 
membrane proteins on the other hand it should be considered that the transmembrane portion 
that in solution is shielded by the detergent might not contribute the relevant surface charges. 
All Ion Exchange Columns were equilibrated with buffer NPB0 for 5 column volumes. NAR1 
as obtained from IMAC (2.2.7.2.1) was diluted in ten volumes of buffer NPB0, to reduce 
ionic strength, facilitate binding to the ion exchange resin, and loaded onto the various ion 
exchange columns, 1 ml/min. The column was washed with 5 column volumes of buffer 
NPB0 and eluted with linear gradient from 0 % NPB1000 buffer to 20 % NPB1000 buffer 
over 20 column volumes, and further by a second linear gradient from 20 % NPB1000 buffer 
to 100 % NPB1000 buffer over another 20 column volumes. Fractions were analyzed by SDS-
PAGE and Western Blotting. 
 
2.2.7.2.5 HiTrap Blue HP 
The HiTrap Blue Column material was tested, which is composed of the dye Cibacron
TM Blue 
F3G-A, which structurally resembles naturally occurring co-factors NAD
+ and NADP
+, and 
allowed for the affinity purification of different enzymes that required either one. Additionally 
it has been used for the purification of a number of different proteins, and given the fact that it 
contained a nicotine amide moiety, which is closely related to nicotinic acid and might be 
used as a ligand column. 
NAR1 as obtained from IMAC (2.2.7.2.1) was diluted in ten volumes of NPB0 buffer, to 
reduce ionic strength, and loaded onto a 1ml HiTrapHP Blue column, previously equilibrated 
with 5 column volumes NPB0 buffer. The column was washed with 5 column volumes of 
NPB0 buffer and NAR1 was eluted with linear gradient from 0% NPB1000 buffer to 20 % 
NPB1000 buffer over 20 column volumes, and further by a second linear gradient from 20 % 
NPB1000 buffer to 100 % NPB1000 buffer over another 20 column volumes. Fractions were 
analyzed by SDS-PAGE and Western Blotting. Material & Methods 
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2.2.7.2.6 Immobilized Monomeric Avidin 
2 ml resin were packed into a 5 ml column (manufactured in the MPIBP workshop), and 
blocked with 50 column volumes IMA blocking buffer, and regenerated with 20 column 
volumes IMA regeneration buffer. Then the column was equilibrated with 5 column volumes 
NPB100A buffer. After IMAC (2.2.7.2.1) purification NAR1 containing fractions were 
loaded onto the immobilized monomeric avidin column, 0.2 ml/min, and washed until 
baseline of UV280 nm monitor was reached. NAR1 was eluted with NPB100A buffer 
containing 2 mM D-biotin. Upon formation of a stable baseline at UV absorbance at 280 nm, 
the column was washed with IMA regeneration buffer. All fractions were pooled and 
analyzed by SDS-PAGE. 
 
2.2.7.2.7 Superose 6 Gel Filtration (Analytical) 
Superose 6 gel filtration was performed on a SMART system. The column was equilibrated 
with 4 ml NPB100A buffer. The NAR1 samples were concentrated, and 60µl thereof were run 
through a 0.2 µM spin filter, 4 min, 2000 g at 4 °C. 50 µl were injected onto the column at a 
flow rate of 50 µl/min. 
 
2.2.8 Stability Screen 
For the stability screen, 3x buffers were prepared using detergents DM+CHS, LM+CHS, 
Cymal-6+CHS, C12E9+CHS, Fos-12+CHS and Fos-14+CHS, that adjusted the pH (4.0-9.5), 
NaCl (0 mM, 100 mM, 500 mM) and detergent (1x cmc, 3x cmc) conditions according to 
table 3. The reservoir of a CrystalQuickSW plate (Greiner) was filled with a 200 µl of a 
mixture of 3x buffer, H2O and NPB0 in a ratio 1:1:1. Two out of three wells were filled by a 
Cartesian Robot with 100 nl of the corresponding 3x buffer, 100 nl of either TEV (1:10 
diluted into H2O) or H2O and 100 nl NAR1 as obtained from HisTrap HP (IMAC, 2.2.7.2.1) 
purification. Stability Screen plates were stored at 4 °C and analyzed after 18 h, 42 h, 72 h, 96 
h and 168 h for visible precipitates, and ranked accordingly. 
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 3x  Buffer  TEV/H2O NAR1 
1 mg/ml 
pH 4.0  100 nl 
100 mM Na-formiate 
0/0.3/1.5 M NaCl 
3x/9x cmc detergent 
100 nl TEV (1:10) 
or 
100 nl H2O 
100 nl NAR1 
pH 4.5  100 nl 
100 mM Na-acetate 
0/0.3/1.5 M NaCl 
3x/9x cmc detergent 
100 nl TEV (1:10) 
or 
100 nl H2O 
100 nl NAR1 
pH 5.0  100 nl 
100 mM Na-citrate 
0/0.3/1.5 M NaCl 
3x/9x cmc detergent 
100 nl TEV (1:10) 
or 
100 nl H2O 
100 nl NAR1 
pH 5.5  100 nl 
100 mM Na-citrate 
0/0.3/1.5 M NaCl 
3x/9x cmc detergent 
100 nl TEV (1:10) 
or 
100 nl H2O 
100 nl NAR1 
pH 6.0  100 nl 
100 mM MES 
0/0.3/1.5 M NaCl 
3x/9x cmc detergent 
100 nl TEV (1:10) 
or 
100 nl H2O 
100 nl NAR1 
pH 6.5  100 nl 
100 mM ADA 
0/0.3/1.5 M NaCl 
3x/9x cmc detergent 
100 nl TEV (1:10) 
or 
100 nl H2O 
100 nl NAR1 
pH 7.0  100 nl 
100 mM MOPS 
0/0.3/1.5 M NaCl 
3x/9x cmc detergent 
100 nl TEV (1:10) 
or 
100 nl H2O 
100 nl NAR1 
pH 7.5  100 nl 
100 mM HEPES 
0/0.3/1.5 M NaCl 
3x/9x cmc detergent 
100 nl TEV (1:10) 
or 
100 nl H2O 
100 nl NAR1 Material & Methods 
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pH 8.0  100 nl 
100 mM Tris 
0/0.3/1.5 M NaCl 
3x/9x cmc detergent 
100 nl TEV (1:10) 
or 
100 nl H2O 
100 nl NAR1 
pH 8.5  100 nl 
100 mM Tris 
0/0.3/1.5 M NaCl 
3x/9x cmc detergent 
100 nl TEV (1:10) 
or 
100 nl H2O 
100 nl NAR1 
pH 9.0  100 nl 
100 mM Na-Borate 
0/0.3/1.5 M NaCl 
3x/9x cmc detergent 
100 nl TEV (1:10) 
or 
100 nl H2O 
100 nl NAR1 
pH 9.5  100 nl 
100 mM CAPSO 
0/0.3/1.5 M NaCl 
3x/9x cmc detergent 
100 nl TEV (1:10) 
or 
100 nl H2O 
100 nl NAR1 
 
Table 3: List of buffers used for the stability screen, and the composition of the drops. 
 
2.2.9 Activity Measurements 
2.2.9.1 Immobilization on IMAC-Beads 
NAR1 as obtained from HiTrap HP (IMAC) purification (2.2.7.2.1), was dialyzed against 
NPB0, to remove excess imidazole overnight at 4 °C, and rebound for 30 min to Ni-NTA 
beads, with gentle agitation. NAR1 was then incubated with [
3H]-nicotinic acid:[
1H]-nicotinic 
acid mixture 1:50 (2 µM) for 2 h in NPB0 buffer at room temperature. Beads were then 
pelleted by centrifugation at 4 °C for 2 min at 500 g, the supernatant removed, beads were 
washed three times with 500 µl ice cold NPB0 buffer and pelleted again. Remaining 
radioactivity was measured by scintillation counting, negative control experiments were 
performed in the presence of 1 mM [
1H]-nicotinic acid. 
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2.2.9.2 Immobilization on Streptavidin Coated Plates 
NAR1 as obtained from HiTrap HP (IMAC) purification (2.2.7.2.1) was bound to the wells of 
Streptavidin coated plates for 30 min and washed once with NPB0 buffer. NAR1 was then 
incubated with [
3H]-nicotinic acid:[
1H]-nicotinic acid mixture 1:50 (2 µM) for 2 h in NPB0 
buffer at room temperature. The wells were washed 3 times with 200 µl ice cold NPB0 buffer 
and remaining radioactivity, bound to NAR1 was eluted with 200 µl IMA regeneration buffer, 
and measured by scintillation counting. Control experiments were carried out in the presence 
of 1 mM [
1H]-nicotinic acid, to determine non specific binding [67]. 
 
2.2.9.3 Gel Filtration 
BioGel P60-Gel medium was packed into 5 ml polypropylene columns. NAR1 as obtained 
from HiTrap HP (IMAC) purification (2.2.7.2.1) was diluted to reduce the imidazole content 
of the sample five fold in NPB0 buffer, and reconcentrated. NAR1 was then mixed with [
3H]-
nicotinic acid:[
1H]-nicotinic acid mixture 1:50 (2 µM) for 2 h in NPB0 buffer at room 
temperature and then chilled on ice for 5 min. 200 µl of sample were applied to the top of the 
column, and allowed to enter the chilled (4 °C) resin by gravity flow. After the sample had 
entered the column completely, additional 2 ml of ice cold buffer NPB0 were added to the 
reservoir of the column and allowed to enter the matrix by gravity flow. Elution fractions 
were collected in 100 µl steps, and analyzed by scintillation counting [68]. 
 
2.2.9.4 Scintillation Proximity Assays (SPA) 
For SPA 50 µl NAR1 was mixed with 50 µl streptavidin PVT or YSi SPA scintillation beads 
suspension in NPB0 buffer and 50 µl [
3H]-nicotinic acid (200 nM, final concentration) or 
[
14C]-nicotinic acid (20 nM, final concentration). Light emission was measured in a 
MicroBeta Scintillation Counter after 60 min, 120 min and 180 min at 25 °C. Unspecific 
binding was determined in the presence of 2 µM [
1H]-nicotinic acid. 
 
2.2.9.5 Equilibrium Dialysis 
NAR1 as obtained from HiTrap HP (IMAC) purification (2.2.7.2.1) was diluted to reduce the 
imidazole content of the sample five fold in NPB0 buffer, and reconcentrated. NAR1 was 
then mixed with [
3H]-nicotinic acid:[
1H]-nicotinic acid mixture 1:50 (2 µM) and filled into Material & Methods 
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the sample chamber of the RED device. The buffer reservoir was filled with NPB0. 50 µl 
samples from the sample chamber and the buffer reservoir were analyzed by liquid 
scintillation counting after 1 h, 2 h and 3.5 h. Control experiments contained 2 mM [
1H]-
nicotinic acid. 
 
2.2.9.6 Saturation Transfer Difference Spectroscopy (STD) 
Reference solutions of each compound (nicotinic acid, Acifran, Acipimox) were prepared at 1 
mM in NPB0 with [
2H]-glycerol. 1D [
1H] NMR spectra were recorded on a DRX600 
spectrometer using following parameters: 
 
Parameters DRX  600 
Pulse Sequence  Normal 1D [
1H] (standard BRUKER pulse 
program) with 3-9-19 WATERGATE sequence for 
water suppression, gaussian shaped pulses 
T (K)  298 
Number of Scans  128 
Spectral window [ppm]  13.979 
O1P [ppm]  4.701 
TD  32768 
  
 
NAR1 was concentrated after HisTrap HP (IMAC) purification (2.2.7.2.1) and diluted into 
NPB0 buffer prepared with [
2H]-glycerol and re-concentrated. This procedure was repeated 
twice, to reduce the amount of [
1H]-glycerol. The final concentration was determined at 10 
µM in a volume of 450 µl. 50 µl of D2O and 10µM TSPA (as concentration reference) were 
added. 
1D [
1H] Saturation Transfer Difference (STD) spectra were recorded on a DRX600 
spectrometer using the following parameters: 
 
 
Parameters DRX  600 
Pulse Sequence  STD (standard BRUKER pulse program) with 3-9-
19 WATERGATE sequence for water suppression, Material & Methods 
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gaussian shaped pulses 
T (K)  298 
Number of Scans  128 
Spectral window [ppm]  13.979 
O1P [ppm]  4.701 
TD  32768 
Delay (D7) between two 
scans [µs] 
2000 
Fq1 on-resonance [Hz]  480-500 
Fq1 off-resonance [Hz]  -10000 
 
 
2.2.10 Reconstitution 
2.2.10.1  Activation of BioBeads
TM 
BioBeads were activated by washing 10 g of BioBeads with 100 ml methanol for 15 min at 
room temperature and thorough stirring. The methanol is then removed, and the BioBeads are 
washed again in 250 ml methanol. The BioBeads are then hydrated in 500 ml dH2O. The 
water is drained and then the BioBeads are resuspended in 1000 ml dH20 and ready for use. 
The detergent binding capacity of BioBeads is now ~100 mg/g. 
 
2.2.10.2  Reconstitution of Solubilized NAR1 
2.2.10.2.1  BioBeads
TM 
NAR1 containing membranes were solubilized in DM+CHS, LM+CHS, Fos-12+CHS, 
C12E9+CHS and Cymal-6+CHS at membrane protein concentration of 5 mg/ml with 1 % of 
detergent, and cleared by ultracentrifugation as described in solubilization. 1ml of the cleared 
solubilizate was mixed with 50 mg of BioBeads for 12 h, vigorous shaking at 4 °C. The 
BioBeads were removed, and the mixture was again incubated with 50 mg of BioBeads. This 
procedure was repeated twice more. At each time point a sample was taken, analyzed for the 
membrane protein content and measured as described in Binding Assay Screening Conditions 
II (2.2.5.1). Material & Methods 
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Alternatively instead of cleared lysate, purified NAR1 in the corresponding 
detergent:CHS:asolectin mixture (5:1:5) was used. For each of the 4 consecutive BioBead 
treatment cycles, the amount of BioBeads was chosen to remove half of the detergent present 
in the purified sample (5 mg BioBeads/mg detergent) according to the manufacturer’s 
suggestions. 
 
2.2.10.2.2  Gel Filtration 
This method was adapted with slight modifications from Cerione et al [69]. 50 µg of lipid thin 
film (Asolectin/Asolectin:PS 1:2, containing 1 mol% of rhodamine labeled PE) were 
resolubilized with100 µl of NAR1 (0.1 mg/ml). 100 µl sample were then loaded onto a 1x20 
cm column packed with BioGel-P100 and pre-equilibrated with 100 µl of equilibration 
vesicles (same lipid as above, but solubilized by sonication) in 3 column volumes NPB0 
buffer w/o detergent. Upon entering the bed, the reconstitution sample of NAR1 was followed 
by a pulse of 200 µl detergent stock (10x cmc). The column was then flown at 9 ml/hr and 0.5 
ml fractions collected on an Abimed Gilson FC 204 fraction collector. Fluorescence signal of 
rhodamine labeled PE was traced in 96 well plate and read at 590 nm emission wave length 
(excitation 550 nm). The first fluorescent peak contained NAR1 reconstituted into liposomes. 
These were analyzed by Radioligand Binding Assays (Screening Conditions; 2.2.5.1) and 
Electron Microscopy (2.2.11). 
 
2.2.10.2.3  Cyclodextrin Method 
This method was essentially performed as described by DeGrip et al. [70]. Purified NAR1 
samples, containing 0.15 % DM, 0.03 % CHS and 0.15 % Asolectin and 1 mol% of the tracer 
lipid Oregon Green labeled phosphatidylethanolamine (PE), were mixed with β-cyclodextrin 
at concentrations equimolar to the detergent concentration and incubated on ice for 30 min. 
Separation of the proteoliposomes from the β-cyclodextrin detergent complexes was achieved 
by centrifugation through a sucrose step gradient (45 % sucrose, 20 % sucrose, 10 % sucrose 
and 10 % sucrose containing 10 mM β-cyclodextrin in a ratio of 2:3:2:2), on which the 
sample was layered carefully. Centrifugation was carried out at 4 °C for 12 h at 200000 g. 
The proteoliposome fraction containing the Oregon green labeled tracer lipid PE indicated the 
position of the proteoliposome fraction, which was recovered and used for binding assay as 
described in Screening Conditions (2.2.5.1) and electron microscopic analysis as described in 
2.2.11. A control experiment where no β-cyclodextrin was added did not show such a band. Material & Methods 
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2.2.10.2.4  Dilution Method 
This method was essentially done as described by Cerione et al. [69] and Ambudkhar et al. 
[71]. 1 ml of purified NAR1, containing 0.15 % DM, 0.03 % CHS and 0.15 % asolectin and 1 
mol% of the tracer lipid Oregon Green labeled phosphatidylethanolamine (PE) was diluted in 
9 ml NPB0 buffer at once or in a stepwise fashion into 1 ml, this mixture then into 2 ml and 
again into 6 ml of buffer NPB0, thus lowering the detergent concentration below cmc. After 
each dilution step the samples were incubated on ice for 10 min. Proteoliposomes were 
recovered by ultracentrifugation 1 h at 4 °C and 100000 g. The fluorescent proteoliposome 
pellet was recovered in 200 µl 1x binding buffer and resuspended. Proteoliposomes were then 
analyzed by the binding assay as described in Screening Conditions (2.2.5.1) and electron 
microscopy (2.2.11). 
 
2.2.11  Electron Microscopic Imaging 
2.2.11.1  Freeze Fracture 
Small amounts of the NAR1 vesicle suspensions were enclosed between
 two 0.1 mm copper 
profiles as used for the sandwich double-replica
 technique. The sandwiches were snap frozen 
by freeze plunging in liquid ethane, cooled to -180 °C by liquid nitrogen. Freeze-fracturing
 
was performed in a BAF400T (BAL-TEC, Liechtenstein) freeze-fracture
 unit at -140 °C at a 
pressure of 2 x 10
-7 mbar using a double-replica stage. The fractured
 samples were shadowed 
without etching with 2–2.5 nm Pt/C
 at an angle of 45°. Additional carbon shadowing was 
performed at an angle of 90°. The heavy metal replicas were plunged in water and cleaned 
with 40-50 % CrO3 H 2SO4 from adhesive organic materials over night. Finally, they were 
rinsed in distilled water and
 mounted onto Formvar® coated copper grids for examination in 
an EM
 208 electron microscope (FEI). All freeze-fracture
 micrographs were mounted with 
direction of shadowing from bottom to top. 
 
2.2.11.2  On-Grid – Immuno-Gold Labeling 
1-4 µl liposome solution were absorbed to poly-L-lysine (0.01 %) laced Formvar® coated 
copper grids. Grids were washed twice with PBS (pH 7.5), blocked for 10 min with PBS 
containing 2 % glycine, and washed again with PBS (pH 7.5). Samples were then blocked 
again with PBS (pH 7.5) containing 0.1 % BSA, and incubated with M2-Flag Antibody (8 
mg/µl). Grids were then washed four times with PBS (pH 7.5)/0.1 % BSA. The secondary Material & Methods 
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goat anti mouse IgG G12 nm antibody was used in a dilution 1:50 for labeling. Grids were 
washed three times with PBS (pH 7.5), fixed with 0.5 % glutharaldehyd/PBS (pH 7.5) and 
rinsed with ddH2O. Staining was performed with 0.5 % uranylacetate, and mounted for 
examination in an EM
 208 electron microscope (FEI). 
 
2.2.12 NMR  Spectroscopic  Measurements 
2.2.12.1  TROSY Spectra 
The [
1H, 
15N] spectra signifying high quality conditions for NMR experiments were recorded 
on a DRX600 using the following parameters. 
 
Parameters DRX  600 
Pulse Sequence  TROSYF3GPGHSI19 (standard BRUKER 
pulse program) using phase sensitivity 
improvement by Echo/Antiecho method on f3-
channel; water suppression by Watergate 
sequence 
T (K)  283/298/310 
Number of Scans  96 
Spectral window (F2) [ppm]  17.959 
Spectral window (F1) [ppm]  36.0015 
O1P [ppm]  4.701 
O3P [ppm]  119.21 
TD (F2)  2048 
TD (F1)  128 
 
 
2.2.12.2  Heteronuclear Overhauser Effects (HetNOEs) 
Pairs of 1D [
1H]-[
15N] HetNOE spectra were recorded at a DRX800 spectrometer. In each 
pair of spectra, the first spectrum is recorded with 3 s presaturation of amide protons (NOE 
buildup time) and the second spectrum is without proton presaturation. Gradient selection was 
utilized to minimize solvent saturation transfer effects in HetNOE data. 
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Parameters DRX  800 
Pulse Sequence  hetnoe1dpr recording NOE/noNOE with 
WATERGATE gradients with/without 
presaturation of amide protons 
T (K)  283/298/308 
Number of Scans  2048 
Spectral window [ppm]  14.076 
Spectral window (F1) [ppm]  36.0015 
O1P [ppm]  4.701 
O3P [ppm]  117.00 
TD (F2)  4096 
Presaturation [µs]  3000 
 
As seen in Figure 14, one dimensional HetNOE data can characterize protein folding as fully 
folded ([
1H]-[
15N] HetNOE effect is positive), as unfolded states (effect is negative). Or the 
protein sample may exist in a dynamic equilibrium between both states (effect is 
approximately zero) or in an intermediate state, e.g. as a molten globule protein, respectively. 
 
 
 
 
 
Figure 14: (A) HetNOE spectra of a typical folded protein displaying amide proton chemical shift 
dispersion and relative similarity in intensities between spectra with and without saturation. (B) 
HetNOE spectra of a typical unfolded protein with the expected narrow range of amide proton 
chemical shifts and negative signal intensity when the spectrum is recorded following proton 
presaturation. (C-D) HetNOE spectra of proteins which are characterized as poor/unfolded by 2D 
TROSY spectra. Weak positive signals in HetNOE spectra are obtained with amide proton 
presaturation. These data are interpreted as indicating an equilibrium between unfolded and folded 
proteins or some partial folded character in the solution state (Figure taken from Snyder et al., 2005 
[10]). Material & Methods 
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2.2.13  Mammalian Cell Culture 
2.2.13.1  Cell Growth 
BHK (Baby Hamster Kidney) and HEK (Human Embryonic Kidney) cells were used for 
transient transfection, and confocal microscopy studies. Therefore both cell types were grown 
in Dulbecco’s Modified Eagle’s Medium (DMEM) and Iscove’s 1:1, supplemented with 5 
mM glutamate and 10 % fetal calf serum (FCS), at 37 °C and 5 % CO2. Cells were passaged 
at a confluency of 70 %, after washing with PBS and detachment with trypsin. 
 
2.2.13.2  Transient Transfection of Mammalian Cells 
Mammalian cells, BHK and HEK cells, were transfected by the calcium phosphate method 
[72, 73]. ~25000 cells were seeded into each of the 4 chambers of a Lab-Tek slide, and grown 
overnight. Cells were washed with PBS at a confluency of 30 % to 40 % and 300 µl of Ham’s 
F-12 media, supplemented with 5 mM Glutamate and 10 % FCS were added. 1 µg of plasmid 
DNA was mixed with 16.2 µl 1xHBS buffer, and 1 µl of CaCl2 (2.5 M), and all components 
were mixed thoroughly, and incubated for 30min at room temperature. The transfection 
mixture was then added to each well in a drop wise fashion with gentle swirling. The cells 
were then incubated for 6 h at 37 °C, 5 % CO2 and another 500 µl Ham’s F-12 medium were 
added. Cells were then grown for another 24 h and analyzed by confocal laser scanning 
microscopy. 
 
2.2.13.3  Confocal Microscopy 
Cells were analyzed on a Zeiss LSM 510 confocal microscope in a climate box (37 °C, 5 % 
CO2, 50 % humidity). CFP was excited with a 405 nm diode laser, and detected with a 420-
480 nm band pass filter. GFP was excited with 488 nm argon laser and detected with a 505 
nm long pass filter. Doubly fluorescent cells were identified in the laser scanning mode. Time 
track mode was initiated taking pictures sequentially of CFP and GFP every 2 min (line 
average: 2). After the first image, 500 µM nicotinic acid were added to stimulate NAR1 and 
trigger β-arrestin 1 translocation. Images were analyzed using programs Imaris and QuantX. 
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2.2.14 Interaction  of  β-Arrestin 1-382 with NAR1 
100 µg purified GST-β-arrestin 1-382 were mixed with a 300-500 µg purified NAR1 in 1 ml 
NPB0 containing appropriate amounts of detergents DM+CHS, LM+CHS or Cymal-6+CHS, 
supplemented with 500 µM nicotinic acid and asolectin. 100 µl of Glutathione 4B resin were 
added and the mixture was incubated for 60 min at 4 °C with gentle agitation. The resin was 
pelleted by centrifugation, 500 g, 4 min, at 4 °C and the supernatant removed. The resin was 
washed twice with 1 ml NPB0 supplemented with detergents DM+CHS, LM+CHS or Cymal-
6+CHS, 500 µM nicotinic acid and asolectin. The beads were then resuspended in 100 µl 
Loading Buffer 4x (SDS-PAGE) and analyzed by SDS-PAGE and Western Blotting. 
 
2.2.15 General  Techniques 
2.2.15.1  Agarose Gel Electrophoresis 
DNA fragments were separated according to size on agarose gels from 1 % to 2 % (w/v). Gels 
were prepared by boiling appropriate amounts of agarose in 1xTAE buffer until the agarose 
was dissolved completely. 2.5 µl ethidium bromide solution were added and poured onto a 
flat bed gel electrophoresis apparatus, equipped with combs. Combs were removed from 
solidified gels to free the wells for loading, and the gel was covered with 1xTAE buffer. 
Appropriate amounts of DNA sample mixed with loading buffer 6x (DNA) were filled into 
the wells and gels run at 75 V until the dye front reached the bottom of the gel. DNA a bands 
were detected due to intercalating ethidium bromide on a Molecular Imager Gel Doc XR 
system (Invitrogen) under UV light. 
 
2.2.15.2  Phenol-Chloroform Extraction (DNA Purification) 
200 µl sample were mixed with 200 µl chloroform/phenol/isoamylalcohol (25:24:1) and 
vortexed thoroughly. The sample was then centrifuged for two minutes at room temperature at 
13000 g, and the supernatant was transferred to a fresh tube. 200 µl of 
chloroform/isoamylalcohol (24:1) were added, and vortexed thoroughly. The sample was 
centrifuged again at room temperature for two min at 13000 g. The supernatant was removed 
and submitted to ethanol precipitation. 
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2.2.15.3  Ethanol Precipitation (DNA Concentration) 
200 µl of sample were mixed with 20 µl 3 M Na-acetate, pH 5.2, 2.5 volumes of ice cold 
ethanol and the sample was vortexed thoroughly. The DNA was precipitated for 30 min at -80 
°C, and centrifuged at 4 °C and 13000 g for 20 min. The pellet was washed with ice cold 70 
% (v/v) ethanol and centrifuged again for at 4 °C and 13000 g 5 min. The pellet was dried in a 
speed vac for 5 min at 30 °C, and then dissolved in sterile ddH2O at 65 °C for 5 min. 
 
2.2.15.4  BCA Assay (Protein Concentration Determination) 
For quantification of protein content the BCA (bichinonic acid) method was used according to 
Smith et al, 1985 [74] and the manufacturer’s instructions for measurement in 96-well plates. 
The membrane samples were diluted 1 in 10 into ddH2O and 1 µg, 2 µg, 4 µg, 6 µg, 8 µg, 10 
µg and 12 µg of bovine serum albumin were used to record a calibration curve. Samples were 
incubated at 37 °C for 30 min and read in a 96-well plate spectrophotometer at 562 nm. 
 
2.2.15.5  TCA Precipitation of Proteins 
Trichloroacetic acid (TCA) precipitation was carried out essentially as described by Tornquist 
and Belfrage (1976) [75]. 500 µl of sample were mixed with 12.5 µl 1 % (w/v) Na-
deoxycholate and incubated at room temperature for 15 min. Upon addition of 500 µl ice cold 
12 % (w/v) TCA the sample was centrifuged at 4 °C at 10000 g for 20 min. The supernatant 
was removed, the sample was then additionally centrifuged for 2 min, 4 °C at 10000 g. 
Residual liquid was removed, and the sample dried at room temperature for 10min. The 
sample was resuspended in 20 µl to 100 µl 2.5 % (w/v) SDS, incubated for 15 min at 37 °C 
and analyzed by SDS-PAGE. 
 
2.2.15.6  SDS-PAGE 
SDS-PAGE analysis was carried out according to a modification of the Laemmli protocol [76] 
by Fling and Gregerson [77]. Gels were poured according to table 4 (given below). Samples 
were mixed with an appropriate amount of 4x SDS-PAGE loading buffer and loaded into 
sample pockets without heating. Gels were run at 140 V through the stacking gel and at 180 V 
in the separation gel, until the dye front reached the bottom of the gel. Gels were stained by 
Coomassie Blue, or used for Western blotting. Material & Methods 
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  Stacking Gel  Separation Gel 
10% 
Separation Gel 
12% 
H2O  11.7 ml  18.1 ml  15.1 ml 
Lower Tris (4x)  -  11.25 ml  11.25 ml 
Upper Tris (4x)  5 ml  -  - 
Acrylamide 
Solution 
3.3 ml  15 ml  18 ml 
APS (10%)  60 µl  600 µl  600 µl 
TEMED  15 µl  40 µl  40 µl 
 
Table 4: Preparation of SDS-Acrylamide Gels: Pipeting scheme for 8 cassettes. 
 
 
2.2.15.7  Western-Blotting 
For Western blotting the gel was stacked onto three layers of Whatman paper, previously 
equilibrated in blotting buffer (1 h), covered with a PVDF membrane, previously activated in 
methanol (5 min) and equilibrated in blotting buffer (1 h), and again covered by three layers 
of as above described equilibrated Whatman papers. Electrotransfer was carried out at 0.75 
mA/cm
2 for 75 min. The membrane was then blocked in 50 ml TBST containing 5 % (w/v) 
milk powder for 1 h at room temperature, washed twice with TBST and incubated either with 
the primary antibody (Anti-His, Anti-Flag) or alkaline phosphatase conjugated streptavidin 
for 30 min at room temperature. The membrane was washed three times for 5 min with 50 ml 
TBST, and incubated with the secondary antibody (Anti-Mouse alkaline phosphatase 
conjugated). Secondary antibody incubation was done for 30 min at room temperature, and 
then washed again three times with 50 ml TBST for 10 min at room temperature. 
Development was carried out by equilibration of the membrane in 10 ml AP buffer for 1 min 
and then incubated with 330 µg/ml NBT and 165 µg/ml BCIP in 10 ml AP buffer. 
 
2.2.15.8  Detergent Assay 
Detergent concentration was measured with the phenol-sulfuric acid method according to 
Mikkelsen 2004 [78]. 12.5 µl sample were combined in a 96 well plate with 12.5 µl 5 % (w/v) 
phenol. A calibration curve was done by serial dilutions of a 1 % LM stock solution. The plate 
is placed on ice and 125 µl of concentrated sulphuric acid were added. The plate was covered Material & Methods 
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and incubated at 80 °C for 30 min. Sulfuric acid hydrolyzes polysaccharides to their 
constituent monosaccharides, which are dehydrated to reactive intermediates. In the presence 
of phenol, these form yellow products. The absorbance is measured at 492 nm in 96 well plate 
spectrophotometer. 
 
2.2.15.9  Mass Spectroscopy 
For mass spectroscopy all tubes and scalpels were rinsed with detergent and 50% 
acetonitrile/trifluoracetic acid 0.1 %. The Coomassie stained band was excised and incubated 
for 45 min at 37 °C in 200 µl 100 mM NH4HCO3/50 % acetonitrile. Gel pieces were shrunk in 
100 % acetonitrile for 10 min and dried in a speed vac for 15 min at room temperature. Gel 
pieces were then soaked with 20 µl trypsin solution (20 µg/ml), until their white color 
disappeared. Remaining trypsin solution was removed, and the gel pieces were covered with 
40 µl 40 mM NH4HCO3 and incubated for digest over night at 37 °C. The sample was 
sonicated for 5 min, the supernatant removed, combined with 2 µl 10 % trifluoracetic acid and 
kept. Remaining gel pieces were covered with 50 µl 50 % acetonitrile/5 % trifluoracetic acid, 
sonicated for 5 min, and incubated at room temperature with vigorous shaking for 1 h. The 
supernatant was removed, pooled with the previous supernatant and the procedure repeated. 
Combined supernatants were dried in a speed vac, washed with 10 µl 1 % trifluoracetic acid 
and dried again. The pellets were resuspended in 5 µl 70 % acetonitrile/0.1 % trifluoracetic 
acid by sonication and vortexing. 
A saturated solution of a-cyano-3-hydroxy cinnamic acid was prepared in a solution of 10 mg 
NH4HCO3 in 1 ml 50 % acetonitrile, and 0.5 µl were spotted onto the target with 0.5 µl 
peptide sample solution. The dried matrix was washed four times with 0.1 % trifluoracetic 
acid and analyzed in a Bruker Daltonic OMNIFLEX MALDI TOF MS mass spectrometer. 
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3 Results 
3.1  Production of the human GPCR HM74A in P. pastoris 
3.1.1 Cloning 
Pichia pastoris was chosen as the heterologous host system for the expression of NAR1, since 
its success in the production of GPCRs had been shown previously [79-82]. 
All pPIC9K vectors employed for this study contain the α-factor mating type prepropeptide 
cDNA of Saccharomyces cerevisiae that serves as signal for membrane insertion. The 
pPIC9K fhT-Tbio vector has an N-terminal Flag-tag for immunodetection and a stretch of ten 
consecutive histidine residues as an affinity handle. A second vector series (pPIC9KnT-T) 
encodes for the nano9-tag as the affinity handle in conjunction with a streptavidin matrix. To 
stabilize the receptor two proteins were used as fusions to the C-terminus: 
•  The first fusion protein, in the case of the pPIC9KfhT-Tbio is the biotinylation domain 
of the transcarboxylase of Propionibacterium shermanii. The fusion protein has a 
twofold effect: on the one hand it allows for affinity purification using immobilized 
monomeric avidin that specifically binds to the biotin moiety, on the other hand it has 
a positive effect on the stability and functionality of heterologously expressed GPCRs 
in Pichia pastoris [79, 80, 83]. 
•  For the pPIC9KnT-Tstab vector the Stab-tag, which is a modified version of the 
biotinylation domain, was used. The biotin accepting lysine 56 is replaced by an 
arginine (Dr. H. Reiländer) to prevent biotin attachment, but preserve the stabilizing 
effect of the fusion protein. 
•  Two different length constructs of β-arrestin 1 were introduced as a fusion partner of 
the GPCR: i) a truncated version, residues 1-382, that is constitutively active 
(pPIC9KnanoT-Tβarr1-382) and ii) the full length sequence (pPIC9KnanoT-Tβarr1-
fl). Reports indicate a stabilizing and protecting effect of such a fusion and an 
enhanced pharmacological profile [84]. 
The Stab-tag was amplified by PCR with primers stab-for and AOX1rev from the template 
pSK+Stab (kindly provided by G. Maul & Dr. H. Reiländer), β-arrestin 1-382 using primers 
βarr1for and βarr1-382rev,  β-arrestin 1-fl with primers βarr1for and βarr1-flrev from the 
template provided by Sanofi-Aventis Deutschland GmbH. These DNA fragments were ligated 
after restriction digestion into the EcoRI and NotI sites of pPIC9KnT (Genetic Engineering 
2.2.1). Results 
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All vectors contain two Tobacco etch virus (TEV) cleavage sites flanking the BamH1 and 
EcoR1 restriction sites for integration of the GPCR sequence, to allow the removal of all 
flexible tags. 
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The HM74A/GPR109A DNA was mutated to remove an intrinsic BamHI site (Genetic 
Engineering 2.2.1). The modified DNA of HM-74A/GPR109A was amplified by PCR 
(primers: NAR1for, NAR1rev) resulting in a band of apparent size of ~1100bp and 
successfully cloned between BamHI and EcoRI sites into the pPIC9K fhT-Tbio and the newly 
engineered derivatives pPIC9KnanoT-Tstab, pPIC9KnanoT-Tβarr1-382 and pPIC9KnanoT-
Figure 7: Schematic drawing of constructs for the expression of NAR1 in P. pastoris. BamHI, 
EcoRI, NotI: Restriction enzyme sites; TEV: Tobacco Etch Virus Protease cleavage site; Bio: 
Biotinylation Domain; Stab: Stab-Tag; NAR1: coding sequence of the gene HM74A; Results 
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Tβarr1-fl. These four vectors were called pPIC9KfhT-NAR1-Tbio, pPIC9KnanoT-NAR1-
Tstab, pPIC9KnanoT-NAR1-Tβarr1-382 and pPIC9KnanoT-NAR1-Tβarr1-fl (Figure 7). 
 
3.1.2 Transformation & Multi-Copy Clone Selection 
The vector DNAs were linearized with PmeI and subsequently transformed into the protease 
deficient Pichia pastoris strain SMD1163, and selection of transformed clones on histidine 
deficient media was performed. 
The task was to identify the highest expressing clone of each NAR1 construct. Although not 
observed in the production of soluble proteins, it was observed in our laboratory that highest 
G418 resistance did not always correlate with the highest receptor expression level [79]. 
Therefore a screen of two different methods for the selection of the highest expressing clone 
was used. These two methods included the standard antibiotic concentration dependent 
resistance screen, selecting colonies on the basis of the vector integration number, and a 
direct-expression colony-blot, selecting on the basis of the target protein expression. Clones 
selected by both methods were compared on the basis of functional expression in radioligand 
binding assays and Western-Blot analysis. 
96 clones were randomly selected out of the transformands for each expression construct and 
selection of clones that grew between 0.05 and 1.0 mg/ml final concentration of G418 
followed. Based on tolerance to G418, a total of five colonies of pPIC9KfhT-NAR1-Tbio 
were identified. Clone 1A10 behaved inconsistently in growing on 0.05 mg/ml G418 and on 
0.3 mg/ml, but not on intermediate concentrations, and clones 1B2 and 1C4 grew on 0.075 
mg/ml, but not on 0.05 mg/ml. Similarly for pPIC9KnanoT-NAR1-Tstab, pPIC9KnanoT-
NAR1-Tβarr1-382 and pPIC9KnanoT-NAR1-Tβarr1-fl four, eleven and seven colonies were 
selected, respectively. 
The same 96 clones were analyzed in a direct-expression colony-blot. Instead of the mere 
copy number of the vector that is the selection basis in the G418 resistance screen, this 
procedure allows a direct assessment of the production of the desired target protein. For 
construct pPIC9KfhT-NAR1-Tbio, six clones were selected on the basis of the direct-
expression colony-blots. 
The direct-expression colony-blot did not allow the identification of nano9-tagged proteins 
(pPIC9KnanoT-NAR1-Tstab, pPIC9KnanoT-NAR1-Tβarr1-382, pPIC9KnanoT-NAR1-
Tβarr1-fl), since streptavidin cross reacts with intracellular biotinylated proteins. Therefore it 
was neither possible to verify the G418 positive clones, nor to identify additional ones. Results 
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Only two clones growing on G418 containing media produced a signal in the direct-
expression colony-blots. On the basis of these two methods, a total number of nine clones for 
pPIC9KfhT-NAR1-Tbio was selected for further analysis, three exclusively on the basis of 
the G418 screen, four exclusively by the direct-expression colony-blot, and two in agreement 
to both methods. 
 
3.1.3 Expression Analysis 
These nine clones were used for small scale culture growth (2.2.3.2.1) and membrane 
preparation and entered the second stage of analysis along with the 22 clones obtained for 
pPIC9KnanoT-NAR1-Tstab, pPIC9KnanoT-NAR1-Tβarr1-382 and pPIC9KnanoT-NAR1-
Tβarr1-fl constructs. 
 
3.1.3.1 Western Blotting 
For the comparison of NAR1 expression levels, Western-Blots with equal amounts of 
membrane protein were performed. Western Blot analysis was done using either M2-Flag 
antibody or Anti-His antibody both directed against N-terminal tag sequences, or with a  
 
 
 
Figure 8: Western Blot analysis of 
membranes from pPIC9KfhT-NAR1-Tbio 
clones, 10 µg membrane protein loaded in 
each lane. Upper pannel: developed with 
Anti M2-Flag Antibody. Middle pannel: 
developed with Anti-His antibody. Lower 
pannel: developed with alkaline 
phosphatase conjugated Streptavidin. 
 Results 
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streptavidin conjugate directed against the C-terminal biotinylation domain. Clones 1A10, 
1F4 showed a strong band with either antibody, migrating at an apparent size of 55kDa, in 
good agreement with the calculated molecular weight of the NAR1 construct. A smaller 
signal with all three antibodies was observed for clones 1A6, 1E9, and 1G12. Clones 1D7 and 
1E10 only showed a signal in M2-Flag and streptavidin blots, but not in the Anti-His blot. 
Empty pPIC9K transformed cells showed no such band (Figure 8). 
 
All the six clones that were selected on the basis of the direct-expression colony-blot also 
showed expression in the Western-Blot analysis. Out of the five clones selected due to their 
resistance to G418, only three produced NAR1 protein according to Western-Blot analysis. 
The two clones 1A10 and 1F4 that exhibited highest expression levels in the Western-Blot 
analysis are the two that were selected in both screens, the G418 screen and the direct-
expression colony-blot. 
Membranes prepared from cultures of clones for the pPIC9KnanoT-NAR1-Tstab, 
pPIC9KnanoT-NAR1-Tβarr1-382 and pPIC9KnanoT-NAR1-Tβarr1-fl constructs failed to 
produce a clear signal in a Streptavidin-Blot. 
 
3.1.3.2 Radioligand Binding Assay 
The membrane preparations of nine selected clones of pPIC9KfhT-NAR1-Tbio, four of 
pPIC9KnT-NAR1-Tstab, eleven of pPIC9KnT-NAR1-Tβarr1-382 and the seven clones of 
pPIC9KnT-NAR1-Tβarr1-fl were also subjected to a functional analysis. Radioligand binding 
analysis of pPIC9KfhT-NAR1-Tbio clones showed that the two clones 1A10 and 1F4 were 
binding nicotinic acid above 6000 specific cpm, and another one, 1G12 producing 
approximately 2500 specific cpm above background. The remaining clones bound radioligand 
only at low levels, barely above the background value, as determined with membranes from 
cells transfected with empty pPIC9K vector. Calculation of NAR1 content in membranes 
revealed at this stage an expression level of 1 pmol/mg for two clones 1A10 and 1F4, 
although the radioligand binding assay was carried out at non saturating levels of nicotinic 
acid. These two clones yielding the highest binding level were also the ones that exhibited 
high level expression in the Western-Blot analysis (Figure 9) (Table 5).  
 
 Results 
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Figure 9: Binding analysis of [
3H]-nicotinic acid (97.7 nM) to membranes (50 µg protein) from 
clones of pPIC9KfhT-NAR1-Tbio. Red: Total binding, blue: Background binding. Unspecific 
binding was determined with membranes of P. pastoris clones transformed with empty pPIC9K 
vector. The values are the mean of three independent experiments. 
Figure 10: Binding analysis of [
3H]-nicotinic acid (111.5 nM) to constructs pPIC9KnT-NAR1-
Tstab, pPIC9KnT-NAR1-Tβarr1-382 and pPIC9KnT-NAR1-Tβarr1-fl. Red: Total Binding, blue: 
Background binding. Background levels were determined with membranes prepared from P. 
pastoris clones transformed with empty pPIC9K vector. Values are the mean of three different 
experiments. Results 
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Out of four clones of pPIC9KnT-NAR1-Tstab, one, 2E2, exhibited binding at a level of 8000 
dpm above a background of 1000 dpm. Six of the clones selected for pPIC9KnT-NAR1-Tbarr 
1-382 exhibited binding between ~3000 and ~4000 specific dpm, while the remaining clones 
displayed binding between ~1000 and ~2800 specific dpm. All seven clones of pPIC9KnT-
NAR1-βarr1-fl showed low level binding, with the best, 4F3, having ~2800 specific dpm 
(Figure 10). 
 
 
 
 
Out of the 96 clones that were selected for high level expression screening of pPIC9KfhT-
NAR1-Tbio, only two were found to express NAR1 at levels suitable for future experiments. 
The initial screening methods, the G418 resistance screen and the direct expression blot, have 
a limited success rate. Out of all positive clones produced by the G418 screening method, 
only 40 % could be verified by thorough analysis, while from the direct colony blot 34 % 
could be verified. By combining both methods and selecting their intersection, both high level 
expressing clones were obtained (Figure 11). 
 
Figure 11: Flow chart of clone selection for pPIC9KfhT-NAR1-Tbio expression construct. Results 
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3.1.3.3 Determination of the Total Amount of NAR1 produced 
For each construct, the clone with the highest expression level was selected for analysis of 
total amount of receptor produced. To determine the total amount of receptor accurately, 
saturation binding curves were recorded. Binding curves were recorded for the best clone of 
all four constructs and allowed for the calculation of Bmax and Kd values. Clone 1F4, 
(pPIC9KfhT-NAR1-Tbio) produced NAR1 initially at a level of 14.3 pmol/mg and a Kd of 
224 nM (Figure 12). 
The other clones containing NAR1 in constructs pPIC9KnT-NAR1-Tstab, pPIC9KnT-NAR1-
Tβarr1-382 and pPIC9KnT-NAR1-Tβarr1-fl revealed slightly lower Kds, 140 nM, 149 nM 
and 186 nM respectively, but the expression level was also lower than in clone 1F4. The level 
for clone 2E2 (pPIC9KnT-NAR1-Tstab) was 10.7 pmol/mg and those for pPIC9KnT-NAR1-
Tβarr1-382 and pPIC9KnT-NAR1-Tβarr1-fl were 3.7 pmol/mg and 5.5 pmol/mg, 
Table 5: Summary of data collected on clones for pPIC9Kfht-NAR1-Tbio. The G418 row gives the 
antibiotic concentration the selected clones tolerated. A + in the Direct Blot row indicates 
identification of the clone due to the direct expression colony blot. M2 shows whether the clones 
produced a signal in the M2 anti Flag blot, ++: strong signal; +: lower signal; -: no signal. The His row 
shows whether the clones produced a signal in the anti-His blot, ++: strong signal; +: lower signal; -: 
no signal. The Strep row shows whether the clones produced a signal in the Streptavidin blot, ++: 
strong signal; +: lower signal; -: no signal. Binding assay (cpm) gives the values of specific radio 
active signal observed in single point measurements, and Binding assay (pmol/mg) gives the 
calculated amount of NAR1 observed due to single point measurements. Results 
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respectively. Therefore, clone 1F4 of pPIC9KfhT-NAR1-Tbio was selected for further 
expression optimization. 
 
 
 
 
3.1.4 Expression Optimization 
According to the pattern developed by André et al, 2006 [79], to improve the amount of 
functional expression of GPCRs, four parameters were adjusted. 
•  the temperature during expression 
•  the addition of DMSO to the expression media 
•  the addition of a ligand for the receptor to the expression media 
•  the addition of histidine to the expression media 
Cells were either grown at 22 °C or 30 °C and every six hours samples were analyzed for the 
amount of functional receptor and cell mass. Expression level of NAR1 peaked at 30 °C after 
18 h, dropped sharply after and rose again at 36 h. At 22 °C the expression level rose steadily 
up to 24 h and plateaued between 24 h and 30 h. The cell mass between the expression at 30 
Figure 12: Initial binding curve recorded for construct pPIC9KfhT-NAR1-Tbio clone 1F4 yielded a 
Bmax value of 14.3 pmol/mg and a Kd of 224.8 nM. ○: Total Binding of [
3H]-nicotinic acid; 
⁬:Unspecific binding, determined in the presence of 1mM unlabelled nicotinic acid; -◊-: Specific 
Binding. Results 
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°C for 18 h and 22 °C for 24 h to 30 h was nearly identical. Therefore, the expression time 
and temperature were adjusted for the final expression condition to be 22 °C and 24 hours. 
DMSO had been shown previously to have a positive effect on the level of functional receptor 
produced if added to the culture media [79, 85]. The DMSO concentration was screened 
ranging from 0 % as control to 7.5 %, and it was found that 2 %DMSO increased the Bmax by 
50 % (Figure 13), although it did not seem to have an effect on the total amount of receptor 
produced, according to Western Blot analysis (data not shown). 
 
 
 
 
 
In the MePNet screen [79], the positive effect of ligands, agonists as well as antagonists, on 
the amount of functional receptor production has been observed, but for the addition of 
nicotinic acid no positive effect on the production level of NAR1 was observed. The addition 
of histidine also had no observable effect. 
 
No difference could be seen whether membranes from freshly harvested cells were used, or 
whether membranes were frozen before analysis (data not shown). No effect was found for 
Figure 13: Increased binding observed on membranes from cultures grown in media with DMSO 
added.Results 
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the cell disruption method, whether small scale vortexing with glass beads, larger scale 
stirring with a baffled steel stick or the cell disruptor was used (data not shown).  
The incubation time of the radio ligand binding assay could be reduced from three and a half 
hours [13, 15] to two hours (Figure 14) as, after that time, the measurable activity did not 
 
 
 
 
increase significantly. Furthermore, it was observed that incubation at 22 °C yielded about 60 
% more total activity than at 30 °C. Additionally, in a pulse-chase experiment, it was 
determined that a pulse of excess unlabeled nicotinic acid could displace all previously bound 
radiolabeled nicotinic acid molecules from the receptor within 30 min (Figure 14). 
 
After optimizing handling parameters and assay conditions as described above, the Bmax value 
increased three-fold up to 42 pmol/mg in saturation binding experiments, while the Kd 
remained in a similar range at 252 nM (Figure 15 a, b). Homologous competition 
experiments, where unlabeled nicotinic acid was used to compete out radiolabeled nicotinic 
acid resulted in an affinity of 328 nM and comparable Bmax (Figure 16 b). Heterologous 
inhibition curves were performed with the agonists Acifran and Acipimox (Figure 16 a), and 
resulted in inhibitory constants of 4.57 µM for Acifran and 50.5 µM for Acipimox (Figure 16 
b). 
Figure 14: a) Time dependent saturation of NAR1 with [
3H]-nicotinic acid in P. pastoris membranes, b) 
Blue: control experiment without cold ligand, total binding barely decreases over time; Pink: [
3H]-
nicotinic acid displacement by excess unlabelled nicotinic acid. Results 
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Figure 15: a) Saturation Binding Curve of NAR1 Clone 1F4, Bmax: 42 pmol/mg, Kd: 252 nM; ○: 
Total binding of [
3H]-nicotinic acid (max.: 2 µM); ⁬:Unspecific binding, determined with 2 mM 
unlabelled nicotinic acid; -◊-: Specific Binding; 50 µg total membranes; b) Scatchard analysis of 
binding experiment a), Bmax: 42 pmol/mg, Kd: 252 nM. 
Figure 16: a) Structure of Nicotinic Acid and the Agonists Acifran and Acipimox. b) Inhibition 
curves, 25 µg membrane protein with 27 nM [
3H]-nicotinic acid displaced with ○ [
1H]-nicotinic acid 
concentrations ranging from 3 pM to 1 mM, calculated Kd: 328 nM; ⁬ Acifran, calculated Ki: 4.57 
µM; and -◊-Acipimox over a concentration range from 3 pM to 10 mM, calculated Ki: 50.5 µM. Results 
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3.1.5 Effect of Various Buffer Components: cations, pH, imidazole, 
DMSO and DTT 
Buffer conditions during future solubilization and purification experiments must be varied to 
meet the experiments’ requirements. Therefore, the influence of various components common 
to solubilization and purification buffers was assessed, and measured by monitoring the ligand 
binding activity of NAR1 in membranes and the presence of increasing amounts of additives 
such as NaCl, DTT, imidazole and DMSO. 
It has been shown before for NAR1 that agonist binding is diminished by high concentrations 
of sodium ions [13], while for other receptors an enhancing effect on antagonist binding was 
demonstrated [86, 87]. Therefore, different cations were screened in various concentrations to 
monitor ligand binding properties of NAR1 in membranes in this respect. NaCl had the most 
detrimental effect on nicotinic acid binding by NAR1. Potassium and lithium chloride had a 
somewhat less severe effect and it appeared that ammonium chloride, or the ammonium 
cation, affected the binding reaction least. Ammonium chloride reduced the amount of 
functionally observed receptor at 250 mM only to 70 % of the initial value without salt, 
whereas sodium chloride reduced the detectable binding to less than 20 % at concentrations of 
100 mM (Figure 17a). 
Furthermore, the pH optimum of the receptor ligand interaction was determined. It is evident 
from the data that the binding optimum for the receptor is at a physiological pH of around 7.0 
(Figure 17b).  
The effect of imidazole in the binding reaction was assessed because it is used routinely to 
elute proteins from metal chelate affinity resins. Imidazole shares a similar scaffold with 
nicotinic acid as it comprises a nitrogen substituted aromatic ring structure. Therefore, it was 
crucial to know if imidazole competes with nicotinic acid and would impair the binding 
experiments. Imidazole did reduce the observed binding in radioligand binding assays to 80 % 
at concentrations of 100 mM and further to a level of 25 % of the initial value recorded 
without imidazole at 250 mM imidazole (Figure 17c). 
DMSO is a solubilizing agent that is frequently used for the preparation of pharmacological 
compound stock solutions that are poorly soluble in water. The question of whether DMSO 
would impair the binding of nicotinic acid to NAR1, and therefore render NMR STD 
Saturation Transfer Difference) studies or binding experiments with compounds in DMSO 
useless, was addressed. DMSO dramatically affects the observable binding of NAR1 to 
nicotinic acid in the standard radioligand binding filtration assay.   Results 
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Figure 17: a) Cation concentration dependence of NAR1 binding to [
3H]-nicotinic acid. ♦ NaCl, ■ 
KCl, ● LiCl, ▲ NH4Cl; b) NAR1 binding to [
3H]-nicotinic acid at different pH values; c) Effect of 
the imidazole concentration on NAR1 binding to [
3H]-nicotinic acid; d) Effect of DMSO 
concentration on NAR1 binding to [
3H]-nicotinic acid; e) Effect of the concentration of reducing 
agent DTT on [
3H]-nicotinic acid binding to NAR1 Results 
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Concentrations of 1 % DMSO reduce the detectable binding to less than 60 % and at 5 % 
DMSO only little more than 20 % is observed compared to initial binding without DMSO 
(Figure 17d). 
As already mentioned previously, a disulfide bond between the extracellular loops 2 and 3 is a 
common feature in family A GPCRs. Its pivotal function in receptor activity can be shown by 
the addition of reducing agents like DTT that reduce binding activity. 
In contrast to protein portions on the extracellular side of the membrane, intracellular portions 
need to be protected from oxidation by addition of reducing agents like DTT to the buffer. 
Otherwise non-specific formation of disulfide bonds between free cysteine residues can occur 
and lead to protein aggregation. In any standard preparation of the cytosolic β-arrestin, 
reducing agents would be present, therefore it was assessed how much DTT could be added 
along with β-arrestin for complexation with the receptor without affecting its structural and 
functional integrity. The radioligand binding activity of NAR1 in the presence of increasing 
amounts of DTT was measured and 1 mM DTT reduced receptor binding to 20 % of its 
original value. The detrimental effect of DTT on receptor activity furthermore confirms the 
crucial role for the conserved disulfide bond between extracellular loops 2 and 3 (Figure 17e). 
 
 
3.1.6 Solubilization 
As mentioned already in this work (1.2), the standard procedure for purification of membrane 
proteins is their extraction from the membrane and solubilization in detergents. In an initial 
experiment it was tested which out of a standard set of 18 detergents (LM, α-LM, NG, OG, 
UM, DM, DG, D/C, L-sucrose, Fos-12, Fos-14, Fos-16, LDAO, Cymal-6, C12E9, 
Zwittergent3-12, CHAPS and SDS) is capable of extracting NAR1 from Pichia pastoris 
membranes. The Western Blot analysis showed that all of the 18 chosen detergents can extract 
NAR1 from the membranes with the exception of DG (Figure 18). 
 
An additional preliminary screen addressed the question of whether the addition of detergent 
would have an effect on the observable binding of NAR1 in membranes. Therefore each 
detergent was added to the binding assay at a concentration of either ten times below and at 
the critical micellar concentration (cmc). Radioligand binding analyses showed that below the 
cmc, with the exception of SDS, all detergents were tolerated by the assay format and NAR1. Results 
  110 
 
 
 
Still, variations in the binding level were also observed in all cases. α-LM, UM, DM, DG, LS, 
Fos-14, Fos-16 Cymal-6 and C12E9 led to even higher binding levels, while OM, LDAO and 
Zwittergent3-12 reduced binding levels compared to control membranes. At detergent 
concentrations of one time cmc, only with α-LM, DM, Fos-16, Cymal-6 and C12E9 
significant binding activity could be detected (Figure 19). The same detergents shown above  
 
 
 
were tested at concentrations routinely used for solubilization. At detergent concentrations ten 
times above the cmc no binding was observed in the filtration radioligand binding assay for 
any of the detergents (data not shown).  
Figure 19: Detergent effect on NAR1 binding to [
3H]-nicotinic acid. Blue Bars: Binding activity 
at 0.1 times the cmc of the detergent in the binding assay, Red Bars: Binding activity at the cmc of 
the detergent added to binding assay. Control was performed on membranes without detergent. 
Figure 18: Solubilization of NAR1 from P. pastoris membranes with 18 detergents. For each 
detergent: 1
st lane: Solubilization Mixture, 2
nd lane: Supernatant; 10 µg membrane protein per 
lane. Results 
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In a further set of experiments the question asked was whether the loss of binding due to 
detergent addition was reversible. NAR1 containing membranes were solubilized with 1% 
detergent (w/v) containing 0.2 %(w/v) cholesteryl hemisuccinate, insoluble material was 
pelleted by centrifugation and then the detergent was subsequently removed with BioBeads. 
BioBead treatment did not show any effect on the binding activity of unsolubilized 
membranes, while DM/CHS solubilized membranes showed a recovery rate of up to 35 % of 
binding activity. The recovery rate with LM/CHS was much lower and yielded finally 15 % 
recovery of binding activity. Cymal-6/CHS behaved in a similar way, but yielded 20 % of the 
reference value after complete detergent removal. Furthermore the amount of detergent left in 
the DM/CHS, LM/CHS and Cymal-6/CHS samples was determined and recovery of the 
activity could only be seen once the detergent had been removed completely (Figure 20a, b). 
 
Table 6: Summary of data collected on radioligand binding assays in the presence of detergents 
with CHS without centrifugation prior to the assay. Column Solubilization Western Blot shows 
the capability of the detergent to extract NAR1 from the membrane: ++: all receptor was 
Solubilized; +: most of the receptor was Solubilized; -: the receptor was not Solubilized. Columns 
Ligand Binding [%] give the amount of ligand binding at detergent concentrations in the assay of 
0.1 cmc and the cmc. Values are given relative to those measured in membrane samples assayed 
without detergent. Results 
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It was more thoroughly investigated at which concentration detergents inhibit the interaction 
between NAR1 and nicotinic acid or that with the receptor and the glass fiber filter. Therefore 
increasing amounts of DM+CHS, LM+CHS and Cymal-6+CHS mixtures were added to the 
binding reaction and the remaining ligand binding activity was analyzed. It is clearly evident, 
that as soon as the detergent concentrations come close to the critical micellar concentration, 
the measurable binding activity is lost (Figure 20c). 
 
Figure 20: a) Recovery of ligand binding activity after solubilization and stepwise detergent 
removal with BioBeads (4 rounds); light blue bars: membranes; dark blue: DM+CHS solubilized 
NAR1 membranes; pink bars: LM+CHS solubilized NAR1 membranes; yellow bars: Cymal-
6/CHS solubilized NAR1 membranes; b) remaining detergent in samples from a) ♦: DM 
concentration;  ■: LM concentration; ▲: Cymal-6 concentration; ▬: membranes without 
detergent. c) Loss of [
3H]-nicotinic acid binding of NAR1 with increasing detergent 
concentrations; ♦: DM+CHS; ■: LM+CHS; ▲: Cymal-6+CHS; ▌DM cmc (~0.086 %(w/v)); 
▌LM cmc (~0.0086 %(w/v)); ▌Cymal-6 cmc (~0.028 %(w/v)).
c) 
a) b)Results 
  113
3.1.7 Purification & Enzymatic Processing 
3.1.7.1 HisTrap
TMHP (IMAC) 
The first purification step was chosen to be an immobilized metal affinity chromatography 
(IMAC) step that uses the decahistidine tag for specific interaction with the nickel loaded 
resin. The cleared solubilizate of membrane proteins was loaded onto a HisTrap HP column 
and eluted initially with a shallow linear gradient up to 300 mM imidazole. It was found that 
NAR1 remained tightly bound to the column up to concentrations of 60 mM imidazole 
(Figure 21a). Additionally it was found that an endogenous Pichia pastoris protein running at 
an apparent molecular weight of 40 kDa, that appeared as recurrent impurity in the 
purification of several other proteins expressed in Pichia pastoris, could be significantly 
reduced by the introduction of an additional no-salt washing step (Figure 21b) (C. Reinhart, 
personal communication). 
 
3.1.7.2 Post-Translational Modifications & TEV Cleavage 
Crude preparations of NAR1 were used for characterization of the post translational state of 
the protein and cleavability by TEV protease. SDS-PAGE and Western-Blot analysis 
confirmed the identified band, migrating at an apparent molecular weight of 55 kDa as NAR1. 
Additionally, TEV cleavage produced a truncated fragment of an apparent molecular weight 
of ~40 kDa that corresponds to the expected size of the untagged NAR1 expression construct 
(Figure 22). Furthermore, the signal for that band disappeared in the anti-His Western-Blot. 
The Coomassie gel excised band was identified as NAR1 by mass spectrometric analysis at 
the laboratories of Sanofi-Aventis Deutschland GmbH. 
 
One problem that arises with the heterologous overexpression of membrane proteins is the 
differential glycosylation pattern compared to its pattern in a homologous organism. The 
NAR1 amino acid sequence evaluated with a bioinformatics tool, NetOGlyc 3.1 [88], 
identifies two potential consensus sequences for O-linked glycosylation, Threonine 360 and 
Serine 361. A similar tool, NetNGlyc 1.0 [89], predicts N-linked glycosylation sites, and 
found two within the NAR1 sequence, Lysine 140 (NRTA) and Lysine 335 (NKTR) (Figure 
23a). All these signature sequences are found within the cytosolic parts of NAR1, and 
therefore not subjected to glycosylation, which occurs only at the extracellular portions of 
proteins. This in silico prediction could be confirmed by enzymatic assays using PNGase F Results 
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and Endo-H. After treatment with these two enzymes no altered mobility on SDS-PAGE 
could be observed (Figure 23b). 
 
 
 
 
 
Figure 21: a) 10 % SDS-PAGE, Coomassie stained and corresponding Anti-His Western-Blot of 
initial NAR1 IMAC purifiaction, with DM+CHS as detergent. M: Membranes (10 µg); S: 
Solubilizate; FT I: First Flow Through Fraction; FT II: Second Flow Through Fraction; The grey bar 
indicates 15 µl samples of 2 ml fractions from the imidazole gradient (0 mM – 300mM). b) 
Chromatogram of final purification and corresponding Coomassie stained 12 % SDS-PAGE. 
a) 
b) Results 
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After TEV cleavage most of the NAR1 protein precipitated, and the intended inverse affinity 
chromatography was not possible. Therefore a number of different chromatographic steps 
were evaluated as a second one, to separate unfolded precipitating species after TEV cleavage 
from folded ones. 
Figure 22: left panel: 12% SDS-PAGE, Coomassie stained (10µg total protein loaded each 
lane); NAR1 cleaved by TEV protease; right pannel: Corresponding Anti-His Western-Blot 
(10µg total protein loaded each lane). 
Figure 23: a) NAR1 piktogram, predicted N-linked glycosylation sites (N140, N335) marked with 
a green arrow, predicted O-linked glycosylation sites (T360, S361) are indicated by a red arrow. b) 
10 % SDS-PAGE showing PNGase F treated NAR1, NAR1 and EndoH treated NAR1 (10 µg total 
protein loaded each lane). 
a)  b) Results 
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3.1.7.3 Ion Exchange Chromatography of TEV cleaved NAR1 
Five different ion exchange columns, the anion exchange resins DEAE, Q and ANX 
Sepharose as well as the cation exchange materials CM and SP Sepharose were tested 
according to their ability to separate folded from unfolded, precipitating NAR1. 
 
 
 
NAR1 was initially purified on an IMAC column as described above (3.1.7.1), genetically 
engineered tags were removed by TEV cleavage, loaded onto the various resins, and eluted 
with a linear salt gradient. 
The cation exchangers CM and SP did not bind NAR1 and did not result in an increased 
purity of the sample. Anion exchange columns did bind the receptor and NAR1 was eluted in 
Figure 24: a) Chromatogram comparison of NAR1 purification on various ion exchange resins. 
Blue: DEAE; Light Blue: Q; Grey: ANX; Red: CM; Yellow: SP; Green: Gradient; Orange: 
Conductivity. b) 12 % SDS-PAGE, Coomassie stained. Lanes show 15 µl samples of the indicated 
fractions from the different column materials. M: Marker; L: Load; FT: Flow Through; 1: Fr. 1from 
a); 2: Fr. 2 from a); 3: Fr.3. from a). 
a) 
b) Results 
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a salt concentration dependent manner. SDS-PAGE analysis showed however that the major 
peak did not correspond to the receptor. NAR1 was found in DEAE and Q elution profiles in 
the fraction following the major peak. In the DEAE column elution profile, this corresponds 
to a distinct shoulder of the major peak. The fraction that contained NAR1 in the SDS-PAGE 
did not show a peak in the Q elution profile. No fraction could be identified that contained 
NAR1 in the ANX elution profile. In fact, the NAR1 protein did not appear in any of the 
ANX fractions (Figure 24). Although the DEAE column improved protein purity slightly, the 
major problem remained protein stability and could not be overcome by the addition of ligand 
and asolectin. The major part of the protein precipitated either during TEV cleavage, during 
the second chromatography step or shortly after. 
 
3.1.8 Stability Screen 
Finding buffer conditions that preserved the activity of NAR1 was an important goal. The 
tested conditions varied with respect to pH, detergent type, detergent concentration, ionic 
strength and, for the tag-containing and the TEV processed state the NAR1 construct. An 
artificial stability score was set up, where samples were attributed a value of 2 for clear 
samples without precipitation, and 0 for massive precipitation. Intermediate scores of 0.5 and 
1 were attributed to samples that displayed only slight precipitation. Tested detergents 
included DM/CHS, LM/CHS, Cymal-6/CHS, C12E9/CHS and the harsher detergents Fos-
12/CHS and Fos14/CHS that produced good results for other receptors in our group. The 
detergent concentrations were varied between 1.5 times the cmc and 3 times the cmc. 
Furthermore, the pH was varied between 4.0 and 9.5, and the NaCl concentration was tested 
at values of 0 mM, 100 mM and 500 mM. 
The results of this stability screen showed that differences between detergents are tremendous. 
While in DM/CHS the addition of TEV protease led to the precipitation of nearly all 
conditions within 24 hours, harsher detergents like Fos-12/CHS were capable of keeping 
NAR1 in solution for more than 144 hours, despite TEV cleavage (Figure 25a). Another 
observation showed increased stability at higher detergent concentrations for cleaved NAR1. 
For example at 3 times cmc TEV cleaved NAR1 was stable in DM/CHS for up to 48 hours, 
compared to only 24 hours at 1.5 times cmc (Figure 25b). The phenomenon of prolonged 
solubility was also observed at higher salt concentrations (Figure 25c). Yet, most importantly, 
even in milder detergents at low concentrations, the tagged NAR1 was more stable than the  Results 
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Figure 25: a) Comparison of NAR1 stability in 
respect to detergents DM and Fos-12 after 
144h. Blue Bars: 1x cmc DM + TEV showed 
precipitation at all conditions and were 
attributed scores between 0 and 1; Red Bars: 1x 
cmc Fos12 + TEV remained clear throughout 
the experiment and were attributed the score 2. 
Figure 25: b) Comparison of NAR1 stability with respect to detergent concentration 
without TEV at 24 h and 144 h, Blue Bars: 1x cmc DM/CHS; after 24 h only at pH 5.5 
slight precipitation occurred and increased after 48 h. All other samples showed massive 
precipitation. Red Bars: 3x cmc DM; Most samples remained clear and were attributed 
score 2. After 48 h precipitation increased but was less severe than at lower DM 
concentrations 
Figure 25: c) Comparison of NAR1 
stability with respect to NaCl 
concentration at 24 h, 48 h, 72 h with 
TEV. Blue Bars 0 mM NaCl show 
precipitation after 24 h; Red Bars: 100 
mM NaCl display massive precipitation 
after 48 h; Yellow Bars: 500 mM NaCl 
even after 72 h half of the samples still 
show clear drops.  
a) 
b) 
c) Results 
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cleaved one which precipitated rapidly after tag removal. Furthermore, it was observed that 
three pH values, pH 6.0, pH 7.0 and pH 9.0, irrespective of detergent, salt concentration and 
TEV cleavage, did not result in precipitation, or at least less severe precipitation than at other 
pH values (Figure 25d). 
 
3.1.9 Chromatographic Purification of NAR1 (with tags) 
Further purifications were run at pH 5.5, 6.0, 7.0 (both solubilized and loaded on HisTrapHP 
material at pH7.4) and pH 9.0 using six detergents (Fos-12/CHS, Fos-14/CHS, C12E9/CHS, 
DM/CHS, LM/CHS, Cymal-6/CHS) and subsequently compared. Results from the stability 
screen could not easily be adapted to large scale preparations, since TEV cleavage of NAR1 
in detergents Fos-12/CHS, Fos-14/CHS and C12E9/CHS that showed no precipitation in the 
stability screen resulted in massive precipitation in large scale preparations. Elution from the 
HisTrapHP material at pH 5.5 and 6.0 resulted also in massive precipitation. The focus then 
turned again onto LM/CHS, DM/CHS and Cymal-6/CHS which already indicated positive 
results in previous functional assays. In comparable purification runs 50% more protein was 
Figure 25: d) Comparison of NAR1 
stability with and without cleavage by 
TEV protease, Blue Bars: No TEV; at 
most conditions the samples remained 
clear and did not show precipitation. Red 
Bars: with TEV; after 24 h almost half of 
the samples show precipitation and only 
4 samples remain clear after 72h. 
Detergent used in this set of experiments 
was DM/CHS at 1.5 cmc. 
d) Results 
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eluted at pH 9.0 than at pH 7.0 according to peak height at UV monitor at 280nm. Further 
analysis of initial purified NAR1 was done by analytical gel filtration. 
 
3.1.9.1 Analytical Gel Filtration 
 
 
 
Figure 26: Superose 6 Gel Filtration of NAR1 after Ni-NTA purification. a) Chromatogram Blue: 
with LM, CHS and Asolectin; Green: with DM, CHS and Asolectin; Yellow: with Cymal-6, CHS 
and Asolectin. b) 12 % SDS-PAGE 15 µl samples of 2 ml fractions from LM run as indicated above, 
Coomassie stained, c) 12 % SDS-PAGE 15 µl samples of 2 ml fractions from DM run as indicated 
above, Coomassie stained, d) 12 % SDS-PAGE 15 µl samples of 2 ml fractions from Cymal-6 run as 
indicated above, Coomassie stained. 
a) 
b) 
c) 
d) Results 
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NAR1 protein in DM/CHS, LM/CHS, or Cymal-6/CHS purified by immobilized metal 
affinity chromatography at pH 7.0 or pH 9.0 was subjected to analytical gel filtration. Protein 
purified at pH 7.0 did not elute from the gel filtration column, indicating aggregation on the 
prefilter or the column. Protein preparation at pH 9.0 in contrast prevented this aggregation. 
LM/CHS showed a pronounced peak in the void volume, indicating higher order 
oligomerization or aggregation of the protein. DM/CHS and Cymal-6/CHS showed profiles 
without such a pronounced aggregation peak but the elution profile was still a broad one, 
consisting of multiple species. SDS-PAGE analysis of the gel filtration run showed that 
NAR1 was present in the highest concentration in the void volume peak if LM/CHS was used 
as detergent, while when purified in DM/CHS or Cymal-6/CHS it was found in the broad 
peak of the elution profile, with none detectable in the void volume (Figure 26). 
As already seen in the reversibility of solubilization (Solubilization 3.1.7) the detergents 
DM/CHS and Cymal-6/CHS seem to be tolerated best by NAR1 with respect to ligand 
binding. 
 
 
3.1.9.2 Purification on Immobilized Monomeric Avidin 
 
Immobilized monomeric avidin column was tested as a second affinity purification step 
following IMAC purification. The performance of the resin further increased the purity of 
NAR1 (Figure 27a, b). Most dramatically was its effect on the gel filtration behavior of NAR1 
(Figure 27c). 
The concentrated NAR1 protein gave a single peak on the gel filtration column after IMAC 
and immobilized monomeric avidin purification (Figure 27c). This peak corresponds to a 
monomeric form of the receptor, if the retention volume on the Superpose-6 is compared to 
other GPCRs purified in our group. Furthermore, the fractions of this peak correspond to the 
fractions of the broad gel filtration profile just after immobilized metal affinity 
chromatography that contained the receptor. However, significant amounts of protein were 
lost on the immobilized monomeric Avidin column and only eluted under harsh column 
regeneration conditions. Typically, only 10% to 20 % of NAR1 that was bound on the column 
was eluted with biotin, while the remainder could only be eluted under regeneration 
conditions at pH 2.8. 
 
 Results 
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3.1.9.3 Alternative Chromatographic Steps to increase the purification yield 
 
The HP Blue material was tested as additional resin. It is made of a dye that contains a 
nicotinic acid moiety and was evaluated as ligand column. NAR1 did not bind to this material, 
either at pH 7.0 or pH 9.0. 
Figure 27: Purification of NAR1 on immobilized monomeric avidin and by gel filtration on 
superpose 6. a) monomeric avidin affinity chromatography of NAR1: Chromatogram and b) 12 % 
SDS-PAGE analysis. Black bars indicate fractions from the chromatogram. c) Superose 6 gel 
filtration of NAR1 after monomeric avidin: Chromatogram and 12 % SDS-PAGE of fraction 
indicated. 
a) 
b) 
c) Results 
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The DEAE column material which already proved to bind cleaved NAR1 at pH 7.5 was used 
again. Scouting purification runs were performed for pH values 6.0, 7.0, 8.0 and 9.0. NAR1 
bound to the column at all pH values, indicated by no UV280 nm absorbance during loading.  
 
 
 
 
Figure 28: DEAE ion exchange chromatography at different pH values: a) Chromatograms, Blue: pH 
9; Red: pH 8; Yellow: pH 7; Green: Gradient. b) 12 % SDS-PAGE, Coomassie stained, 15 µl samples 
of fractions indicated above, run at pH 7. c) 12 % SDS-PAGE, Coomassie stained, 15 µl samples of 
fractions indicated above, run at pH 8. d) 12 % SDS-PAGE, Coomassie stained, 15 µl samples of 
fractions indicated above, run at pH 9. Lane 1: load; following lanes are samples from the fractions 
corresponding to the ones in the chromatogram. 
a) 
b) 
c) 
d) Results 
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Elution with increasing salt concentration resulted in peaks only for pH values of 7.0, 8.0 and 
9.0. The sharpest and highest peak was observed at pH 7.0, but according to SDS-PAGE this 
peak did not contain any NAR1. In contrast, pH 8.0 and pH 9.0 which resulted in a 
comparable elution chromatogram contained NAR1 (Figure 28). Although the purity could be 
increased, the loss of protein was severe, and the purification on immobilized monomeric 
avidin could not be rivaled. 
 
3.2  Interaction of NAR1 with β-Arrestin 1 in vivo 
To prove the hypothesis that β-arrestin 1 interacts with NAR1 in vivo, NAR1 was cloned into 
a pcDNA3.1 derivative and equipped with a C-terminal GFP fusion partner resulting in vector 
construct pcDNA3.1 NAR1-GFP. A truncated version of human β-arrestin 1 (residues 1-382) 
and the wild type full length sequence were cloned into the same pcDNA3.1 derivative and 
equipped with an N-terminal CFP fusion, resulting in vectors pcDNA3.1 CFP-βarr1-382 and 
pcDNA3.1 CFP-βarr1-fl. In both constructs the fluorescent protein variant was separated from 
the target protein by a spacer of ten amino acids. The resulting vectors were analyzed by 
restriction digestion and verified by DNA sequencing. 
Transfection of the different constructs into Human Embryonic Kidney (HEK) or Baby 
Hamster Kidney (BHK) cells yielded the expected fluorescence, and confocal laser scanning 
microscopy showed the correct cellular localization of both constructs. NAR1-GFP was 
correctly localized at the plasma membrane and internal membranes, indicated by a clearly 
fluorescent cell periphery and further fluorescence around the nucleus, while the CFP 
fluorescence of both arrestin constructs was distributed evenly throughout the cytoplasm 
(Figure 29). 
Cotransfection of the pcDNA3.1 NAR1-GFP construct with either pcDNA3.1 CFP-βarr1 
construct yielded double fluorescent cells with easily distinguishable signals for both proteins, 
β-arrestin 1 being in both cases distributed throughout the cytoplasm, while NAR1 was 
located in the plasma membrane or in internal membrane compartments of the secretory 
pathway (Figure 29). 
Addition of nicotinic acid resulted in the recruitment of cytosolic β-arrestin to the membrane, 
as evidenced from the CFP-fluorescence signal, where the GFP signal indicated the presence 
of NAR1 (Figure 30). Control cells that were not co-transfected with NAR1, and therefore 
devoid of GFP fluorescence, did not react to the addition of nicotinic acid. CFP-fluorescence 
remained in the cytoplasm of the cell and did not translocate to its membrane.  Results 
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Figure 30: BHK cells cotransfected with CFP-βarr1-382 (excitation 405 nm; emission detection 
420-480 nm) and NAR1-GFP (excitation 488 nm; emission detection >505 nm). a) before nicotinic 
acid addition, left: CFP-βarr1-382, right: NAR1-GFP. b) 10 min after nicotinic acid stimulation, left 
CFP-βarr1-382 translocation marked by white arrows, right: NAR1-GFP. The white bar corresponds 
to 4 µm. 
Figure 29: Doubly transfected HEK cells, a) CFP-βarr1-fl fluorescence imaging, excitation 405 nm, 
detection 420–480 nm. b) NAR1-GFP fluorescence image; excitation 488 nm, detection 
> 505 nm. White bar corresponds to 20 µm. 
a) 
b) 
a) b)Results 
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3.3  Comparative Multi-Host Expression of β-Arrestins in E. coli 
and P. pastoris 
3.3.1 Cloning & Expression 
The amino acid sequence of the crystallized bovine β-arrestin 1 [64] was aligned with the 
sequences of human β-arrestin 1 and human β-arrestin 2. The sequence identity between the 
bovine and the human isoforms of β-Arrestin 1 is 99 %, within the length of the crystallized 
fragments only two amino acids differ. The identity between human β-arrestin 1 and β-
arrestin 2 is 74 %. The major differences are found in loop regions while the secondary 
structure elements are well conserved. The regions flanking the activating mutation R169E 
[90] and the truncation of the crystallized constructs, comprising residues 1 to 382 and 1 to 
393, are well conserved, and easily identified in the human sequences (Figure 31). 
Additionally, the shortest crystallized version of β-arrestin 1 (residues 1-382) has been shown 
to be another constitutively active variant [89]. 
 
To increase the hydrophilic portions of NAR1 and potentially stabilize it, the reconstitution of 
the complex with β-arrestin 1 should be attempted. For the production of β-arrestin 1 a 
comparative expression in two heterologous systems, E. coli and P. pastoris was set up. For 
reasons of completeness constructs of β-arrestin 2 were included. Therefore, both β-arrestin 
sequences were amplified by PCR introducing restriction sites EcoRI and NotI and an N-
terminal TEV cleavage site in three different versions, comprising residues 1-382, 1-393 and 
full length. The amplified DNA 1-393 was derivatized by a PCR overlap extension 
exchanging arginine169 for a glutamate in β-arrestin 1 (R169E), arginine170 for a glutamate 
in β-arrestin 2 (R170E), and all versions were ligated into a pPIC3.5K vector derivative with 
an N-terminal GST-tag for P. pastoris expression resulting in vectors pPIC3.5K GST-βarr1-
382, pPIC3.5K GST-βarr1-393R169E and pPIC3.5K GST-βarr1-fl for β-arrestin 1 and 
pPIC3.5K GST-βarr2-382, pPIC3.5K GST-βarr2-393R170E and pPIC3.5K GST-βarrr2-fl for 
β-arrestin 2. 
The same β-arrestin cDNAs were ligated into a pGEX vector, containing an N-terminal GST 
moiety, a pET vector derivative, containing an N-terminal hexahistidine tag, resulting in 
vectors pGEX βarr1-382, pGEX βarr1-393R169E, pGEX βarr1-fl, pGEX βarr2-382, pGEX 
βarr2-393R170E, pGEX arr2-fl and pET βarr1-382, pET βarr1-393R169E, pET βarr1-fl, pET 
βarr2-382, pET βarr2-393R170E and pET βarr2-fl, respectively. Additionally, the DNAs were 
amplified without the TEV recognition site and ligated into a pTrc vector, resulting in  Results 
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Figure 31: Sequence Alignment of arrestins (bovine β-arrestin 1; human β-arrestin 1; human β-
arrestin 2; human visual arrestin). Secondary structure elements depicted above are derived from the 
structure of bovine β-arrestin 1. Strictly conserved residues are given in red, conservatively 
exchangeded residues in yellow. The length of truncated constructs is depicted below, and the 
activating mutation R169E in β-arrestin 1 is marked with a red arrow. Results 
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vectors pTrc βarr1-382, pTrc βarr1-393R169E, pTrc βarr1-fl, pTrc βarr2-382, pTrc βarr2-
393R170E and pTrc βarr2-fl. 
 
All pPIC3.5K vectors were transformed into protease deficient P. pastoris strain SMD1163, 
and multi-copy clones selected on G418-containing YPD plates. E. coli vectors were 
transformed into strains BL21 DE3, BL21 Codon plus and Rosetta gami DE3 pRARE and 
tested for expression (Figure 32). 
The β-arrestin 1 variants were expressed significantly better than the β-arrestin 2 constructs, 
and the best expression was achieved with the shortest version of β-arrestin 1, pET βarr1-382. 
The full length wild type construct pET βarr1-fl showed lower expression levels. The worst 
expression among β-arrestin 1 constructs was pET βarr1-393R169E. Furthermore, the pET 
derivative containing the HisTEV-tag displayed a higher expression than the pTrc constructs 
without the modifications. Expression in both LB and M9 minimal media was possible. 
Compared to LB medium, M9 minimal medium had a lower expression. For LB medium, the 
induction time of four hours, and a growth temperature of 25°C were sufficient. Higher 
temperature led to more insoluble material, and longer expression time did not obviously 
increase the amount of produced protein. 
Although significant overexpression of GST-β-Arrestin constructs was not evident from E. 
coli whole cell lysates, conditions were adapted so that the GST-fusion proteins could be 
detected on Glutathione Sepharose 4B beads after incubation with E. coli whole cell lysates. 
 
 
 
Figure 32: Whole Cell Lysates of β-arrestin in E.coli. a) BL21 DE3 cells with pTrc βarr1-382, 
producing βarr1-382, grown in M9 medium, 25 °C; -: uninduced, +:4 h after induction. 12 % SDS-
PAGE, Coomasssie stained, b) BL21 Codon Plus cells with pET βarr1-382, producing His-βarr1-
382, grown in LB media, 25 °C; -: uninduced, +: 4 h after induction; 14 % SDS-PAGE, Coomassie 
stained. 
a) b)Results 
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SDS-PAGE analysis of GST- β-arrestin 1 immobilized on glutathione beads allowed the 
selection of the P. pastoris clone with the highest apparent expression. The shortest construct, 
pPIC3.5K GST-βarr1-382 and the pPIC3.5K GST-βarr1-fl construct yielded the best 
expression; the construct version pPIC3.5K GST- βarr1-393R169E displayed lower 
expression, while no clones derived from vectors pPIC3.5K GST-βarr2-382, pPIC3.5K GST-
βarr2-393R170E and pPIC3.5K GST-βarrr2-fl could be detected that expressed β-arrestin 2 in 
any version. 
 
 
3.3.2 Purification 
An affinity purification step initiated β-arrestin 1 purification. HisTrap HP resin was used in 
the case of the His-tagged version, and a Glutathione Sepharose 4B matrix for GST 
constructs. 
MALDI-TOF analysis of the fragments derived from tryptic digestion was used to confirm the 
identity of the protein. 17.7% of the proteins’ sequence was covered by the retrieved   
 
 
 
Figure 33: Mass Spectrometric Identification of β-arrestin 1-382 produced in P. pastoris after 
Tryptic Digest. Results 
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fragments of characteristic masses (Figure 33), which along with the fact that the protein was 
susceptible to TEV cleavage and displayed an altered mobility in SDS-PAGE analysis 
afterwards unambiguously identified the protein. 
 
 
Fragment 
Position 
Peptide Sequence  Calculated 
Mass 
Observed 
Mass 
26-49 DFVDHDILVPDVDGVVLVDPEYLK  2711.3813  2711.35 
52-62 RVYVTLTCAFR  1399.7514  1277.74 
53-62 VYVTLTCAFR  1172.6132  1172.64 
53-62 Cys 59PAM  VYVTLTCAFR  1243.6503  1243.66 
63-76 YGREDLDVLGLTFR  1653.8594  1653.85 
66-76 EDLDVLGLTFR  1277.6735  1277.74 
313-322 EILGIIVSYK  1134.6768  1134.68 
 
 
The second chromatographic step employed a HiTrap HeparinHP column. Elution with 
increasing ionic strength yielded a single peak for GST- β-arrestin 1-382 and two peaks for 
the TEV-cleaved and the His-tagged protein product. SDS-PAGE analysis of each peak 
demonstrated that each of them contained pure GST- β-arrestin 1-382 or pure β-arrestin 1-382 
respectively. In case of the TEV cleaved product, the TEV protease and GST moieties could 
be separated from β-arrestin 1-382. 
 
Since the HiTrap Heparin HP column yielded two peaks for the cleaved β-arrestin 1-382 that 
were only partially resolved by elution with a linear salt gradient, anion exchange 
chromatography was assessed for its purification. Chromatographic analysis on a Q-
Sepharose column yielded a single homogeneous peak that contained only β-arrestin 1-382 
according to SDS-PAGE analysis. Both samples of the HiTrap Heparin HP column and the Q-
Sepharose column were compared by Gel Filtration on a Superdex 75 10/30GL column and 
by 1D NMR spectroscopy. All three samples produced comparable gel filtration profiles 
consisting of two peaks, the first one right within the void volume of the column and the 
second one with a retention volume of 52 ml. The major difference between the three samples 
was the ratio between the 2 peaks. The sample produced by purification using the Q-
Sepharose column and by the first peak of the HiTrap Heparin HP column showed ratios in 
favor of the aggregation peak, while only within the sample corresponding to the second peak 
Table 7: Masses of observed peptide fragments of β-arrestin 1-382 by mass spectrometric analysis. Results 
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of the HiTrap Heparin HP column the ratio changed, and the portion of monomeric β-arrestin 
1-382 was superior to the aggregated one (Figure 34). 
 
All the experiments described above were performed with samples derived from GST-β-
arrestin 1-382 produced in Pichia pastoris, and His-β-arrestin 1-382 produced in Escherichia 
coli. Neither the purification protocol with its functionality test of Heparin binding nor the 
NMR analysis showed differences in quality of the samples produced either in E. coli or P. 
pastoris. One liter of shaking flask culture from P. pastoris yielded typically 1.25 mg of 
purified β-arrestin 1-382, while E. coli produced only 0.35 mg per liter culture. 
 
 
 
 
 
3.4  Interaction of NAR1 with β-Arrestin 1 in vitro 
Samples of NAR1 purified in DM/CHS, LM/CHS or Cymal-6/CHS in the presence of 
nicotinic acid and asolectin were mixed with GST-β-arrestin 1-382 and Glutathione 4B 
Sepharose beads. SDS-PAGE and Western Blot analysis showed that NAR1 was specifically 
bound to the beads if the pull down experiment was done with DM/CHS (Figure 35) or 
LM/CHS as detergents. If Cymal-6/CHS was used as detergent, NAR1 was not retained on 
the beads. Still, it is obvious from SDS-PAGE analysis that only a small fraction of NAR1 
was bound by β-arrestin 1, since it could only be visualized by Western-blotting. 
Figure 34: Upper Pannel: Superdex 75 Gel Filtration of β-arrestin 1-382, and 12% SDS-PAGE, 
Coomassie stained of fractions indicated above. Results 
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Furthermore, the β2-adrenergic receptor could be bound in the same manner to GST-β-arrestin 
1-382 (data not shown). The β2-adrenergic receptor was bound more efficiently, and could be 
visualized on silver stained SDS-PAGE yet, as for NAR1, the majority of the receptor was not 
retained. 
 
 
 
 
3.5 Activity  Measurements  of  Solubilized & Purified NAR1 
Only substoichiometric amounts of NAR1 were bound by β-arrestin1. Therefore it was to be 
assessed which fraction of the receptor was in an active state, capable of being bound by β-
arrestin1-382. Given that the addition of detergent impairs the standard radioligand filtration 
assay, as demonstrated above, other methods had to be tested. 
•  Since NAR1 already proved to be bound by immobilized metal affinity resins, NAR1 
was immobilized onto these beads, allowed to capture radioligand nicotinic acid, and 
excess, free, radioactive material was removed by washing. This method was again 
evaluated for the detergents that were found to be promising in above mentioned 
experiments. DM/CHS, α-LM/CHS, Cymal-6/CHS, C12E9/CHS and Fos-14/CHS 
were compared, but none produced an observable binding signal, despite the fact that 
the receptor was highly enriched compared to membrane binding assays. 
 
Figure 35: Pull Down experiment using GST-β-arrestin 1-382 as bait for activated NAR1 
receptor. 12 % SDS-PAGE analysis and Anti-His Western-Blot. Results 
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•  The use of streptavidin coated plates that had been proven successful in demonstrating 
binding activity for A2A-adenosine receptor [67], failed to produce a result with 
NAR1. [
3H]-nicotinic acid was not retained, and no signal was observed. 
 
•  In gel filtration assays that had been used to demonstrate ligand binding activity of the 
β2-adrenergic receptor [68], the separation of bound from free radioactive material is 
achieved by differential retention times of the receptor ligand complex and the free 
ligand. The equilibrated reaction mix containing the radio ligand and the receptor are 
loaded onto the column. The radio ligand which is bound to the receptor molecule will 
travel faster through the column, while free radio ligand will take longer to pass 
through, thus separating bound from free material. NAR1 functionality was assessed 
by this method, again with the five above mentioned detergents. Best results were 
obtained with α-LM/CHS, which produced only a miniscule signal, two-fold above 
background, while NAR1 handled in other detergents failed to produce any signal at 
all. 
 
•  Equilibrium Dialysis 
Equilibrium dialysis is a method for determining the binding activity in a given sample 
of soluble proteins [91]. Its advantage over the above described methods relies on the 
fact that the fraction of bound ligand is measured as an increase in radioactivity 
compared to the reference compartment. The removal of free ligand is not required, 
and concentration dependent disassembly of the complex does not occur during 
separation. This experimental method was adapted for NAR1 binding analysis, and a 
preparation of purified NAR1 was assayed on its binding ability. As with the previous 
attempts, no productive binding of radioligand was detected. 
 
•  Scintillation Proximity Assay 
Similar scintillation proximity assays are a technique that does not require the 
separation of free and bound radioactivity. The scintillant is embedded in a small bead, 
which is covered with an affinity matrix. Binding of a receptor to the affinity ligands 
on the beads and, in turn, the binding of a radiolabeled ligand to the receptor, will 
concentrate radioactivity around the bead, and increase the stimulation of the 
scintillant within the bead, resulting in a signal. This method had been shown to 
identify a synthetic agonist for the CRHT2 receptor [92]. A preparation of NAR1 was Results 
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subjected to these experiments, which were performed in collaboration with Dr. Irvin 
Winkler at Sanofi-Aventis Deutschland GmbH, but demonstrated no detectable 
activity of the receptor. 
 
•  Saturation Transfer Difference Spectroscopy 
The only method that was finally capable of demonstrating activity of NAR1 was 
Saturation Transfer Difference Spectroscopy. This is a method that targets the small 
molecule ligand, in this case nicotinic acid. Within an NMR Spectrometer, the 
compound nicotinic acid has a unique signal, its peak shifts and their magnitude is 
related to the concentration of the compound. In the presence of a binding protein, 
magnetism is transferred from the compound to the protein molecule. The detected 
signal for the small molecule compound is diminished, and the difference between the 
compound by itself and the compound in the presence of the binding protein indicates 
whether binding events between both partners occur. Saturation Transfer Difference  
 
 
 
Spectroscopy was done in collaboration with Alexis Rozenknop and Dr. Stefan 
Bartoschek at Sanofi-Aventis Deutschland GmbH, and remains the only method that 
has been able to show a binding signal for solubilized and purified NAR1. STD 
Figure 36: STD Spectra of NAR1 with Acipimox. Blue: 1D Spectra at day 1; Green: 1D Spectra at 
day 2 (offset by 0.1 ppm); Red: STD Spectra at day 1; Purple: STD Spectra at day 2 (offset by 0.1 
ppm). The red shaded area shows specific signals of Acipimox at day 1 which reappear in the STD 
spectra and indicate binding. The green shaded area displays the same specific peaks for Acipimox 
that are diminished at day 2, indicating reduced binding due to protein instability over time. Results 
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measurements demonstrated binding of Acipimox and Acifran, the clinical used drugs, 
to NAR1 (Figure 36). STD measurements with each compound in a reference buffer 
did not show any signal, indicating that binding observed in samples is specific. 
 
3.6  Reconstitution of NAR1 into Liposomes 
Since activity measurements of NAR1 in solution appeared to be far from straightforward, 
and the functionality of membrane proteins is intimately linked with its correct placement into 
the lipid bilayer, the reconstitution of NAR1 into lipid vesicles was attempted. 
There are a number of ways to reconstitute membrane proteins into lipid vesicles. The 
simplest method is to mix preformed liposomes with solubilized membrane protein in excess 
detergent. The detergent will render the liposomes accessible for incorporating proteins, and 
subsequent detergent removal results in proteoliposomes. DM/CHS solubilized and purified 
preparations of NAR1 were used for this kind of reconstitution experiment. Vesicles obtained 
were analyzed in two ways. First, binding activity was measured by the standard radioligand 
binding assay. Second, freeze fracture imaging of prepared vesicles was performed to 
visualize and estimate the content of protein incorporated into the lipid bilayer. Activity 
measurements remained without result, which is in good agreement with the results obtained 
by freeze fracture images taken by Dr. Winfried Haase. The liposomes that are seen in these 
images are devoid of protein, while in between the liposomes irregular structures are observed 
which most likely represent larger aggregates of the protein. 
 
At low concentrations detergent molecules exist in solution as monomers, but above a certain 
concentration, the cmc, in equilibrium between monomers and micelles. On the other hand, 
detergent molecules will dissolve in the lipid bilayer of added vesicles resulting in a different 
equilibrium between detergent molecules dissolved in lipid membranes, in free monomers and 
micelles, if the concentration of free monomers is still above the cmc. To prevent detergent 
molecules from being removed from the solution, lipid vesicles were presaturated with 
detergent, just below the point of bilayer disruption, as monitored by light scattering at 550 
nm. These presolubilized lipids were mixed with purified NAR1 and the detergent was 
subsequently removed by BioBead addition. Recovered activity by this method did not exceed 
2 % of that measured in membranes. 
 Results 
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The second approach began from a different point. Solubilized lipids were included in the 
purification buffers of NAR1. Due to the fact that lipids can already associate with the 
membrane protein in solution, mixed micelles are formed containing NAR1 and lipids. The 
removal of detergent molecules should lead to the association of mixed micelles to form 
larger mixed micelles eventually leading to membrane fragments and finally vesicles 
containing membrane protein. 
Removal of detergent was accomplished by various methods, the first and simplest being the 
incubation with BioBeads. A second one was the removal of detergent with cyclodextrins. 
Two further attempts were based on dilution, one being a very controlled dilution using gel 
filtration and the other one by dilution into buffer without detergent, resulting in a quick drop 
of the detergent concentration below cmc values and thus initiating the aggregation of lipid 
molecules along with membrane protein to form vesicles. 
 
 
 
 
Figure 37: a + b) Electron Microscopic Negative Stain Imaging of NAR1 Reconstituted into 
Liposomes; c) Electron microscopic freeze fracture imaging of NAR1 reconstituted into liposomes; 
d) Electron microscopic image of Immuno-Gold labelling of NAR1. The black bar indicates 1 µm.Results 
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The reconstitution experiments were analyzed again by the functional radioligand binding 
assay and electron microscopic studies (Figure 37). Functional analysis yielded activities of a 
maximum of 12 % of values measured in membranes despite purification and enrichment of 
NAR1. This value was achieved by the gel filtration method. The rapid dilution method 
yielded 5 % of the ligand binding observed in crude membranes. All other methods yielded no 
notable activity recovery. 
Electron microscopic freeze fracture imaging, performed by Dr. Götz Hofhaus, showed the 
same results as described above: no vesicles that contained protein were found. Only a very 
small number of vesicles were seen, while mostly irregular shaped structures were observed, 
that resembled lipid protein aggregates but not functionally reconstituted protein (Figure 37c). 
Since in freeze fracture images only few vesicles were observed, negatively stained images of 
the sample were produced. The analysis of these indicated a similar conclusion. Mostly 
irregular aggregated multi-lamellar lipid protein sheets were observed (Figure 37 a, b). To 
confirm that these structures are the ones that contain NAR1 protein, an antibody labeling of 
the vesicle preparation was performed by Dr. Götz Hofhaus. NAR1 protein was prevalently 
found within these dense structures, and not in the few regular vesicles (Figure 37d). 
 
 
3.7  NMR Measurements of β-Arrestin 1-382 
As with the only high resolution structure available for GPCRs, that of rhodopsin, all 
structures of arrestin are in its unliganded form. Nevertheless, rearrangements of arrestin upon 
receptor engagement have been demonstrated [3]. To address the question of how liganded β-
arrestin 1-382 looks like, it was grown and purified metabolically labeled [
15N] variant to 
obtain [
1H]-[
15N] 2D NMR TROSY spectra and a receptor derived peptide was added. 
TROSY spectra obtained by Dr. Marco Betz (Johann Wolfgang Goethe-Universität, Frankfurt 
am Main) led to the observation that the spectral properties of β-arrestin 1 are improved by 
higher temperature. The peak dispersion was best at 37 °C, while measurements at 25 °C and 
at 10 °C reduced the quality of the 2D spectra (Figure 38). But even at 37 °C the TROSY 
spectra did not yield a single peak for each amino acid, which is a prerequisite for NMR 
structure determination. Still, a number of the side-chain amide [
15N]-[
1H] correlation peaks 
were degenerate, which resembles the general pattern of peaks characteristically obtained 
from intrinsically unfolded proteins. Yet the information obtained from a TROSY experiment 
is not always sufficient to discriminate between a folded protein with degenerate proton Results 
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chemical shifts, i. e. a molten globule that can be driven to complete folding under certain 
circumstances or a protein that exists in equilibrium of folded and unfolded states, and a 
largely disordered and unstructured protein. Therefore, [
1H]-[
15N] NOESY (HetNOE) spectra 
were recorded. In some cases such experiments can distinguish between intrinsically unfolded 
proteins and those that exist in a dynamic equilibrium of   
 
 
unfolded and folded states [10, 93]. HetNOE measurements for [
15N]-β-arrestin 1-382 
indicated the latter (Figure 38). 
Addition of a peptide with the sequence N-CIDRYLAVVHAVFAL-C derived from the 
CCR5 chemokine receptor that had been shown to bind β-arrestin1 with an affinity of 12 µM 
Figure 38: 2D [
1H]-[
15N] TROSY spectra of β-arrestin 1-382. Upper left: Void volume peak of gel 
filtration. Right Pannel: Second peak of gel filtration, spectra recorded at 10°C, 25°C and 37°C. 
Lower left: HetNOE spectra, upper trace: at [
15N] saturation, lower trace: below [
15N] saturation. Results 
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[94] did not lead to observable changes in the [
1H]-[
15N] 2D NMR TROSY spectra that would 
indicate interaction between β-arrestin 1-382 and the peptide (data not shown). 
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4 Discussion 
4.1  Production of the human GPCR HM74A in P. pastoris 
The human GPCR HM74A, along with most other human GPCRs, is an important drug target 
for the pharmaceutical industry. The successful clinical use of nicotinic acid within the last 50 
years underlines this fact. To facilitate a rational approach for the discovery of new drugs that 
enhance blood lipid profiles, having HM74A as target, high resolution structural data is 
needed. Despite the fact that the crystallization of membrane proteins, and especially GPCRs, 
remains a difficult and challenging task, with the crystallization of bovine rhodopsin in 2000 
[37] showed that it is a feasible goal. Nevertheless, rhodopsin remains unique among GPCRs, 
since it is very abundant in native tissue, covalently bound to its ligand and its quality, folding 
state and conformation can be monitored by spectroscopic methods. For most other GPCRs, 
the first step in the long way to obtaining a high resolution crystal structure is the 
heterologous large scale production of the target. 
The present work’s focus lies on the heterologous production of the human gene HM74A, 
whose protein product is termed NAR1, a GPCR, in the methylotrophic yeast Pichia pastoris. 
Until recently, most structures of integral membrane proteins deposited in the Protein Data 
Bank (PDB) represented either heterologously expressed bacterial or archaebacterial proteins, 
or membrane proteins that could be isolated from native tissues, either from prokaryotes or 
eukaryotes. Only recently were the structures of the voltage-gated potassium channel from rat 
and that of the spinach aquaporin determined after heterologous production in Pichia pastoris. 
Other successes were the rabbit calcium ATPase (Saccharomyces cerevisiae) and rat 
aquaporin (baculovirus infected insect cells). Furthermore, it has been shown previously that 
P. pastoris facilitates the high level production of GPCRs [79, 82, 83]. Despite the fact, that 
other heterologous host systems for the overexpression of recombinant proteins are 
commercially available, P. pastoris has certain advantages. Although mammalian GPCRs 
have been produced at higher levels in mammalian cell culture systems [95], production scale 
up is hampered by limitations of costly large scale and high density cell cultivation. Similar 
limitations exist for baculovirus transfected insect cells, where the virus production is a long 
and tedious process, and cultivation of large cell masses is expensive. Compared to other 
yeast systems, P. pastoris offers the advantage of being easily fermentable to high cell 
densities at relatively low costs. Furthermore, the robust and inducible target protein 
expression is accomplished by the simple addition of methanol. In contrast to expression in E. Discussion 
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coli, the eukaryotic P. pastoris offers analogous pathways for the integration of membrane 
proteins into the lipid bilayer as mammalian cells, which are different in bacteria. This 
promotes the production of functional GPCRs, and measurable activity within membranes. 
Nevertheless, the expression level is influenced by vast number of other factors such as the 
integration machinery, the folding and quality control apparatus and the transport machinery. 
If any one is overwhelmed by the produced protein amount, yeasts can activate an Unfolded 
Protein Response (UPR) that leads to the degradation of target proteins and the shut down of 
further protein production [96, 97]. E. coli based systems follow two strategies i) the first 
favors the high yield production of unfolded GPCRs in inclusion bodies and subsequent 
refolding to obtain functional material [53], while ii) the second relies on functional 
production of receptors integrated into the membrane [98, 99] (for review see [97]). Although 
both of these E. coli based methods yielded amounts suitable for structural studies, the 
refolding protocol up to 3 mg pure receptor [100], and the functional expression up to 0.4 
mg/ml (~0.4 pmol/mg) [99], no crystal structures have yet been obtained, either for a GPCR 
or for any other eukaryotic membrane protein expressed heterologously in E. coli [99]. 
 
4.1.1 Multi-Copy Clone Selection 
The stable integration of multiple copies of the vector into the P. pastoris genome determines 
the gene dosage effect. In combination with a strong promoter, multiple copies of a single 
gene give rise to a higher number of messenger RNA molecules, and should increase the 
target protein expression level. The G418 high throughput screen that allows for the selection 
of multi-copy clones is based on this gene dosage effect. Nevertheless, in the case of NAR1 
clone selection it displayed inconsistencies. Some colonies grew on intermediate antibiotic 
concentrations, but not on lower ones, and since it had been shown that the highest expression 
of a given GPCR does not always correlate with the highest copy number a second high 
throughput screen was employed. The direct expression colony blot enabled the selection of 
clones with high levels of target protein expression [65]. This is important, since the copy 
number does not always correlate with the level of target protein overexpression. Still, the 
direct expression colony blot alone was not capable of unambiguously identifying or verifying 
clones selected based on G-418 screening. Selection of the intersection of positive clones that 
were obtained by these two methods resulted in the identification of high level expression 
clones for the pPIC9K fhT-NAR1-Tbio construct. The nano9-tag, although praised as robust 
affinity handle and detection tag [101] failed to produce signals in the direct expression Discussion 
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colony blot and Western blots, and rendered those constructs useless for further purification 
experiments. Activity was subsequently demonstrated for the chosen constructs in the 
functional radioligand binding assay, enabling the assessment of the effect of the three 
different C-terminal tags, the biotinylation/stab tag, β-arrestin 1-382 and β-arrestin 1-fl. 
Although an enhanced pharmacological profile has been reported for the fusion of β-arrestin 1 
to the C-terminus of the neurokinin NK1 receptor, resulting in an increased agonist binding 
affinity, no such effect was observed for the fusion of β-arrestin 1 to NAR1. The fusion of 
NK1 and β-arrestin 1 was studied in COS-7 cells, which have a different lipid composition in 
membranes than does P. pastoris [102]. Lipids, in particular acidic lipids, have been shown to 
be crucial for the interaction of β-arrestin 1 in vitro [23]. Furthermore, mammalian cells 
contain a large number of proteins that interact with GPCRs and β-arrestins that modulate the 
binding of ligand and receptor, and homologs might not be present in P. pastoris. Either of 
these differences could explain the altered functionality of the P. pastoris produced β-arrestin 
1 fusion. 
 
 
4.1.2 Pharmacological Characterization 
The binding affinity, Kd, provides a good assessment for the quality of the produced protein. 
In native tissues the affinity of NAR1 for nicotinic acid has been reported to be between 60 
nM and 90 nM [13, 16, 103-105]. The affinities that were measured for the P. pastoris 
produced constructs lay between 140 nM and 252 nM and are well in the range of what could 
be expected for a heterologously overexpressed protein. Furthermore, the Ki values for 
agonists Acifran and Acipimox are similarly lowered. It has been observed previously that 
agonist binding is diminished in a heterologous expression system. This effect can be 
explained in part by different membrane lipid composition and the absence of allosteric 
modulators that are present in native tissue. GPCRs have been found to be sensitive to the 
presence or the absence of their signaling partners, especially their cognate heterotrimeric G 
proteins, resulting in a low affinity state regarding agonist binding [106-108]. These findings 
might as well be one explanation for the long incubation time of 2 hours during the binding 
assay that is in contrast to the rapid response in vivo, where reduced free fatty acid levels in 
plasma occur in mouse already 15min after nicotinic acid injection [15]. Nevertheless, the 
saturation binding experiments on membranes were performed at room temperature, ~15 °C 
below body temperature in mice, explaining the delayed occurrence of the maximum 
response. Furthermore, a physiological response might not require the saturation of all Discussion 
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available binding sites, for the calculation of the total amount of receptor present in a given 
membrane preparation it is crucial. The notion that measured binding events are due to a 
degradation product of the radioligand can be ruled out by the fact, that membrane 
preparations of P. pastoris cells that were transformed with either the empty pPIC9K vector 
or the β2-adrenergic receptor did not show any specific binding. 
 
4.1.3 Expression Optimization of NAR1 
Optimization of the NAR1 production level was achieved by two measures i) decreasing the 
growth temperature from 30 °C to 22 °C and ii) the addition of DMSO to the culture medium. 
•  That beneficial effect on heterologous protein production of lowering the temperature 
has been observed many times previously [98, 109, 110], and likely has several 
causes. At lower temperature the cell’s metabolism is slowed, decreasing the speed of 
translation and allowing more time for the machinery to insert the nascent membrane 
proteins into the lipid bilayer. Additionally, the population of produced proteins is 
allowed more time to acquire the correct folding and ensure extended time for the 
cell’s chaperones to aid in adopting the correct fold. Furthermore protease activity is 
decreased, reducing protein degradation. 
•  The way DMSO exerts its beneficial effect on protein production levels is not clear. 
DMSO has not only been shown to modify membrane properties [111], it furthermore 
changes gene expression profiles in yeasts and upregulates genes involved in lipid 
metabolism [112, 113]. For the production of NAR1, the addition of 2 % DMSO was 
found best and increased the production level 1.5 fold. 
 
The fact that ligands might serve as a folding template and stabilize proteins has been 
exploited for protein overexpression efforts, and in particular for GPCRs [80, 83, 114]. In 
some cases, the addition of ligand to the growth media increased the expression level up to 
seven-fold [79]. Nevertheless, this effect was not observed for the production of NAR1, as 
addition of nicotinic acid to the expression media had no effect on the level of functional 
NAR1 production. 
Another parameter assessed by André et al. [79] was the addition of histidine to the growth 
media. Whereas histidine addition resulted in one to two fold increase in production of all 
receptors tested, it had no effect on the production level of NAR1. 
Under optimized conditions NAR1 expression levels reached 42 pmol/mg, which corresponds 
to ~0.4 mg/l culture. Compared to the 20 receptors tested for P. pastoris expression by André Discussion 
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et al. [79], the production level can be considered as reasonably good. Of the three categories 
defined by André et al., - those that displayed low level expression (binding < 2 pmol/mg), 
mid range expression (binding 2-20 pmol/mg) and high level expression (binding > 20 
pmol/mg) - NAR1 would belong accordingly to the high level expression receptors. 
It has been observed that the use of an antagonist in radioligand binding assays revealed 
significantly more binding activity on the same membrane samples than was seen with the use 
of an agonist. Therefore it can be speculated that the actually produced amount of receptor is 
larger than what could be measured. 
In their native environment, membrane proteins face two different compartments, the cytosol 
son one side and the extracellular matrix on the other. These two compartments not only 
differ in their oxidizing properties, but also with respect to the concentrations of various ions 
and metabolites. With the preparation and solubilization of membranes, this sidedness is 
abolished. 
The fact that sodium ions act on GPCRs as allosteric modulators of agonist affinity was 
shown for the opioid receptors as early as 1974 [115]. Since then, this effect has been 
observed for other receptors [116-118], and shown to involve a conserved aspartic acid 
residue in transmembrane helix 2. This aspartic acid is present as Asp73 in the second 
transmembrane segment of NAR1. Therefore, it is not surprising that this effect could also be 
shown for NAR1, and was reported in 2001 [13]. On the other hand it was shown that the 
binding of antagonists, as in the case of A2A-adenosine receptor [86, 87] is enhanced by 
sodium ions. Given the fact that antagonists for NAR1 are not known to date, this study could 
only confirm that sodium ions inhibit the binding of nicotinic acid to NAR1. Concentrations 
of 100 mM reduced the specific agonist binding to 20 %, while other cations like potassium, 
lithium or ammonium had a less detrimental effect, and at similar concentrations reduced 
binding to only 60 % of the reference value without salt. 
As already mentioned, a disulfide bridge between extracellular loops 2 and 3 is common 
among family A GPCRs. This disulfide bridge can only form in the oxidizing environment of 
the extracellular space. Its importance to receptor function has been shown previously, and 
reduction by DTT abolishes ligand binding capability [119]. It has been argued that the 
disulfide bond stabilizes the receptor, yet other receptors, such as the cannabinoid receptor 
CB1, do not have this conserved disulfide bond [120], and are not sensitive to reducing agents 
(Chandramouli Reddy, personal communication). NAR1 does have this conserved disulfide 
bond and it is required for its function, since as little as 500 µM DTT reduces the binding 
activity of NAR1 by 50 %. This observation demonstrates that the disulfide bridge is crucial Discussion 
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to the structural integrity and function of NAR1. This fact has to be kept in mind for further 
experiments that involve the reconstitution of NAR1 with β-arrestins, as these are purified in 
the presence of high concentrations of DTT. 
Imidazole is commonly used to elute His-tagged proteins from IMAC columns, and therefore 
hardly avoidable in preparations of HisTrap purified NAR1. Histidine resembles the nicotinic 
acid scaffold as does imidazole. It shares a similar scaffold with its ligand, nicotinic acid, thus 
the effect of imidazole effect on the binding of NAR1 was tested, and found to impair 
nicotinic acid binding already in membranes. Concentrations of 250 mM reduced the 
observable binding to less than 30 % of the original value. Whether this is due to imidazole 
competing with nicotinic acid or for a different reason is unknown. 
The organic solvent DMSO is required for the preparation of stock solutions of Acifran and 
Acipimox, because both have a low solubility in water. Along with the addition of Acifran or 
Acipimox to the activity test DMSO is inevitably added. Therefore its effect was tested, and 
found that small amounts of up to 1 % will be tolerated, although diminishing the observable 
binding to 60 %. 
 
4.1.4 Solubilization 
One of the crucial steps of membrane protein purification is the extraction from the 
membrane. This is routinely achieved by the solubilization of the membrane with detergents. 
At concentrations below the cmc detergents partition into the lipid bilayer and change the 
membrane properties. In some cases they even compete with ligand for receptor binding sites 
[121], or block the access to the ligand binding site of the receptor. These effects might 
already influence the NAR1 radioligand binding assay and were tested by adding detergent at 
concentrations below cmc. Most tested detergents did not interfere with the assay format at 
concentrations below the cmc. But as soon as the cmc was approached, no more binding could 
be observed. The explanation for this effect could be the denaturation of the receptor by 
detergents during the removal of the surrounding membrane. However, the measured decrease 
in ligand binding does not necessarily mean the loss of function of NAR1. For a number of 
receptors, a reduced affinity has been reported upon solubilization [122]. Lowered affinity 
would be harder to measure with standard techniques like radioligand binding assays. The 
fact, that titration of detergents to the binding assay abolished observable binding as soon as 
the cmc is approached suggests an interference of the detergents with the receptor ligand 
interaction. Furthermore, the treatment of the glass fiber filters with PEI creates a surface for Discussion 
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electrostatic interactions between PEI laced glass fibers and charged filtrates [122]. 
Phospholipids carry charges and membrane fragments with embedded membrane proteins 
exhibit different electrostatic properties than solubilized receptors in detergent micelles. Thus, 
the interaction between solubilized NAR1 and the filters might not occur anymore and be the 
cause for not observed ligand binding. In addition, partial binding was regained by the 
removal of detergents DM, LM and Cymal-6 from solubilizate with BioBeads. BioBead 
treatment leads to the reduction of the detergent concentration, leading to reconstitution of the 
solubilized lipids into vesicles accommodating membrane proteins. Thus, the solubilization 
event does not denature NAR1 completely. 
 
4.1.5 Purification 
The initial purification step of NAR1 using a HisTrap HP column allowed robust enrichment 
of NAR1, but the preparations were not of the desired purity. The first strategy to eliminate 
impurities that bound to the HisTrap HP column was a second pass over the same column 
after enzymatic removal of the decahistidine tag on NAR1. The impurities would bind the 
resin again, while NAR1 devoid of the decahistidine-tag should pass through the column. 
Unfortunately, enzymatic removal of the engineered tags with TEV protease decreased the 
protein’s stability and the cleaved NAR1 precipitated. In addition to the detergent, the 
hydrophilic tags might have shielded further hydrophobic patches and stabilized the receptor 
conformation, while without them NAR1 integrity was lost and it aggregated. Since the 
removal of the hydrophilic engineered tags resulted in precipitation of NAR1, purification 
strategies that required enzymatic cleavage failed. A systematic screen, varying pH, 
detergents, detergent concentration and salt concentration was performed to identify buffer 
conditions that would promote protein stability, but none was identified that tolerated removal 
of the tags. Therefore further purification was attempted with the tagged version of NAR1. 
Various chromatographic media were tested: HiTrap Blue material, ion exchange resins and 
the affinity matrix immobilized monomeric avidin. Immobilized monomeric avidin makes use 
of the C-terminal Bio-tag as an affinity ligand for purification and had been used successfully 
for the purification of the adenosine A2A receptor [67]. In conjunction with the initial HisTrap 
HP purification step, immobilized monomeric avidin allowed pure and stable protein to be 
obtained at pH 9. Adjusting the pH from the physiological pH of 7.5 to pH 9 yielded a NAR1 
preparation that was sufficiently stable to give a single peak on a Superose 6 gel filtration 
column, using DM as detergent. Nevertheless, substantial amounts of NAR1 protein were lost Discussion 
  147
on the immobilized monomeric avidin column. It is conceivable that only properly folded 
biotinylation domains are biotinylated in P. pastoris, and that due to overexpression only 
partial biotinylation takes place. Non biotinylated receptor molecules are inevitably lost by 
this method. Additionally, non-specific binding to the column was observed, so that only little 
of the receptor could be eluted specifically. These are potential explanations for the low yield 
of this strategy. 
 
4.1.6 Activity Measurements & Reconstitution 
To assess functionality of NAR1, two different approaches were initiated. First, ligand 
binding assays of the solubilized, purified protein, and second the reconstitution of purified 
NAR1 into liposomes, to mimic its native environment. 
 
4.1.6.1 Activity Measurements of Solubilized & Purified NAR1 
GPCRs are very flexible proteins that can adopt a multitude of pharmacologically different 
conformations [123], and detergent solubilization likely increases this flexibility. It has been 
observed that the ligand binding affinity of solubilized receptors can decrease [122] or 
disappear completely [124] and kinetics may be altered. 
During a radioligand binding filtration experiment an equilibrium between free and receptor-
bound radioligand is established, which is changed during the washing steps, since washing 
buffers do not contain any radioligand. Although the time for washing was always kept as 
short as possible, substantial amounts of weakly bound ligand can be released from the 
receptor, and therefore not be detected anymore. 
Another method for the separation of receptor-bound from free radioligand was gel filtration 
that had been used previously for the characterization of β2-adrenergic receptor binding sites 
upon solubilization [68]. But no activity was observed for NAR1. 
A completely different method is a scintillation proximity assay, and has successfully been 
used to demonstrate radio ligand binding to GPCRs [125, 126]. If the receptor is bound to the 
affinity ligand coated bead, a very high density of receptor molecules surrounding the 
scintillant is achieved, and the decay of bound radioligand will stimulate light emission. This 
method did not show activity for solubilized NAR1 and was also not successful in 
demonstrating activity on crude membranes containing NAR1 used as reference. 
Interestingly, it was found for the α2-adrenergic receptor that, although radioligand binding 
could be observed by SPA in membranes, the assay could not be adopted for the solubilized Discussion 
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receptor. For this solubilized receptor, filtration assays were also unsuccessful, but receptor 
functionality could be demonstrated by surface plasmon resonance experiments [127]. 
A standard procedure for the observation of binding events to soluble proteins is equilibrium 
dialysis. It is routinely used in clinics for the determination of the binding of a certain radio 
ligand to blood plasma samples [91]. The binding reaction was dialyzed against a buffer that 
did not contain radio ligands. By diffusion, an equilibrium of free radio ligand is achieved 
between both compartments. Bound radio ligand increases the amount of radioactivity in the 
sample compartment, and binding is measured as a difference between both compartments. 
This method has a number of drawbacks. It is slow, has a low reproducibility and a low signal 
to noise ratio [121]. These drawbacks might already explain the failure of this procedure, 
since it could not demonstrate the activity of NAR1. 
As a last method NMR based Saturation Transfer Difference was tested. This method relies 
on the transfer of magnetism from the receptor to the ligand. Each chemical compound has a 
unique set of peaks in an NMR spectrum and the peak height corresponds to the concentration 
of the ligand. If the ligand is bound by the receptor, magnetism is transferred from the 
receptor to the ligand, diminishing its observable signal. Thus, the comparison of a reference 
spectrum containing only ligand in an appropriate buffer with a spectrum obtained from a 
sample containing ligand with receptor indicates binding if peaks for the ligand are observed. 
By this means ligand binding activity of NAR1 could be demonstrated. Furthermore, the 
diminishing of the signal from one day to the next further demonstrated the limited stability of 
purified NAR1 in solution. Although promising, this experiment was only able to provide a 
qualitative answer to the question of receptor activity, and quantification of the data was not 
possible. Although the method of saturation transfer difference spectroscopy is becoming 
more and more a standard method for the detection of binding events between small 
molecules and proteins, this appears to be the first application of the method to a solubilized 
GPCR. 
 
4.1.6.2 Reconstitution of NAR1 into Liposomes 
It has been mentioned previously, that the measurement ligand binding on solubilized 
receptors is difficult. Since measuring ligand binding was far from straightforward for 
solubilized NAR1, its reconstitution into membranes was attempted. It was hoped that 
restoring the constraining influence of a lipid bilayer might also restore ligand affinity and 
binding activity. To achieve this reconstitution of NAR1 into liposomes, purified NAR1 was Discussion 
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combined with lipid vesicles or detergent saturated vesicles and detergent was removed by 
treatment with BioBeads. This method has been used for the functional reconstitution of the 
CCR5 receptor [128], but similar experiments with NAR1were unsuccessful. 
In another set of experiments NAR1 was mixed with detergent solubilized lipids rather than 
with preformed liposomes. At this stage mixed micelles exist that are composed of i) 
detergent and membrane protein, ii) detergent and lipids and iii) detergent, lipid and 
membrane protein. During subsequent detergent removal, these mixed micelles should 
associate with each other and eventually form proteoliposomes. The reconstitution of NAR1 
was attempted by different methods, i) removal of detergent by BioBeads as was shown for 
the reconstitution of the metabotropic glutamate receptor [129], ii) removal of detergent by 
cyclodextrins [70] which was used for the reconstitution of the histamine H1 receptor [130], 
iii) a controlled slow dilution by gel filtration, used for the reconstitution of the β2-adrenergic 
receptor [69] and iv) by a fast dilution into large volume of buffer without detergent [69, 71, 
131]. None of these methods yielded functionally reconstituted NAR1. Although a variety of 
methods under different conditions were tested, the right conditions were either not found or 
NAR1 was not in a state allowing successful reconstitution. 
 
4.2  Multi-Host Expression of β-Arrestins 
For the production of a complex with NAR1, β-arrestin 1 was cloned in three different 
versions i) the full length coding sequence, ii) a truncation version comprising residues 1-393, 
corresponding to one of the crystallized fragments of bovine β-arrestin 1 with the 
constitutively activating mutation R169E, that renders β-arrestin active in the absence of 
receptor phosphorylation and iii) the shortest version containing residues 1-382, 
corresponding to the second crystallized fragment of bovine β-arrestin 1, which is by itself 
constitutively active, capable of binding the unphosphorylated receptor. Similar versions of β-
arrestin 2 were cloned also. 
Although the structure of β-arrestin 1 is derived from the bovine homologue, the similarity 
between human and bovine β-arrestin 1 isoforms is 99 %, and for reasons of scientific 
significance human β-arrestins were chosen for expression and recomplexation with human 
NAR1. Thus proteins from the same source organism were used. 
The comparative heterologous expression in two different host organisms, namely the 
bacterial expression in E. coli and in parallel the eukaryotic expression in the methylotrophic 
yeast P. pastoris was set up to compare protein yields. That the expression of bovine β-Discussion 
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arrestin 1 in E. coli was feasible had been shown before, not at least by its crystallization [64] 
but its expression was labor intensive. Hoping to boost the production similar expression was 
tested in the eukaryotic yeast system P. pastoris. In P. pastoris only four times more protein 
was expressed than in E. coli. This four fold increase does not justify the increase in labor and 
time that is needed for the cultivation and breakage of yeast cells, and alterations of the 
construct always will need rescreening for multi-copy clones that is not required with E. coli. 
Furthermore, metabolic labeling for NMR experiments or selenomethionine labeling for phase 
determination in X-ray diffraction experiments is by far easier accomplished with E. coli than 
in P. pastoris. 
It was found that the shortest version of β-arrestin 1 (β-arrestin1-382) was expressed better 
than the full length version and the construct version β-arrestin 1-393 R169E. Furthermore β-
arrestin 1 constructs were expressed significantly better than constructs of β-arrestin 2 
regardless of the tag and host organism. The reason for this difference remains elusive, but 
this might explain as well the existence of x-ray crystal structures for all arrestins [64, 132-
134] except β-arrestin 2. 
Purification of β-arrestin 1-382 was accomplished essentially as described by Han et al. 2001 
[64]. The major difference being the replacement of the initial HiTrap Heparin purification by 
an affinity purification step, either on a HisTrap HP column or Glutathione 4B Sepharose for 
His-tagged and GST-tagged versions respectively. The purification with a GST-tag allowed 
for simple pull down interaction experiments with NAR1 and detection via the decahistidine-
tag. The second purification step utilized a HiTrap Heparin HP column and elution by a linear 
salt gradient. Heparin and phosphorylated light activated rhodopsin had been shown to bind 
visual Arrestin in a competitive manner [135]. Therefore the HiTrap Heparin HP column can 
be considered as a ligand column and furthermore binding of β-arrestin demonstrates its 
functionality. 
Further evaluation of the quality of β-arrestin 1-382 was done by NMR spectroscopic studies, 
with [
15N] labeled samples from P. pastoris and E. coli. The spectral properties of β-arrestin 
1-382 are not sufficient for NMR assignment of residues and structure determination. 
However, TROSY spectra in combination with HetNOE measurements indicate that β-
arrestin 1-382 exists in a dynamic equilibrium or molten globule like state. Nevertheless, 
proteins with these spectral qualities might sill be good targets for crystallization experiments 
as had been shown by Yee et al. [93]. Potential explanations for the low quality of spectral 
properties are the fact that arrestins do dimerize and tetramerize [136-138]. This is not only 
clear from the crystal structure, where the asymmetric unit consists of two β-arrestin 1-382 Discussion 
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molecules [64], it had furthermore been shown that β-arrestin forms dimers in the cytoplasm 
[138], which are believed to be an inactive storage form of β-arrestins. In addition, it had been 
shown that β-arrestins dimerize at high concentrations [136], hence the high concentration of 
β-arrestin 1-382 (0.1 µM) in NMR experiments might have promoted this dimerization. The 
monomer of β-arrestin 1-382 has a molecular weight of ~44 kDa, which is already 
challenging for standard NMR spectroscopic methods of structure determination. The dimer 
with a molecular mass of ~88 kDa is certainly even more challenging. 
This might also be one explanation why interaction mapping of β-arrestin 1-382 with a 
peptide derived from the second intracellular loop of the human CCR5 receptor failed to 
produce observable peak shifts, although the peptide had been shown in surface plasmon 
resonance experiments to interact with β-arrestin 1 before [94]. In the case of dimer 
formation, peak shifts might not be resolved, or more likely in its inactive storage form as a 
dimer, β-arrestin 1-382 might not be capable of interacting with the peptide. 
 
4.3  Interaction of NAR1 with β-Arrestin 1 
4.3.1 Interaction of NAR1 with β-Arrestin 1 In Vivo 
The crystallization of membrane proteins is a difficult task, since they have to be removed 
from their native membranous environment and their hydrophilic surface areas are often small 
and do not allow the formation of stable crystal contacts. A strategy to overcome this problem 
is complexation with antibody fragments. Since the raising of an antibody that binds NAR1 in 
a conformation dependent manner, is also a difficult task, using alternative proteins that might 
fulfill a similar function was attempted. β-arrestins appeared to be that promising alternative. 
It is sufficiently big, its binding was determined to be in the low nanomolar range [139], and it 
is sensitive to the active conformation of the receptor. Furthermore it might help overcome 
stability problems, lock the receptor in its agonist bound conformation and increase its 
solubility. 
Recent experiments reported consensus sequences for the interaction of GPCRs with β-
arrestin within the second intracellular loop [140]. The reported sequence starts with the 
conserved DRY motive, and further important is a proline residue in position 9 (numbering 
starts with D of the DRY motif). The amino acid sequence in the second intracellular loop of 
NAR1 contains these residues (Figure 39), and therefore the interaction with β-arrestins was 
likely. Nevertheless as the interaction between both proteins has not yet been demonstrated, 
therefore their interaction in vivo had to be confirmed. This was achieved by laser scanning Discussion 
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microscopy of cells cotransfected with a NAR1-GFP construct and two versions of CFP-β-
arrestin 1. Two versions of β-arrestin were chosen because, for the interaction of full length β-
arrestin with NAR1 not only is the conformation of the receptor important, but also 
phosphorylation of serine and threonine residues within its cytoplasmic domains. This 
phosphorylation is achieved by a cognate GRK. Since it is not known which GRK 
phosphorylates NAR1 in vivo and whether it is present in BHK and HEK host cells, a second 
version of β-arrestin was employed that does not require phosphorylation. Truncation of β-
arrestin 1 at residue 382 results in a phosphorylation insensitive version that only depends on 
the activated receptor conformation. Both versions of β-arrestin 1 could be shown to migrate 
from the cytoplasm to the membrane upon addition of nicotinic acid and activation of NAR1. 
 
 
 
 
4.3.2 Interaction of NAR1 with β-Arrestin 1 In Vitro 
After proof of the interaction of β-arrestin1-fl and β-arrestin 1-382 with NAR1 in vivo, the 
reconstitution of purified β-arrestin 1-382 and NAR1 was attempted. Since it had been shown 
previously that the interaction of visual arrestin and rhodopsin could only be established in 
vitro in the presence of lipids, but not in purified delipidated state of rhodopsin [23], NAR1 
Figure 39: Snake-like plot of NAR1. The 2
nd intracellular loop is magnified and contains the DRY 
motif and the downstream proline residue that are important for β-arrestin binding. Discussion 
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was mixed with GST-β-arrestin 1-382 in the presence of asolectin and the agonist nicotinic 
acid. The interaction was analyzed by a pull down assay using Glutathione 4B Sepharose 
matrix, capturing GST-β-arrestin 1-382, and bound NAR1. This interaction could be 
demonstrated for NAR1 samples purified in DM+CHS and LM+CHS, but not for NAR1 
purified with Cymal-6+CHS. Although roughly stoichiometric amounts of NAR1 and GST-β-
arrestin 1-382 were used as input at quantities producing a clearly visible band in Coomassie 
stained SDS-PAGE, the amount of bound NAR1 had to be visualized by much more sensitive 
Western blotting, while the band for GST-β-arrestin 1-382 that was captured on the beads was 
still visible in Coomassie stain. Thus, clearly sub-stoichiometric amounts of NAR1 were 
bound by β-arrestin 1-382. Therefore the question that arises immediately is why NAR1 could 
not be captured quantitatively. Since GST-β-arrestin 1-382 bound to heparin during its 
purification, and heparin was shown to competitively inhibit the interaction between visual 
arrestin and rhodopsin, it has to be considered functional and should not be the cause for the 
partial interaction. NAR1’s activity regarding nicotinic acid binding was established by STD 
studies. Potential reasons for the low stoichiometric binding might be the interference of 
detergents with the interaction of NAR1 and β-arrestin 1, or the removal of the membrane, 
since β-arrestin is expected to partially insert its amphipathic N-terminal helix 1 into the 
membrane bilayer for strong binding of GPCRs. Yet, the low amount of NAR1 captured 
corresponds well to similar experiments performed by C. Krettler using the β2-adrenergic 
receptor. These experiments demonstrated the same low ratio of receptor bound to GST-β-
arrestin 1-382, although the ability of the β2-adrenergic receptor to bind ligand in solubilized 
form had been shown. 
Another intriguing explanation for this inefficient capturing might be the interaction of 
arrestins with receptor dimers (Figure 40). Very little is known to date about the stoichiometry 
of the interactions of a GPCR with arrestins, whether they bind a monomeric receptor, a dimer 
or a higher order oligomeric state. Although this is highly speculative, more and more 
evidence accumulates in favor of this interpretation. Recent AFM studies showed that 
rhodopsin is present in native membranes as a densely packed array of dimers [6, 49]. High 
concentrations of detergent and the purification of rhodopsin abolish this dimeric state [141]. 
The loss of lipids during purification abolishes the interaction of visual arrestin with 
rhodopsin in vitro, but can be rescued by the addition of lipids [23]. The existence of dimers 
and higher order oligomers has also been shown for the β2-adrenergic receptor in vivo [18, 
19]. Recent modeling experiments compared the interactions of the cytoplasmic face of the 
rhodopsin monomer with i) the N-domain cavity of visual arrestin, ii) the C-domain, iii) the Discussion 
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N- and C-domain of visual arrestin forming a pincer, and iv) the cytoplasmic domains of a 
rhodopsin dimer with one being engaged to the N-domain and the other to the C-domain 
simultaneously, and found that the interaction of visual arrestin with the dimer should be 
twice as favorable as that with a monomer [22]. 
 
 
 
Since most production and purification strategies so far aimed at producing a uniform sample 
that in most cases corresponded to a monomeric form of the receptor according to gel 
filtration analysis, and dimerization is abolished by detergent addition [141], it might be that 
these strategies were prone to abolish the reconstitution between receptors and β-arrestins. All 
other experiments that demonstrated the interaction of wild type arrestins or constitutively 
active variants as in this study were performed with either reconstituted receptors, receptors in 
native membranes or in living cells, disregarding the oligomeric states of the receptor [90, 
139, 142-146]. The only report that measured quantitatively the affinity for the β2-adrenergic 
receptor and β-arrestin 1, and determined it to be 1.8 nM [140], used reconstituted receptors 
and found a stoichiometry of one β-arrestin 1 molecule for three molecules of β2-adrenergic 
receptors. It was argued in this case that phosphorylation occurred only at one third of the 
molecules of the receptor population giving rise to a 1:1 stoichiometry. But given that these 
experiments were performed before the dimerization of receptors became widely accepted, 
and furthermore one activated receptor molecule within the dimer might be enough for the 
interaction with arrestins, these conclusions might have to be reconsidered. One photon can 
Figure 40: Hypothetical model of visual arrestin (red) binding a dimer of rhodopsin [6] Discussion 
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only activate only one molecule of rhodopsin, but already might lead to the recruitment of 
visual arrestin to a rhodopsin dimer. 
Nevertheless it has to be kept in mind that this present study was exclusively performed with 
a constitutively active β-arrestin 1 variant and unphosphorylated receptors that have a 
somewhat lower binding affinity than that of wild type arrestins to phosphorylated receptors, 
and this could be the explanation for the low yields of reconstitution. Discovering conditions 
that favor the dimeric form of receptors might overcome this issue and lead to a higher yield 
of complex reconstitution and support crystallization of the complex. 
 
4.4 Conclusion 
This present PhD work is the first report about heterologous large scale expression of the 
human GPCR NAR1, and the only one to date that is capable of supplying quantities suitable 
for future structural studies. Additionally, it could be shown that the heterologously produced 
receptor resembles the pharmacological profile of the native receptor. Therefore the produced 
material can be used for biochemical and biophysical in vitro studies of NAR1 in membranes 
to elucidate the binding and signaling mechanism of this receptor. Furthermore, its 
solubilization and purification was successfully achieved, although it will require additional 
work to find conditions that preserve the receptor in a fully active state throughout 
solubilization and purification, and a simpler assay to prove this than NMR STD 
measurements. Similarly more effort has to be put into the reconstitution of the receptor into 
liposomes, since all attempts failed so far. 
This is the first report about the interaction of NAR1 with β-arrestin 1 in vivo and in vitro. 
Although the reconstitution of the complex of NAR1 with β-arrestin 1-382 in vitro was very 
inefficient, the results are promising and indicate that crystallization of the complex will be 
feasible in the future. Nevertheless will it take substantial amounts of work to develop a solid 
protocol for the formation of this complex, since the potential explanations for the low yield 
at present are manifold. 
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6 Abbreviations 
 
7TM  7 Trans Membrane 
ACTH Adrenocorticotropic  Hormone 
ADP Adenosine  Di-Phosphate 
Amp Ampicillin 
AP-2  Adaptor Protein 2 
BCIP 5-Bromo-4-chloro-3-indolylphosphate 
BGH  Bovine Growth Hormone 
BHK  Baby Hamster Kidney 
BSA  Bovine Serum Albumin 
cAMP  Cyclic Adenosine Mono-Phosphate 
cAR cAMP  Receptor 
CFP  Cyan Fluorescent Protein 
cGMP  cyclic Guanosine Mono-Phosphate 
CGRF Calcitonin  Gene-Related  Peptide 
CHS Cholesteryl  Hemisuccinate 
CIAP Calf  Intestinal  Alkaline Phosphatase 
CMV Cauliflower  Mosaic  Virus 
CRD  Cysteine Rich Domain 
CRF Corticotropin-releasing  Factor 
DAG Diacylglycerol 
Dermal DC  Dermal Dendritic Cell 
DM n-decyl-ß-D-maltopyranoside 
DMEM  Dulbecco's Modified Eagles Medium 
DMF Dimethylformamide 
DMSO Dimethyl  sulfoxide 
DNA   Deoxyribonucleic Acid 
dNTP Deoxyribonucleotides 
DP Prostaglandin  D2 
DTT Dithiothreitol 
EDTA Ethylenediaminetetracetic  Acid 
EL Extracellular  Loop Abbreviations 
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EGFR  Epidermal Growth Factor Receptor 
EP2 Prostaglandin  E2 
EP4 Prostaglandin  E4 
ERK  Extracellular Signal Regulated Kinase 
Fab  Fragment Antigen Binding 
FCS  Fetal Calf Serum 
Fv Variable  Fragment 
FYVE  Fab1, YOTB/ZK632.12, Vac1, and EEA1 
GABA  γ-Aminobutyricacid 
GAP  GTPase Activating Protein 
GDP Guanosine  Di-Phosphate 
GEF  Guanosine Nucleotide Exchange Factor 
GFP  Green Fluorescent Protein 
GHRH  Growth Hormone Releasing Hormone 
GIP Gastric  Inhibitory  Polypeptide 
GPCR  G-Protein Coupled Receptor 
Grb2  Growth Factor Receptor-Bound Protein 2 
GRK  G-Protein Coupled Receptor Kinase 
GST Glutathione-S-Transferase 
GTP Guanosine  Tri-Phosphate 
HDL  High Density Lipoprotein 
HEK  Human Embryonic Kidney 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HetNOE  Heteronuclear Overhauser Effect 
HIS4 Histidinol  Dehydrogenase 
IL Intracellular  Loop 
IP3 Inositol  Trisphosphate 
IPTG Isopropyl  β-D Thiogalactoside 
IR Insulin  Receptor 
IRS1  Insulin Receptor Substrate 1 
JNK  c-Jun N-terminal Kinase 
Kan Kanamycin 
LDL  Low Density Lipoprotein 
LM n-dodecyl-β-D-maltopyranoside Abbreviations 
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MAP  Mitogen Activated Protein 
MAPK  Mitogen Activate Protein Kinase 
MCS  Multiple Cloning Site 
MSH  Melanin Stimulating Hormone 
NAD+  Nicotinamide Adenine Dinucleotide 
NADP+  Nicotinamide Adenine Dinucleotide Phosphate 
NAR1  Nicotinic Acid Receptor 1 
NBT Nitrobluetetrazolium 
NMR  Nuclear Magnetic Resonance 
NO Nitric  Oxide 
NSF N-maleimide  Sensitive  Factor 
NK1 Neurokinin  1 
OD Optical  Density 
PACAP  Pituary Adenylate Cyclase Activated Polypeptide 
PAGE  PolyAcrylamide Gel Electrophoresis 
PBS  Phosphate Buffered Saline 
PCR  Polymerase Chain Reaction 
PDZ  PSD95/SAP90, Discs large, Zonula occludens-1 
PE Phosphatidylethanolamine 
PEI Polyethyleneimine 
PGD2 Prostaglandin  D2 
PGE2 Prostaglandin  E2 
PH Pleckstrin  Homology 
PI3-Kinase Phosphatidyl-Inositol  3  Kinase 
PIP2 Phosphatidylinositol-(4,5)-Bisphosphate 
PKA  Protein Kinase A 
PKC  Protein Kinase C 
PMSF Phenylmethylsulfonylfluoride 
PtdIns(4,5)-P Phosphatidylinositol-(4,5)-Bisphosphate 
PtdIns(3,4,5)-P Phosphatidylinositol-(3,4,5)-Trisphosphate 
PTH Parathyroid  Hormone 
PTHrP Parathyroid  Hormone-Related  Protein 
PTK  Protein Tyrosine Kinase 
PTB  Phospho-Tyrosine Binding  Abbreviations 
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PUMA-G Protein  Upregulated  in Macrophages by Interferon γ 
PVDF Polyvinylidenfluorid 
RGS  Regulator of G-Protein Signaling 
RTK  Receptor Tyrosine Kinase 
SDS Sodium  Dodecyl  Sulfate 
SH2 Src-Homology  2 
SH3 Src-Homology  3 
Shc  Src Homology 2 domain Containing 
SPA  Scintillation Proximity Assay 
Src  v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene 
homolog (avian) 
STAT  Signal Transducer and Activator of Transcription 
STD  Saturation Transfer Difference 
TBS  Tris Buffered Saline 
TBST  Tris Buffered Saline + Tween20 
TEMED N,N,N'N'-tetramethylethylenediamine 
TEV  Tobacco Etch Virus 
TM Transmembrane  Helix 
VIP  Vasoactive Intestinal Peptide 
VLDL  Very Low Density Lipoprotein 
YNB  Yeast Nitrogen Base 
 
 Appendix 
  173
7 Appendix 
7.1  Amino Acid Sequneces 
7.1.1 Proteins 
7.1.1.1 NAR1 (human) 
N-terminus: 
MNRHHLQDHFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALWIFCFHLKS
WKSSRIFLFNLAVADFLLIICLPFLMDNYVRRWDWKFGDIPCRLMLFMLAMNRQGSII
FLTVVAVDRYFRVVHPHHALNKISNRTAAIISCLLWGITIGLTVHLLKKKMPIQNGGA
NLCSSFSICHTFQWHEAMFLLEFFLPLGIILFCSARIIWSLRQRQMDRHAKIKRAITFIM
VVAIVFVICFLPSVVVRIRIFWLLHTSGTQNCEVYRSVDLAFFITLSFTYMNSMLDPVV
YYFSSPSFPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGE
PWSPSYLGPTSP –C-terminus 
7.1.1.2 β-Arrestin 1 (human) 
N-terminus: 
MGDKGTRVFKKASPNGKLTVYLGKRDFVDHIDLVDPVDGVVLVDPEYLKERRVYV
TLTCAFRYGREDLDVLGLTFRKDLFVANVQSFPPAPEDKKPLTRLQERLIKKLGEHAY
PFTFEIPPNLPCSVTLQPGPEDTGKACGVDYEVKAFCAENLEEKIHKRNSVRLVIRKV
QYAPERPGPQPTAETTRQFLMSDKPLHLEASLDKEIYYHGEPISVNVHVTNNTNKTV
KKIKISVRQYADICLFNTAQYKCPVAMEEADDTVAPSSTFCKVYTLTPFLANNREKR
GLALDGKLKHEDTNLASSTLLREGANREILGIIVSYKVKVKLVVSRGGLLGDLASSDV
AVELPFTLMHPKPKEEPPHREVPENETPVDTNLIELDTNDDDIVFEDFARQRLKGMKD
DKEEEEDGTGSPQLNNR –C-terminus 
7.1.1.3 β-Arrestin 2 (human) 
N-terminus: 
MGEKPGTRVFKKSSPNCKLTVYLGKRDFVDHLDKVDPVDGVVLVDPDYLKDRKVF
VTLTCAFRYGREDLDVLGLSFRKDLFIATYQAFPPVPNPPRPPTRLQDRLLRKLGQHA
HPFFFTIPQNLPCSVTLQPGPEDTGKACGVDFEIRAFCAKSLEEKSHKRNSVRLVIRKV
QFAPEKPGPQPSAETTRHFLMSDRSLHLEASLDKELYYHGEPLNVNVHVTNNSTKTV
KKIKVSVRQYADICLFSTAQYKCPVAQLEQDDQVSPSSTFCKVYTITPLLSDNREKRGAppendix 
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LALDGKLKHEDTNLASSTIVKEGANKEVLGILVSYRVKVKLVVSRGGDVSVELPFVL
MHPKPHDHIPLPRPQSAAPETDVPVDTNLIEFDTNYATDDDIVFEDFARLRLKGMKD
DDYDDQLC -C-terminus 
 
7.1.2 Recombinant Tags 
7.1.2.1 Flag-Tag 
N-terminus: DYKDDDDK –C-terminus 
7.1.2.2 His-Tag (Decahistidine Tag) 
N-terminus: HHHHHHHHHH –C-terminus 
7.1.2.3 Nano9-Tag 
N-terminus: DVEAWLGAR –C-terminus 
7.1.2.4 GST-Tag 
N-terminus:  
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELGLEFPNLPY
YIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAVLDIRYGVSRIAYSKDF
ETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVTHPDFMLYDALDVVLYMDPMCL
DAFPKLVCFKKRIEAIPQIDKYLKSSKYIAWPLQGWQATFGGGDHPPKSDLEVLFQGP
LGSDLNSDDSTDDEAHPRKPIPTWARGTPLSQAIIHQYYQPPNLLELFGTILPLDLEDIF
KKSKPRYHKRTSSAVWNSPPLQGARVPSSLAYSLKKH–C-terminus 
7.1.2.5 TEV cleavage site 
N-terminus: ENLYFQG –C-terminus 
7.1.2.6 Bio-Tag 
N-terminus: 
GGGTGGAPAPAAGGAGAGKAGEGEIPAPLAGTVSKILVKEGDTVKAGQTVLVLEAM
KMETEINAPTDGKVEKVLVKERDAVQGGQGLIKIG –C-terminus Appendix 
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7.1.2.7 Stab-Tag 
N-terminus: 
GGGTGGAPAPAAGGAGAGKAGEGEIPAPLAGTVSKILVKEGDTVKAGQTVLVLEAM
RMETEINAPTDGKVEKVLVKERDAVQGGQGLIKIG –C-terminus 
7.1.2.8 GFP 
N-terminus: 
MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEV
KFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRH
NIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTA
AGITLGMDELYK –C-terminus 
 
7.1.2.9 CFP 
N-terminus: 
MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVP
WPTLVTTLTWGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEV
KFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYISHNVYITADKQKNGIKANFKIRHNI
EDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAA
GITLGMDELYK –C-terminus 
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